10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
	OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

or

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
	SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

OMEGA HEALTHCARE INVESTORS, INC.

OHI HEALTHCARE PROPERTIES HOLDCO, INC.

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

(Exact name of Registrant as specified in its charter)

Maryland	1-11316	38-3041398
(Omega Healthcare Investors, Inc.)	(Omega Healthcare Investors, Inc.)	(Omega Healthcare Investors, Inc.)
Delaware	333-203447-12	47-2148273
(OHI Healthcare Properties Holdco, Inc.)	(OHI Healthcare Properties Holdco, Inc.)	(OHI Healthcare Properties Holdco, Inc.)
Delaware	333-203447-11	36-4796206
(OHI Healthcare Properties Limited Partnership)	(OHI Healthcare Properties Limited Partnership)	(OHI Healthcare Properties Limited Partnership)
(State of incorporation or organization)	(Commission file number)	(IRS Employer Identification No.)

303 International Circle, Suite 200, Hunt Valley, MD 21030

(Address of principal executive offices)

(410) 427-1700

(Telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Omega Healthcare Investors, Inc. Yes    x    No ¨          OHI Healthcare Properties Holdco, Inc. Yes    ¨          No    x

OHI Healthcare Properties Limited Partnership Yes    ¨   No    x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Omega Healthcare Investors, Inc. Yes    x          No    ¨          OHI Healthcare Properties Holdco, Inc. Yes    x          No    ¨

OHI Healthcare Properties Limited Partnership Yes    x   No    ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one:)

Omega Healthcare Investors, Inc.
	Large accelerated filer x	Accelerated filer ¨	Non-accelerated filer ¨
	Smaller reporting company ¨	Emerging growth company ¨
OHI Healthcare Properties Holdco, Inc.
	Large accelerated filer ¨	Accelerated filer ¨	Non-accelerated filer x
	Smaller reporting company ¨	Emerging growth company ¨
OHI Healthcare Properties Limited Partnership
	Large accelerated filer ¨	Accelerated filer ¨	Non-accelerated filer x
	Smaller reporting company ¨	Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

Omega Healthcare Investors, Inc. ¨ OHI Healthcare Properties Holdco, Inc. ¨

OHI Healthcare Properties Limited Partnership ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Omega Healthcare Investors, Inc. Yes    ¨         No    x         OHI Healthcare Properties Holdco, Inc. Yes    ¨      No    x

OHI Healthcare Properties Limited Partnership Yes    ¨         No    x

Indicate the number of shares outstanding of each of the issuers’ classes of common stock as of August 2, 2017

Omega Healthcare Investors, Inc.
Common Stock, $.10 par value	197,241,081
OHI Healthcare Properties Holdco, Inc.
Common Stock, $.01 par value	1,000
OHI Healthcare Properties Limited Partnership
N/A	No common stock outstanding
(Class)	(Number of shares)

EXPLANATORY NOTES

Amendment No. 1

This Amendment No. 1 on Form 10-Q/A (the “Amendment”) amends the Quarterly Report on Form 10-Q filed by Omega Healthcare Investors, Inc. (“Parent”), for the quarterly period ended March 31, 2017, originally filed with the SEC on May 5, 2017 (the “Original Filing”). This Amendment is being filed to provide the consolidated financial statements of OHI Healthcare Properties Holdco, Inc. (“OHI Holdco”) and OHI Healthcare Properties Limited Partnership (“Omega OP” and together with OHI Holdco, the “Guarantors”) pursuant to Rule 3-10 of Regulation S-X, and other related disclosures related to the Guarantors. Subsequent to March 31, 2017, all of the subsidiary guarantors of Parent’s outstanding senior notes other than OHI Holdco and Omega OP were released as guarantors of the Parent’s senior notes. As a result, the composition of the Company’s guarantor and non-guarantor subsidiaries has changed from the composition reflected in Note 17 of the consolidated financial statements included in the Original Filing. Accordingly, this Amendment provides the consolidated financial statements of the current Guarantors in lieu of the information previously set forth in Note 17 relating to the prior guarantor structure. The consolidated financial statements of Omega Healthcare Investors, Inc. included in this Amendment are unchanged from those included in the Original Filing except changes to the Notes to such financial statements relating to the guarantors including the deletion of Note 17 in the Original Filing. In addition, this Amendment revises “Part I, Item 4-Controls and Procedures” of the Original Filing.

For the convenience of the reader, this Amendment sets forth the entire Form 10-Q. Except as expressly set forth herein, this Amendment speaks as of the filing date of the Original Filing and does not reflect events occurring after the date of the Original Filing or modify or update any of the other disclosures contained therein, other than as required in an Amendment to reflect the changes referenced above. References in this Amendment to the "Form 10-Q" refer to the Original Filing as amended hereby. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company’s other filings made with the SEC on or subsequent to May 5, 2017.

Co-Registrants

This report combines the annual reports on Form 10-Q for the quarterly period ended March 31, 2017 of Omega Healthcare Investors, Inc., OHI Holdco and Omega OP. Unless stated otherwise or the context otherwise requires, (i) references to “Omega” or the “Company” means Omega Healthcare Investors, Inc. and its consolidated subsidiaries, (ii) references to “Parent” refer to Omega Healthcare Investors, Inc. without regard to its consolidated subsidiaries, (iii) references to “OHI Holdco” means OHI Healthcare Properties Holdco, Inc. and its consolidated subsidiaries, and (iv) references to “Omega OP” means OHI Healthcare Properties Limited Partnership and its consolidated subsidiaries.

Omega is a self-administered real estate investment trust (“REIT”) under the Internal Revenue Code of 1986, as amended, (the “Internal Revenue Code”). Omega is structured as an umbrella partnership REIT (“UPREIT”) under which, all of Omega's assets are owned directly or indirectly, and all of Omega's operations are conducted directly or indirectly, by its subsidiaries, the OHI Holdco and the Omega OP.

Parent owned either directly or indirectly approximately 96% of the issued and outstanding partnership units in Omega OP (the “Omega OP Units”) at March 31, 2017. Parent owned approximately 74% of the Omega OP Units directly and controls an additional approximately 22% through its 100% ownership in OHI Holdco. Omega OP Units, other than those owned by Parent and OHI Holdco, are exchangeable on a one-for-one basis for Parent’s common shares. The management of Parent consists of the same members as the management of OHI Holdco and Omega OP.

The financial results of OHI Holdco and Omega OP are consolidated into the financial statements of Omega. Omega has no significant assets other than its investments in OHI Holdco and Omega OP. Omega, OHI Holdco and Omega OP are managed and operated as one entity. OHI Holdco has no assets other than its interests in Omega OP. Omega OP has no significant assets other than its interests in non-guarantor subsidiaries.

We believe it is important for investors to understand the few differences between Omega, OHI Holdco and Omega OP in the context of how we operate as a consolidated company. Omega and OHI Holdco act as the general partners of Omega OP. Net proceeds from equity issuances by Parent are contributed to Omega OP in exchange for additional partnership units. Parent and Omega OP incur indebtedness. The outstanding senior notes and certain other debt of Parent is guaranteed by OHI Holdco and Omega OP.

We believe combining the quarterly reports on Form 10-Q of Omega, OHI Holdco and Omega OP into this single report results in the following benefits:

· combined reports better reflect how management and the analyst community view the business as a single operating unit;

· combined reports enhance investors’ understanding of the Omega, OHI Holdco and Omega OP by enabling them to view the business as a whole and in the same manner as management;

· combined reports are more efficient for the Omega, OHI Holdco and Omega OP and result in savings in time, effort and expense; and

· combined reports are more efficient for investors by reducing duplicative disclosure and providing a single document for their review.

In order to highlight the differences between Omega, OHI Holdco and the Omega OP, the separate sections in this report for Omega, OHI Holdco and the Omega OP specifically refer to Omega, OHI Holdco and the Omega OP. In the sections that combine disclosure of Omega, OHI Holdco and the Omega OP, this report refers to “we” and “us” actions or holdings as being “our” actions or holdings. Although Omega OP and its subsidiaries hold all of our assets, we believe that reference to “we,” “us” or “our” in this context is appropriate because the business is one enterprise and we operate substantially all of our business through OHI Holdco and Omega OP.

OMEGA HEALTHCARE INVESTORS, INC.

OHI HEALTHCARE PROPERTIES HOLDCO, INC.

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

FORM 10-Q/A

March 31, 2017

TABLE OF CONTENTS
		Page No.
PART I	Financial Information
Item 1.	Financial Statements of Omega Healthcare Investors, Inc.:
	Consolidated Balance Sheets March 31, 2017 (unaudited) and December 31, 2016	2
	Consolidated Statements of Operations (unaudited) Three months ended March 31, 2017 and 2016	3
	Consolidated Statements of Comprehensive Income (unaudited) Three months ended March 31, 2017 and 2016	4
	Consolidated Statement of Changes in Equity (unaudited) Three months ended March 31, 2017	5
	Consolidated Statements of Cash Flows (unaudited) Three months ended March 31, 2017 and 2016	6
	Financial Statements of OHI Healthcare Properties Holdco, Inc.:
	Consolidated Balance Sheets March 31, 2017 (unaudited) and December 31, 2016	8
	Consolidated Statements of Operations (unaudited) Three months ended March 31, 2017 and 2016	9
	Consolidated Statements of Comprehensive Income (unaudited) Three months ended March 31, 2017 and 2016	10
	Consolidated Statement of Changes in Equity (unaudited) Three months ended March 31, 2017	11
	Consolidated Statements of Cash Flows (unaudited) Three months ended March 31, 2017 and 2016	12
	Financial Statements of OHI Healthcare Properties Limited Partnership:
	Consolidated Balance Sheets March 31, 2017 (unaudited) and December 31, 2016	14
	Consolidated Statements of Operations (unaudited) Three months ended March 31, 2017 and 2016	15
	Consolidated Statements of Comprehensive Income (unaudited) Three months ended March 31, 2017 and 2016	16
	Consolidated Statement of Changes in Owners’ Equity (unaudited) Three months ended March 31, 2017	17
	Consolidated Statements of Cash Flows (unaudited) Three months ended March 31, 2017 and 2016	18
	Notes to Consolidated Financial Statements March 31, 2017 (unaudited)	20
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	40
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	54
Item 4.	Controls and Procedures	54
PART II	Other Information
Item 1.	Legal Proceedings	55
Item 1A.	Risk Factors	55
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	55
Item 6.	Exhibits	56

PART I – FINANCIAL INFORMATION

Item 1 - Financial Statements

OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

	March 31,			December 31,
	2017			2016
	(Unaudited)
ASSETS
Real estate properties
Real estate investments (see Note 2)	$	7,581,665		$	7,566,358
Less accumulated depreciation		(1,306,084	)		(1,240,336	)
Real estate investments – net		6,275,581			6,326,022
Investments in direct financing leases – net		604,777			601,938
Mortgage notes receivable – net		644,696			639,343
		7,525,054			7,567,303
Other investments – net		255,899			256,846
Investment in unconsolidated joint venture		40,152			48,776
Assets held for sale – net		23,245			52,868
Total investments		7,844,350			7,925,793
Cash and cash equivalents		40,349			93,687
Restricted cash		12,198			13,589
Accounts receivable – net		272,506			240,035
Goodwill		643,692			643,474
Other assets		29,023			32,682
Total assets	$	8,842,118		$	8,949,260
LIABILITIES AND EQUITY
Revolving line of credit	$	123,000		$	190,000
Term loans – net		1,094,875			1,094,343
Secured borrowings – net		54,052			54,365
Unsecured borrowings – net		3,028,938			3,028,146
Accrued expenses and other liabilities		316,985			360,514
Deferred income taxes		9,746			9,906
Total liabilities		4,627,596			4,737,274
Equity:
Common stock $.10 par value authorized – 350,000 shares, issued and outstanding – 196,761 shares as of March 31, 2017 and 196,142 as of December 31, 2016		19,676			19,614
Common stock – additional paid-in capital		4,878,637			4,861,408
Cumulative net earnings		1,843,377			1,738,937
Cumulative dividends paid		(2,829,718	)		(2,707,387	)
Accumulated other comprehensive loss		(48,478	)		(53,827	)
Total stockholders’ equity		3,863,494			3,858,745
Noncontrolling interest		351,028			353,241
Total equity		4,214,522			4,211,986
Total liabilities and equity	$	8,842,118		$	8,949,260

See notes to consolidated financial statements. 

2

OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

Unaudited

(in thousands, except per share amounts)

	Three Months Ended
	March 31,
	2017			2016
Revenue
Rental income	$	192,537		$	176,703
Income from direct financing leases		15,646			15,442
Mortgage interest income		15,956			16,606
Other investment income – net		6,914			3,431
Miscellaneous income		691			697
Total operating revenues		231,744			212,879
Expenses
Depreciation and amortization		69,993			62,433
General and administrative		12,524			10,455
Acquisition costs		(41	)		3,771
Impairment loss on real estate properties		7,638			34,558
Provision for uncollectible accounts		2,404			5,124
Total operating expenses		92,518			116,341
Income before other income and expense		139,226			96,538
Other income (expense)
Interest income		4			8
Interest expense		(45,041	)		(37,222	)
Interest – amortization of deferred financing costs		(2,502	)		(2,132	)
Interest – refinancing costs		-			(298	)
Contractual settlement		10,412			-
Realized gain (loss) on foreign exchange		61			(22	)
Total other expense		(37,066	)		(39,666	)
Income before gain on assets sold		102,160			56,872
Gain on assets sold – net		7,420			1,571
Income from continuing operations		109,580			58,443
Income tax expense		(1,100	)		(247	)
Income from unconsolidated joint venture		632			-
Net income		109,112			58,196
Net income attributable to noncontrolling interest		(4,672	)		(2,641	)
Net income available to common stockholders	$	104,440		$	55,555
Earnings per common share available to common stockholders:
Basic:
Net income available to common stockholders	$	0.53		$	0.30
Diluted:
Net income	$	0.53		$	0.29
Dividends declared per common share	$	0.62		$	0.57
Weighted-average shares outstanding, basic		197,013			188,228
Weighted-average shares outstanding, diluted		206,174			198,350

See notes to consolidated financial statements.

3

OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Unaudited

(in thousands)

	Three Months Ended
	March 31,
	2017			2016
Net income	$	109,112		$	58,196
Other comprehensive income (loss)
Foreign currency translation		4,334			(4,730	)
Cash flow hedges		1,254			(8,876	)
Total other comprehensive income (loss)		5,588			(13,606	)
Comprehensive income		114,700			44,590
Comprehensive income attributable to noncontrolling interest		(4,911	)		(2,025	)
Comprehensive income attributable to common stockholders	$	109,789		$	42,565

See notes to consolidated financial statements.

4

OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Unaudited

(in thousands, except per share amounts)

	Common Stock Par Value		Additional Paid-in Capital			Cumulative Net Earnings		Cumulative Dividends Paid			Accumulated Other Comprehensive Income (Loss)			Total Stockholders’ Equity			Noncontrolling  Interest			Total Equity
Balance at December 31, 2016 (196,142 common shares & 8,862 Omega OP Units)	$	19,614	$	4,861,408		$	1,738,937	$	(2,707,387	)	$	(53,827	)	$	3,858,745		$	353,241		$	4,211,986
Stock-based compensation expense		—		3,744			—		—			—			3,744			—			3,744
Vesting/exercising of equity compensation plan, net of tax withholdings (103 shares)		10		(2,130	)		—		—			—			(2,120	)		—			(2,120	)
Dividend reinvestment and stock purchase plan (239 shares at an average of $30.67 per share)		24		7,311			—		—			—			7,335			—			7,335
Grant of stock as payment of directors fees (2 shares at an average of $31.19 per share)		—		75			—		—			—			75			—			75
Deferred compensation directors		—		(16	)		—		—			—			(16	)		—			(16	)
Equity Shelf Program (228 shares at $29.71 per share, net of issuance costs)		23		6,736			—		—			—			6,759			—			6,759
Common dividends declared ($0.62 per share)		—		—			—		(122,331	)		—			(122,331	)		—			(122,331	)
Conversion of Omega OP Units to common stock (47 shares at $32.30 per share)		5		1,509			—		—			—			1,514			—			1,514
Redemption of Omega OP Units (48 units)		—		—			—		—			—			—			(1,570	)		(1,570	)
Omega OP Unit distributions		—		—			—		—			—			—			(5,554	)		(5,554	)
Foreign currency translation		—		—			—		—			4,149			4,149			185			4,334
Cash flow hedges		—		—			—		—			1,200			1,200			54			1,254
Net income		—		—			104,440		—			—			104,440			4,672			109,112
Balance at March 31, 2017 (196,761 shares & 8,814 Omega OP Units)	$	19,676	$	4,878,637		$	1,843,377	$	(2,829,718	)	$	(48,478	)	$	3,863,494		$	351,028		$	4,214,522

See notes to consolidated financial statements.

5

OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Unaudited (in thousands)

	Three Months Ended March 31,
	2017			2016
Cash flows from operating activities
Net income	$	109,112		$	58,196
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		69,993			62,433
Impairment loss on real estate properties		7,638			34,558
Provision for uncollectible accounts		2,404			5,124
Refinancing costs and amortization of deferred financing costs		2,502			2,430
Accretion of direct financing leases		(3,016	)		(2,921	)
Stock-based compensation expense		3,744			2,778
Gain on assets sold – net		(7,420	)		(1,571	)
Amortization of acquired in-place leases - net		(3,096	)		(4,300	)
Effective yield receivable on mortgage notes		(593	)		(819	)
Change in operating assets and liabilities – net:
Accounts receivable		(21,377	)		560
Straight-line rent receivables		(11,747	)		(9,947	)
Lease inducements		447			647
Other operating assets and liabilities		(34,653	)		(19,989	)
Net cash provided by operating activities		113,938			127,179
Cash flows from investing activities
Acquisition of real estate		(7,574	)		(416,104	)
Investments in construction in progress		(15,703	)		(16,316	)
Investments in direct financing leases		(2,229	)		—
Deposit to acquire real estate		—			(113,816	)
Placement of mortgage loans		(5,749	)		(6,162	)
Distributions from unconsolidated joint venture		8,587			—
Proceeds from sale of real estate investments		45,848			2,392
Capital improvements to real estate investments		(8,199	)		(9,544	)
Proceeds from other investments		23,181			1,461
Investments in other investments		(22,144	)		(116,003	)
Collection of mortgage principal		333			312
Net cash provided by (used in) investing activities		16,351			(673,780	)
Cash flows from financing activities
Proceeds from credit facility borrowings		148,000			670,000
Payments on credit facility borrowings		(215,000	)		(370,000	)
Receipts of other long-term borrowings		—			350,000
Payments of other long-term borrowings		(318	)		(309	)
Payments of financing related costs		(563	)		(3,576	)
Receipts from dividend reinvestment plan		7,335			19,596
Payments for exercised options and restricted stock		(2,120	)		(2,381	)
Net proceeds from issuance of common stock		6,759			—
Dividends paid		(122,272	)		(107,500	)
Redemption of Omega OP Units		(56	)		(10	)
Distributions to Omega OP Unit Holders		(5,554	)		(5,131	)
Net cash (used in) provided by financing activities		(183,789	)		550,689
Effect of foreign currency translation on cash and cash equivalents		162			(105	)
(Decrease) increase in cash and cash equivalents		(53,338	)		3,983
Cash and cash equivalents at beginning of period		93,687			5,424
Cash and cash equivalents at end of period	$	40,349		$	9,407

6

Supplemental disclosures of cash flow information:

	Three Months Ended March 31,
	2017			2016
Interest paid during the period, net of amounts capitalized	$	61,832		$	36,597
Taxes paid during the period	$	1,173		$	141
Non-cash financing activities
Change in fair value of cash flow hedges	$	(1,291	)	$	8,876

See notes to consolidated financial statements.

7

OHI HEALTHCARE PROPERTIES HOLDCO, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

	March 31,			December 31,
	2017			2016
	(Unaudited)
ASSETS
Real estate properties
Real estate investments (see Note 2)	$	7,581,665		$	7,566,358
Less accumulated depreciation		(1,306,084	)		(1,240,336	)
Real estate investments – net		6,275,581			6,326,022
Investments in direct financing leases – net		604,777			601,938
Mortgage notes receivable – net		644,696			639,343
		7,525,054			7,567,303
Other investments – net		255,899			256,846
Investment in unconsolidated joint venture		40,152			48,776
Assets held for sale – net		23,245			52,868
Total investments		7,844,350			7,925,793
Cash and cash equivalents		40,349			93,687
Restricted cash		12,198			13,589
Accounts receivable – net		272,506			240,035
Goodwill		643,692			643,474
Other assets		29,023			32,682
Total assets	$	8,842,118		$	8,949,260
LIABILITIES AND EQUITY
Term loans – net	$	100,000		$	100,000
Secured borrowings – net		54,052			54,365
Accrued expenses and other liabilities		275,899			302,959
Deferred income taxes		9,746			9,906
Intercompany payable		4,187,899			4,270,044
Total liabilities		4,627,596			4,737,274
Equity:
Common stock – additional paid-in capital		923,218			923,218
Cumulative net earnings		149,360			126,187
Cumulative dividends paid		(202,391	)		(175,289	)
Accumulated other comprehensive loss		(11,253	)		(12,439	)
Total stockholders’ equity		858,934			861,677
Noncontrolling interest		3,355,588			3,350,309
Total equity		4,214,522			4,211,986
Total liabilities and equity	$	8,842,118		$	8,949,260

See notes to consolidated financial statements.

8

OHI HEALTHCARE PROPERTIES HOLDCO, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

Unaudited

(in thousands)

	Three Months Ended
	March 31,
	2017			2016
Revenue
Rental income	$	192,537		$	176,703
Income from direct financing leases		15,646			15,442
Mortgage interest income		15,956			16,606
Other investment income – net		6,914			3,431
Miscellaneous income		691			697
Total operating revenues		231,744			212,879
Expenses
Depreciation and amortization		69,993			62,433
General and administrative		12,524			10,455
Acquisition costs		(41	)		3,771
Impairment loss on real estate properties		7,638			34,558
Provision for uncollectible accounts		2,404			5,124
Total operating expenses		92,518			116,341
Income before other income and expense		139,226			96,538
Other income (expense)
Interest income		4			8
Interest expense		(45,041	)		(37,222	)
Interest – amortization of deferred financing costs		(2,502	)		(2,132	)
Interest – refinancing costs		-			(298	)
Contractual settlement		10,412			-
Realized gain (loss) on foreign exchange		61			(22	)
Total other expense		(37,066	)		(39,666	)
Income before gain on assets sold		102,160			56,872
Gain on assets sold – net		7,420			1,571
Income from continuing operations		109,580			58,443
Income tax expense		(1,100	)		(247	)
Income from unconsolidated joint venture		632			-
Net income		109,112			58,196
Net income attributable to noncontrolling interest		(85,939	)		(45,294	)
Net income available to common stockholders	$	23,173		$	12,902

See notes to consolidated financial statements.

9

OHI HEALTHCARE PROPERTIES HOLDCO, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Unaudited

(in thousands)

	Three Months Ended
	March 31,
	2017			2016
Net income	$	109,112		$	58,196
Other comprehensive income (loss)
Foreign currency translation		4,334			(4,730	)
Cash flow hedges		1,254			(8,876	)
Total other comprehensive income (loss)		5,588			(13,606	)
Comprehensive income		114,700			44,590
Comprehensive income attributable to noncontrolling interest		(90,340	)		(34,705	)
Comprehensive income attributable to common stockholders	$	24,360		$	9,885

See notes to consolidated financial statements.

10

OHI HEALTHCARE PROPERTIES HOLDCO, INC.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Unaudited

(in thousands)

	Common stock – additional paid-in capital		Cumulative Net Earnings		Cumulative Dividends			Accumulated Other Comprehensive Loss			Total Stockholders’ Equity			Noncontrolling Interest			Total Equity
Balance at December 31, 2016 (1 shares)	$	923,218	$	126,187	$	(175,289	)	$	(12,439	)	$	861,677		$	3,350,309		$	4,211,986
Contributions		—		—		—			—			—			17,291			17,291
Distributions		—		—		(27,102	)		—			(27,102	)		(102,353	)		(129,455	)
Foreign currency translation		—		—		—			920			920			3,414			4,334
Cash flow hedges		—		—		—			266			266			988			1,254
Net income		—		23,173		—			—			23,173			85,939			109,112
Balance at March 31, 2017 (1 shares)	$	923,218	$	149,360	$	(202,391	)	$	(11,253	)	$	858,934		$	3,355,588		$	4,214,522

See notes to consolidated financial statements.

11

OHI HEALTHCARE PROPERTIES HOLDCO, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Unaudited

(in thousands)

	Three Months Ended March 31,
	2017			2016
Cash flows from operating activities
Net income	$	109,112		$	58,196
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		69,993			62,433
Impairment loss on real estate properties		7,638			34,558
Provision for uncollectible accounts		2,404			5,124
Refinancing costs and amortization of deferred financing costs		2,502			2,430
Accretion of direct financing leases		(3,016	)		(2,921	)
Stock-based compensation expense		3,744			2,778
Gain on assets sold – net		(7,420	)		(1,571	)
Amortization of acquired in-place leases - net		(3,096	)		(4,300	)
Effective yield receivable on mortgage notes		(593	)		(819	)
Change in operating assets and liabilities – net:
Accounts receivable		(21,377	)		560
Straight-line rent receivables		(11,747	)		(9,947	)
Lease inducements		447			647
Other operating assets and liabilities		(34,653	)		(19,989	)
Net cash provided by operating activities		113,938			127,179
Cash flows from investing activities
Acquisition of real estate		(7,574	)		(416,104	)
Investments in construction in progress		(15,703	)		(16,316	)
Investments in direct financing leases		(2,229	)		—
Deposit to acquire real estate		—			(113,816	)
Placement of mortgage loans		(5,749	)		(6,162	)
Distributions from unconsolidated joint venture		8,587			—
Proceeds from sale of real estate investments		45,848			2,392
Capital improvements to real estate investments		(8,199	)		(9,544	)
Proceeds from other investments		23,181			1,461
Investments in other investments		(22,144	)		(116,003	)
Collection of mortgage principal		333			312
Net cash provided by (used in) investing activities		16,351			(673,780	)
Cash flows from financing activities
Proceeds from intercompany loans from Omega		148,000			1,020,000
Repayment of interompany loans to Omega		(215,318	)		(370,309	)
Payment of financing related costs incurred by Omega		(563	)		(3,576	)
Dividends paid		(27,102	)		(24,916	)
Contribution from noncontrolling interest		11,974			17,215
Distributions to limited partners		(100,780	)		(87,725	)
Net cash (used in) provided by financing activities		(183,789	)		550,689
Effect of foreign currency translation on cash and cash equivalents		162			(105	)
(Decrease) increase in cash and cash equivalents		(53,338	)		3,983
Cash and cash equivalents at beginning of period		93,687			5,424
Cash and cash equivalents at end of period	$	40,349		$	9,407

12

Supplemental disclosures of cash flow information:

	Three Months Ended March 31,
	2017			2016
Interest paid during the period, net of amounts capitalized	$	61,832		$	36,597
Taxes paid during the period	$	1,173		$	141
Non cash financing activities
Change in fair value of cash flow hedges	$	(1,291	)	$	8,876

See notes to consolidated financial statements.

13

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

CONSOLIDATED BALANCE SHEETS

(in thousands)

	March 31,			December 31,
	2017			2016
	(Unaudited)
ASSETS
Real estate properties
Real estate investments (see Note 2)	$	7,581,665		$	7,566,358
Less accumulated depreciation		(1,306,084	)		(1,240,336	)
Real estate investments – net		6,275,581			6,326,022
Investments in direct financing leases – net		604,777			601,938
Mortgage notes receivable – net		644,696			639,343
		7,525,054			7,567,303
Other investments – net		255,899			256,846
Investment in unconsolidated joint venture		40,152			48,776
Assets held for sale – net		23,245			52,868
Total investments		7,844,350			7,925,793
Cash and cash equivalents		40,349			93,687
Restricted cash		12,198			13,589
Accounts receivable – net		272,506			240,035
Goodwill		643,692			643,474
Other assets		29,023			32,682
Total assets	$	8,842,118		$	8,949,260
LIABILITIES AND OWNERS’ EQUITY
Term loans – net	$	100,000		$	100,000
Secured borrowings – net		54,052			54,365
Accrued expenses and other liabilities		275,899			302,959
Deferred income taxes		9,746			9,906
Intercompany payable		4,187,899			4,270,044
Total liabilities		4,627,596			4,737,274
Owners’ Equity:
General partners’ equity		3,863,494			3,858,745
Limited partners’ equity		351,028			353,241
Total owners’ equity		4,214,522			4,211,986
Total liabilities and owners’ equity	$	8,842,118		$	8,949,260

See notes to consolidated financial statements.

14

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

CONSOLIDATED STATEMENTS OF OPERATIONS

Unaudited

(in thousands, except per unit amounts)

	Three Months Ended
	March 31,
	2017			2016
Revenue
Rental income	$	192,537		$	176,703
Income from direct financing leases		15,646			15,442
Mortgage interest income		15,956			16,606
Other investment income – net		6,914			3,431
Miscellaneous income		691			697
Total operating revenues		231,744			212,879
Expenses
Depreciation and amortization		69,993			62,433
General and administrative		12,524			10,455
Acquisition costs		(41	)		3,771
Impairment loss on real estate properties		7,638			34,558
Provision for uncollectible accounts		2,404			5,124
Total operating expenses		92,518			116,341
Income before other income and expense		139,226			96,538
Other income (expense)
Interest income		4			8
Interest expense		(45,041	)		(37,222	)
Interest – amortization of deferred financing costs		(2,502	)		(2,132	)
Interest – refinancing costs		-			(298	)
Contractual settlement		10,412			-
Realized gain (loss) on foreign exchange		61			(22	)
Total other expense		(37,066	)		(39,666	)
Income before gain on assets sold		102,160			56,872
Gain on assets sold – net		7,420			1,571
Income from continuing operations		109,580			58,443
Income tax expense		(1,100	)		(247	)
Income from unconsolidated joint venture		632			-
Net income	$	109,112		$	58,196
Earnings per Omega OP Unit :
Basic:
Net income	$	0.53		$	0.30
Diluted:
Net income	$	0.53		$	0.29
Dividends declared per Omega OP Unit	$	0.62		$	0.57
Weighted-average Omega OP Units outstanding, basic		205,827			197,175
Weighted-average Omega OP Units outstanding, diluted		206,174			198,350

See notes to consolidated financial statements.

15

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Unaudited

(in thousands)

	Three Months Ended
	March 31,
	2017		2016
Net income	$	109,112	$	58,196
Other comprehensive income (loss)
Foreign currency translation		4,334		(4,730	)
Cash flow hedges		1,254		(8,876	)
Total other comprehensive income (loss)		5,588		(13,606	)
Comprehensive income	$	114,700	$	44,590

See notes to consolidated financial statements.

16

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

CONSOLIDATED STATEMENT OF CHANGES IN OWNERS’ EQUITY

Unaudited

(in thousands)

	General Partners’ Omega OP Units		Limited Partners’ Omega OP Units			Total Omega OP Units			General Partners’ Equity			Limited Partners’ Equity			Total Owners’ Equity
Balance at December 31, 2016		196,142		8,862			205,004		$	3,858,745		$	353,241		$	4,211,986
Contributions from partners		619		—			619			17,291			—			17,291
Distributions to partners		—		—			—			(122,331	)		(5,554	)		(127,885	)
Omega OP Unit redemptions		—		(48	)		(48	)		—			(1,570	)		(1,570	)
Foreign currency translation		—		—			—			4,149			185			4,334
Cash flow hedges		—		—			—			1,200			54			1,254
Net income		—		—			—			104,440			4,672			109,112
Balance at March 31, 2017		196,761		8,814			205,575		$	3,863,494		$	351,028		$	4,214,522

See notes to consolidated financial statements.

17

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

CONSOLIDATED STATEMENTS OF CASH FLOWS

Unaudited

(in thousands)

	Three Months Ended March 31,
	2017			2016
Cash flows from operating activities
Net income	$	109,112		$	58,196
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		69,993			62,433
Impairment loss on real estate properties		7,638			34,558
Provision for uncollectible accounts		2,404			5,124
Refinancing costs and amortization of deferred financing costs		2,502			2,430
Accretion of direct financing leases		(3,016	)		(2,921	)
Stock-based compensation expense		3,744			2,778
Gain on assets sold – net		(7,420	)		(1,571	)
Amortization of acquired in-place leases - net		(3,096	)		(4,300	)
Effective yield receivable on mortgage notes		(593	)		(819	)
Change in operating assets and liabilities – net:
Accounts receivable		(21,377	)		560
Straight-line rent receivables		(11,747	)		(9,947	)
Lease inducements		447			647
Other operating assets and liabilities		(34,653	)		(19,989	)
Net cash provided by operating activities		113,938			127,179
Cash flows from investing activities
Acquisition of real estate		(7,574	)		(416,104	)
Investments in construction in progress		(15,703	)		(16,316	)
Investments in direct financing leases		(2,229	)		—
Deposit to acquire real estate		—			(113,816	)
Placement of mortgage loans		(5,749	)		(6,162	)
Distributions from unconsolidated joint venture		8,587			—
Proceeds from sale of real estate investments		45,848			2,392
Capital improvements to real estate investments		(8,199	)		(9,544	)
Proceeds from other investments		23,181			1,461
Investments in other investments		(22,144	)		(116,003	)
Collection of mortgage principal		333			312
Net cash provided by (used in) investing activities		16,351			(673,780	)
Cash flows from financing activities
Proceeds from intercompany loans from Omega		148,000			1,020,000
Repayment of intercompany loans to Omega		(215,318	)		(370,309	)
Payment of financing related costs incurred by Omega		(563	)		(3,576	)
Equity contributions from general partners’		11,974			17,215
Distribution  to general partners		(122,272	)		(107,500	)
Distributions to limited partners’		(5,554	)		(5,131	)
Redemption of Omega OP Units		(56	)		(10	)
Net cash (used in) provided by financing activities		(183,789	)		550,689
Effect of foreign currency translation on cash and cash equivalents		162			(105	)
(Decrease) increase in cash and cash equivalents		(53,338	)		3,983
Cash and cash equivalents at beginning of period		93,687			5,424
Cash and cash equivalents at end of period	$	40,349		$	9,407

18

Supplemental disclosures of cash flow information:

	Three Months Ended March 31,
	2017			2016
Interest paid during the period, net of amounts capitalized	$	61,832		$	36,597
Taxes paid during the period	$	1,173		$	141
Non-cash financing activities
Change in fair value of cash flow hedges	$	(1,291	)	$	8,876

See notes to consolidated financial statements.

19

OMEGA HEALTHCARE INVESTORS, INC.

OHI HEALTHCARE PROPERTIES HOLDCO, INC.

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Unaudited

March 31, 2017

NOTE 1 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Business Overview and Organization

Omega Healthcare Investors, Inc. (“Omega”) was formed as a real estate investment trust (“REIT”) and incorporated in the State of Maryland on March 31, 1992. All of Omega's assets are owned directly or indirectly, and all of Omega's operations are conducted directly or indirectly, through its subsidiaries, OHI Healthcare Properties Holdco, Inc. (“OHI Holdco”), a direct wholly owned subsidiary of Omega, and OHI Healthcare Properties Limited Partnership (“Omega OP”). OHI Holdco was formed as a corporation and incorporated in the State of Delaware on October 22, 2014. Omega OP was formed as a limited partnership and organized in the State of Delaware on October 24, 2014. No substantive assets or activity occurred in either of these entities until the merger with Aviv REIT, Inc. on April 1, 2015. Unless stated otherwise or the context otherwise requires, the terms the “Company,” “we,” “our” and “us” means Omega, OHI Holdco and Omega OP, collectively.

The Company has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States (“U.S.”) and the United Kingdom (“U.K.”). Our core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (“SNFs”) and, to a lesser extent, assisted living facilities (“ALFs”), independent living facilities and rehabilitation and acute care facilities. Our core portfolio consists of long-term leases and mortgage agreements. All of our leases are “triple-net” leases, which require the tenants to pay all property-related expenses. Our mortgage revenue derives from fixed rate mortgage loans, which are secured by first mortgage liens on the underlying real estate and personal property of the mortgagor.

In April 2015, Aviv REIT, Inc., a Maryland corporation (“Aviv”), merged (the “Aviv Merger”) with and into a wholly owned subsidiary of Omega, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of October 30, 2014 (the “Merger Agreement”), by and among Omega, Aviv, OHI Holdco, Omega OP, and Aviv Healthcare Properties Limited Partnership, a Delaware limited partnership.

Prior to April 1, 2015 and in accordance with the Merger Agreement, Omega restructured the manner in which it holds its assets by converting to an umbrella partnership real estate investment trust structure (the “UPREIT Conversion”). As a result of the UPREIT Conversion and following the consummation of the Aviv Merger, all of Omega’s assets are held by Omega OP, through its equity interests in its subsidiaries.

Omega OP is governed by the Second Amended and Restated Agreement of Limited Partnership of OHI Healthcare Properties Limited Partnership, dated as of April 1, 2015 (the “Partnership Agreement”). Pursuant to the Partnership Agreement, Omega and OHI Holdco are the general partners of Omega OP, and have exclusive control over Omega OP’s day-to-day management. As of March 31, 2017, Omega and OHI Holdco together owned approximately 96% of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and investors owned approximately 4% of the Omega OP Units.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods reported herein are not necessarily indicative of results to be expected for the full year. These unaudited consolidated financial statements should be read in conjunction with the financial statements and the footnotes thereto included in our Form 10-K/A filed with the SEC on August 9, 2017.

20

Our consolidated financial statements include the accounts of (i) Omega, (ii) OHI Holdco (iii) Omega OP and (iv) all direct and indirect wholly owned subsidiaries of Omega. All intercompany transactions and balances have been eliminated in consolidation, and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.

Asset Impairment

Management evaluates our real estate investments for impairment indicators at each reporting period, including the evaluation of our assets’ useful lives. The judgment regarding the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance, legal structure, as well as our intent with respect to holding or disposing of the asset. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to the future undiscounted cash flows of the underlying facilities. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows based on our intended use of the property are determined to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the real estate investments for the excess of carrying value over fair value. The fair value of the real estate investment is determined by market research, which includes valuing the property as a nursing home as well as other alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset. Management’s impairment evaluation process, and when applicable, impairment calculations involve estimation of the future cash flows from management’s intended use of the property. Changes in the facts and circumstances that drive management’s assumptions may result in an impairment of the Company’s assets in a future period that could be material to the Company’s results of operations.

If we decide to sell real estate properties or land holdings, we evaluate the recoverability of the carrying amounts of the assets. If the evaluation indicates that the carrying value is not recoverable from estimated net sales proceeds, the property is written down to estimated fair value less costs to sell. Our estimates of cash flows and fair values of the properties are based on current market conditions and consider matters such as rental rates and occupancies for comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers or prospective purchasers.

For the three months ended March 31, 2017 and 2016, we recognized impairment losses of $7.6 million and $34.6 million, respectively. For additional information see Note 2 – Properties and Investments and Note 7 – Assets Held For Sale.

Goodwill Impairment

We assess goodwill for potential impairment during the fourth quarter of each fiscal year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the net assets of the reporting unit. In evaluating goodwill for impairment on an interim basis, we assess qualitative factors such as a significant decline in real estate valuations, current macroeconomic conditions, state of the equity and capital markets and our overall financial and operating performance or a significant decline in the value of our market capitalization, to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of the reporting unit is less than its carrying amount. On an annual basis during the fourth quarter of each fiscal year, or on an interim basis if we conclude it is more likely than not that the fair value of the reporting unit is less than its carrying value, we perform a two-step goodwill impairment test to identify potential impairment and measure the amount of impairment we will recognize, if any.

21

Noncontrolling Interests

Noncontrolling interests is the portion of equity not attributable to the respective reporting entity. We present the portion of any equity that we do not own in consolidated entities as noncontrolling interests and classify those interests as a component of total equity, separate from total stockholders’ equity, or owners’ equity on our Consolidated Balance Sheets. We include net income attributable to the noncontrolling interests in net income in our Consolidated Statements of Operations.

As our ownership of a controlled subsidiary increases or decreases, any difference between the aggregate consideration paid to acquire the noncontrolling interests and our noncontrolling interest balance is recorded as a component of equity in additional paid-in capital, so long as we maintain a controlling ownership interest.

The noncontrolling interest for Omega represents the outstanding Omega OP Units held by outside investors. The noncontrolling interest for OHI Holdco represents the Omega OP Units held by the Parent and the outstanding Omega OP Units held by outside investors.

Foreign Operations

The U.S. dollar is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound. For our consolidated subsidiaries whose functional currency is not the U.S. dollar, we translate their financial statements into the U.S. dollar. We translate assets and liabilities at the exchange rate in effect as of the financial statement date. Revenue and expense accounts are translated using an average exchange rate for the period. Gains and losses resulting from translation are included in accumulated other comprehensive loss (“AOCL”), as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest.

We and certain of our consolidated subsidiaries may have intercompany and third-party debt that is not denominated in the entity’s functional currency. When the debt is remeasured against the functional currency of the entity, a gain or loss can result. The resulting adjustment is reflected in results of operations, unless it is intercompany debt that is deemed to be long-term in nature and then the adjustments are included in AOCL.

Derivative Instruments

During our normal course of business, we may use certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at the inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with the Company’s related assertions. The Company recognizes all derivative instruments, including embedded derivatives required to be bifurcated, as assets or liabilities in the Consolidated Balance Sheets at their fair value which are determined using a market approach and Level 2 inputs. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in earnings. For derivatives designated as qualifying cash flow hedging relationships, the change in fair value of the effective portion of the derivatives is recognized in AOCL as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest, whereas the change in fair value of the ineffective portion is recognized in earnings. We formally document all relationships between hedging instruments and hedged items, as well as our risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific forecasted transactions as well as recognized obligations or assets in the Consolidated Balance Sheets. We also assess and document, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, we discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the current fair value of the derivative. As a matter of policy, we do not use derivatives for trading or speculative purposes. At March 31, 2017 and December 31, 2016, we had $0.2 million and $1.5 million, respectively, of qualifying cash flow hedges recorded at fair value in accrued expenses and other liabilities on our Consolidated Balance Sheets.

22

Accounts Receivable

Accounts receivable includes: contractual receivables, effective yield interest receivables, straight-line rent receivables and lease inducements, net of an estimated provision for losses related to uncollectible and disputed accounts. Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception or renewal of the lease, and are amortized as a reduction of rental revenue over the non-cancellable lease term.

On a quarterly basis, we review our accounts receivable to determine their collectability. The determination of collectability of these assets requires significant judgment and is affected by several factors relating to the credit quality of our operators that we regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement environment, (iv) the ability of the tenant to perform under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying collateral of the agreement.  If we determine collectability of any of our contractual receivables is at risk, we estimate the potential uncollectible amounts and provide an allowance. In the case of a lease recognized on a straight-line basis, a mortgage recognized on an effective yield basis or the existence of lease inducements, we generally provide an allowance for straight-line, effective interest, and or lease inducement accounts receivable when certain conditions or indicators of adverse collectability are present. If the accounts receivable balance is subsequently deemed uncollectible, the receivable and allowance for doubtful account balance are written off.

A summary of our net receivables by type is as follows:

	March 31,			December 31,
	2017			2016
	(in thousands)
Contractual receivables	$	34,751		$	13,376
Effective yield interest receivables		10,343			9,749
Straight-line rent receivables		219,821			208,874
Lease inducements		7,946			8,393
Allowance		(355	)		(357	)
Accounts receivable – net	$	272,506		$	240,035

Related Party Transactions

The Company has a policy which generally requires related party transactions to be approved or ratified by the Audit Committee. On February 1, 2016, we acquired 10 SNFs from Laurel Healthcare Holdings, Inc. (“Laurel”) for approximately $169.0 million in cash and leased them to an unrelated existing operator. A former member of the Board of Directors of the Company, together with certain members of his immediate family, beneficially owned approximately 34% of the equity of Laurel prior to the transaction. Immediately following our acquisition, the unrelated existing operator acquired all of the outstanding equity interests of Laurel, including the interests previously held by the former director of the Company and his family.

23

Accounting Pronouncement Adopted in 2017

In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Compensation-Stock Compensation (Topic 718) (“ASU 2016-09”). ASU 2016-09 amends the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2016. We adopted this accounting standard on January 1, 2017, at which time the Company began prospectively accounting for excess tax benefits or tax deficiencies as an adjustment to income tax expense in our Consolidated Statements of Operations as opposed to the prior requirement that these excess tax benefits be recognized in additional paid-in capital and tax deficiencies be recognized either as an offset to accumulated excess tax benefits, if any, or in the income statement. The Company will continue to account for forfeitures as they occur and present employee taxes paid as a financing activity on our Consolidated Statements of Cash Flows. The adoption of this accounting standard did not have a material impact on our consolidated financial statements.

Recent Accounting Pronouncements - Pending Adoption

In 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment. ASU 2014-09 is effective for the Company beginning January 1, 2018. In addition, the FASB has begun to issue targeted updates to clarify specific implementation issues of ASU 2014-09. These updates include ASU 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016-10, Identifying Performance Obligations and Licensing, and ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. The Company is currently evaluating the provisions of ASU 2014-09 and its related updates and will be closely monitoring developments and additional guidance to determine the potential impact of the new standard. The Company intends to adopt ASU 2014-09 and its subsequent updates in accordance with the modified retrospective approach. We do not expect the adoption of ASU 2014-09 and its updates to have a significant impact on our consolidated financial statements, as a substantial portion of our revenue consists of rental income from leasing arrangements and interest income from loan arrangements, both of which are specifically excluded from ASU 2014-09.

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective for the Company beginning January 1, 2019. Early adoption of ASU 2016-02 as of its issuance is permitted. The new standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact of adopting ASU 2016-02 on our consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) (“ASU 2016-13”), which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. ASU 2016-13 is effective for annual and interim periods beginning after December 15, 2019 and early adoption is permitted for annual and interim periods beginning after December 15, 2018. We are currently evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements.

NOTE 2 – PROPERTIES AND INVESTMENTS

Leased Property

Our real estate properties, represented by 808 SNFs, 101 ALFs, 16 specialty facilities and one medical office building at March 31, 2017, are leased under provisions of single or master leases with initial terms typically ranging from five to 15 years, plus renewal options. Substantially all of our leases contain provisions for specified annual increases over the rents of the prior year and are generally computed in one of three methods depending on specific provisions of each lease as follows: (i) a specific annual percentage increase over the prior year’s rent, generally between 2.0% and 3.0%; (ii) an increase based on the change in pre-determined formulas from year to year (e.g., increases in the Consumer Price Index (“CPI”)); or (iii) specific dollar increases over prior years. Under the terms of the leases, the lessee is responsible for all maintenance, repairs, taxes and insurance on the leased properties.

24

A summary of our investment in leased real estate properties is as follows:

	March 31,			December 31,
	2017			2016
	(in thousands)
Buildings	$	5,980,501		$	5,954,771
Land		756,803			759,295
Furniture, fixtures and equipment		454,288			454,760
Site improvements		206,326			206,206
Construction in progress		183,747			191,326
Total real estate investments		7,581,665			7,566,358
Less accumulated depreciation		(1,306,084	)		(1,240,336	)
Real estate investments - net	$	6,275,581		$	6,326,022

The following table summarizes the significant acquisitions that occurred in the first quarter of 2017:

Number of Facilities				Country/	Total Investment		Land		Building & Site Improvements		Furniture & Fixtures		Initial Annual Cash
SNF		ALF		State	(in millions)								Yield (%)
	-		1	VA	$	7.6	$	0.5	$	6.8	$	0.3		7.50

Asset Sales, Impairments and Other

During the first quarter of 2017, we sold 15 facilities for approximately $45.8 million in net proceeds recognizing a gain of approximately $7.4 million. Eleven of the sold facilities were previously classified as held for sale. In addition, we recorded a provision for impairment of approximately $7.6 million on three facilities, one of which was reclassified to held for sale on March 31, 2017. We reduced the net book value of the impaired facilities to their estimated fair values or, with respect to the facility reclassified to held for sale, to its estimated fair value less costs to sell. To estimate the fair value of the facilities, we utilized a market approach and Level 3 inputs (which generally consist of non-binding offers from unrelated third parties). Also see Note 7 – Assets Held For Sale for details. Our recorded impairments were primarily the result of a decision to exit certain non-strategic facilities and/or operators.

NOTE 3 – DIRECT FINANCING LEASES

The components of investments in direct financing leases consist of the following:

	March 31,			December 31,
	2017			2016
	(in thousands)
Minimum lease payments receivable	$	4,291,940		$	4,287,069
Less unearned income		(3,684,757	)		(3,685,131	)
Less allowance for loss on direct financing lease		(2,406	)		—
Investment in direct financing leases - net	$	604,777		$	601,938
Properties subject to direct financing leases		58			58

25

As of March 31, 2017, the following minimum rents are due under our direct financing leases for the next five fiscal years (in thousands):

2018	2019	2020	2021	2022
$51,319	$52,626	$53,917	$55,199	$56,488

New Ark Investment Inc.

On November 27, 2013, we closed an aggregate $529 million purchase/leaseback transaction in connection with the acquisition of Ark Holding Company, Inc. (“Ark Holding”) by 4 West Holdings Inc. At closing, we acquired 55 SNFs and 1 ALF operated by Ark Holding and leased the facilities back to Ark Holding, now known as New Ark Investment Inc. (“New Ark”), pursuant to four 50-year master leases with rental payments yielding 10.6% per annum over the term of the leases. The purchase/leaseback transaction is being accounted for as a direct financing lease.

The lease agreements allow the tenant the right to purchase the facilities for a bargain purchase price plus closing costs at the end of the lease term. In addition, commencing in the 41st year of each lease, the tenant will have the right to prepay the remainder of its obligations thereunder for an amount equal to the sum of the unamortized portion of the original aggregate $529 million investment plus the net present value of the remaining payments under the lease and closing costs. In the event the tenant exercises either of these options, we have the right to purchase the properties for fair value at the time.

The 56 facilities represent 5,623 licensed beds located in 12 states, predominantly in the southeastern U.S. The 56 facilities are separated by region and divided amongst four cross-defaulted master leases. The four regions include the Southeast (39 facilities), the Northwest (7 facilities), Texas (9 facilities) and Indiana (1 facility).

Additionally, we own four facilities and lease them to New Ark under a master lease which expires in 2026. The four facility lease is being accounted for as an operating lease.

In March 2017, we executed sale agreements with two unrelated third parties to sell the 7 Northwest facilities with a carrying value of approximately $36.4 million for $34.0 million. As a result, we recorded an allowance for loss of approximately $2.4 million. For the three months ended March 31, 2017, we recognized approximately $0.8 million of direct financing lease income on a cash basis related to the Northwest facilities lease. The sale of these facilities is expected to close in the second quarter of 2017.

NOTE 4 – MORTGAGE NOTES RECEIVABLE

As of March 31, 2017, mortgage notes receivable relate to 27 fixed rate mortgages on 49 long-term care facilities. The mortgage notes are secured by first mortgage liens on the borrowers' underlying real estate and personal property. The mortgage notes receivable relate to facilities located in ten states that are operated by eight independent healthcare operating companies. We monitor compliance with mortgages and when necessary have initiated collection, foreclosure and other proceedings with respect to certain outstanding mortgage notes.

Mortgage interest income is recognized as earned over the terms of the related mortgage notes, using the effective yield method. Allowances are provided against earned revenues from mortgage interest when collection of amounts due becomes questionable or when negotiations for restructurings of troubled operators lead to lower expectations regarding ultimate collection. When collection is uncertain, mortgage interest income on impaired mortgage loans is recognized as received after taking into account the application of security deposits.

26

The outstanding principal amounts of mortgage notes receivable, net of allowances, were as follows:

	March 31,			December 31,
	2017			2016
	(in thousands)
Mortgage note due 2024; interest at 9.98%	$	112,500		$	112,500
Mortgage note due 2029; interest at 9.45%		411,807			412,140
Other mortgage notes outstanding (1)		124,323			118,637
Mortgage notes receivable, gross		648,630			643,277
Allowance for loss on mortgage notes receivable		(3,934	)		(3,934	)
Total mortgages — net	$	644,696		$	639,343

⁽¹⁾ Other mortgage notes outstanding have stated interest rates ranging from 8.35% to 12.0% and maturity dates through 2029.

NOTE 5 – OTHER INVESTMENTS

A summary of our other investments is as follows:

	March 31,			December 31,
	2017			2016
	(in thousands)
Other investment note due 2019; interest at 10.73%	$	49,521		$	49,458
Other investment note due 2020; interest at 14.00%		47,856			47,913
Other investment note due 2022, interest at 9.00%		31,987			31,987
Other investment note due 2030; interest at 6.66%		48,705			44,595
Other investment notes outstanding (1)		82,628			87,691
Other investments, gross		260,697			261,644
Allowance for loss on other investments		(4,798	)		(4,798	)
Total other investments	$	255,899		$	256,846

⁽¹⁾ Other investment notes have maturity dates through 2028 and interest rates ranging from 6.50% to 13.0%.

NOTE 6 – INVESTMENT IN UNCONSOLIDATED JOINT VENTURE

On November 1, 2016, we invested approximately $50.0 million for an approximate 15% ownership interest in a joint venture operating as Second Spring Healthcare Investments. The other approximate 85% interest is owned by affiliates of Lindsey Goldberg LLC. We account for the joint venture using the equity method. On November 1, 2016, the joint venture acquired 64 SNFs from Welltower Inc. for approximately $1.1 billion.

We receive asset management fees from the joint venture for services provided. For the three months ended March 31, 2017, we recognized $0.5 million of asset management fees. These fees are included in miscellaneous income in the accompanying Consolidated Statement of Operations. The accounting policies for the unconsolidated joint venture are the same as those of the Company.

27

NOTE 7 – ASSETS HELD FOR SALE

The following is a summary of our assets held for sale:

	Properties Held For Sale
	Number of Properties			Net Book Value (in thousands)
December 31, 2016		20		$	52,868
Properties sold/other (1)		(12	)		(30,023	)
Properties added (2)		1			400
March 31, 2017(3)		9		$	23,245

⁽¹⁾ In the first quarter of 2017, we sold nine SNFs and two ALFs for approximately $29.4 million in net proceeds recognizing a gain on sale of approximately $3.6 million. One SNF classified as an asset held for sale at December 31, 2016 was no longer considered held for sale during the first quarter of 2017 and was reclassified back to leased properties at approximately $5.1 million which represents the facility’s then carrying value adjusted for depreciation that was not recognized while classified as held for sale.

⁽²⁾ In the first quarter of 2017, we recorded a $3.5 million impairment to reduce one ALF’s net book value to its estimated fair value less costs to sell before it was reclassified to assets held for sale.

⁽³⁾ We plan to sell the nine facilities classified as held for sale at March 31, 2017 over the next several quarters.

NOTE 8 – INTANGIBLES

The following is a summary of our intangibles as of March 31, 2017 and December 31, 2016:

	March 31,			December 31,
	2017			2016
	(in thousands)
Assets:
Goodwill	$	643,692		$	643,474
Above market leases	$	22,443		$	22,476
In-place leases		167			167
Accumulated amortization		(16,180	)		(15,864	)
Net intangible assets	$	6,430		$	6,779
Liabilities:
Below market leases	$	164,735		$	165,028
Accumulated amortization		(74,131	)		(70,738	)
Net intangible liabilities	$	90,604		$	94,290

Above market leases and in-place leases, net of accumulated amortization, are included in other assets on our Consolidated Balance Sheets. Below market leases, net of accumulated amortization, are included in accrued expenses and other liabilities on our Consolidated Balance Sheets. The net amortization related to the above and below market leases is included in our Consolidated Statements of Operations as an adjustment to rental income.

For the three months ended March 31, 2017 and 2016, our net amortization related to intangibles was $3.1 million and $4.3 million, respectively. The estimated net amortization related to these intangibles for the remainder of 2017 and the subsequent four years is as follows: remainder of 2017 – $8.9 million; 2018 – $10.5 million; 2019 – $9.5 million; 2020 – $9.3 million and 2021 – $8.7 million. As of March 31, 2017 the weighted average remaining amortization period of above market leases (inclusive of in-place leases) and below market leases is approximately eight years and nine years, respectively.

28

The following is a reconciliation of our goodwill as of March 31, 2017:

	(in thousands)
Balance as of December 31, 2016	$	643,474
Add: foreign currency translation		218
Balance as of March 31, 2017	$	643,692

NOTE 9 – CONCENTRATION OF RISK

As of March 31, 2017, our portfolio of real estate investments consisted of 985 healthcare facilities, located in 42 states and the U.K. and operated by 77 third party operators. Our investment in these facilities, net of impairments and reserve for uncollectible loans, totaled approximately $8.9 billion at March 31, 2017, with approximately 99% of our real estate investments related to long-term care facilities. Our portfolio is made up of 808 SNFs, 101 ALFs, 16 specialty facilities, one medical office building, fixed rate mortgages on 44 SNFs and four ALFs, and 11 facilities that are closed/held-for-sale. At March 31, 2017, we also held other investments of approximately $255.9 million, consisting primarily of secured loans to third-party operators of our facilities.

At March 31, 2017, the three states in which we had our highest concentration of investments were Ohio (10%), Texas (9%) and Florida (9%). No single operator or manager generated more than 10% of our total revenues for the three months ended March 31, 2017.

NOTE 10 – STOCKHOLDERS’/OWNERS’ EQUITY

On April 13, 2017, the Board of Directors declared a common stock dividend of $0.63 per share, increasing the quarterly common dividend by $0.01 per share over the prior quarter, to be paid May 15, 2017 to common stockholders of record as of the close of business on May 1, 2017.

On January 12, 2017, the Board of Directors declared a common stock dividend of $0.62 per share, increasing the quarterly common dividend by $0.01 per share over the previous quarter. The common dividends were paid February 15, 2017 to common stockholders of record as of the close of business on January 31, 2017.

On the same dates listed above, Omega OP Unit holders received the same distributions per unit as those paid to the common stockholders of Omega.

$500 Million Equity Shelf Program

For the three months ended March 31, 2017, we issued 0.2 million shares of common stock at an average price of $29.71 per share, net of issuance costs, generating net proceeds of $6.8 million under our $500 million Equity Shelf Program.

Dividend Reinvestment and Common Stock Purchase Plan

For the three months ended March 31, 2017, approximately 0.2 million shares of our common stock at an average price of $30.67 per share were issued through our Dividend Reinvestment and Common Stock Purchase Program for gross proceeds of approximately $7.3 million.

29

Accumulated Other Comprehensive Loss

The following is a summary of our accumulated other comprehensive loss, net of tax where applicable:

	Omega						OHI Holdco						Omega OP
	As of and For the Three Months Ended March 31,
	2017			2016			2017			2016			2017			2016
	(in thousands)
Foreign Currency Translation:
Beginning balance	$	(54,948	)	$	(8,413	)	$	(54,948	)	$	(8,413	)	$	(54,948	)	$	(8,413	)
Translation gain (loss)		4,273			(4,708	)		4,273			(4,708	)		4,273			(4,708	)
Realized gain (loss)		61			(22	)		61			(22	)		61			(22	)
Ending balance		(50,614	)		(13,143	)		(50,614	)		(13,143	)		(50,614	)		(13,143	)
Cash Flow Hedges:
Beginning balance		(1,420	)		(718	)		(1,420	)		(718	)		(1,420	)		(718	)
Unrealized gain (loss)		490			(8,876	)		490			(8,876	)		490			(8,876	)
Realized gain (loss)		764			-			764			-			764			-
Ending balance		(166	)		(9,594	)		(166	)		(9,594	)		(166	)		(9,594	)
Total accumulated other comprehensive loss		(50,780	)		(22,737	)		(50,780	)		(22,737	)		(50,780	)		(22,737	)
Add: portion included in noncontrolling interest		2,302			1,035			39,527			17,681			-			-
Total accumulated other comprehensive loss	$	(48,478	)	$	(21,702	)	$	(11,253	)	$	(5,056	)	$	(50,780	)	$	(22,737	)

NOTE 11 – TAXES

OHI Holdco is a wholly owned subsidiary of Omega and is a qualified REIT subsidiary for United States federal income tax purposes, and Omega OP is a pass through entity for United States federal income tax purposes.

Since our inception, we have elected to be taxed as a REIT under the applicable provisions of the Internal Revenue Code (“Code”). A REIT is generally not subject to federal income tax on that portion of its REIT taxable income which is distributed to its stockholders, provided that at least 90% of such taxable income is distributed each tax year and certain other requirements are met, including asset and income tests. So long as we qualify as a REIT under the Code, we generally will not be subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions.

If the Company fails to qualify as a REIT in any taxable year, the Company will be subject to federal income taxes on its taxable income at regular corporate rates and dividends paid to our stockholders will not be deductible by us in computing taxable income. Further, we will not be permitted to qualify for treatment as a REIT for federal income tax purposes for four years following the year in which qualification is denied, unless the Internal Revenue Service grants us relief under certain statutory provisions. Failing to qualify as a REIT could materially and adversely affect the Company’s net income; however, we believe we are organized and operate in such a manner as to qualify for treatment as a REIT. We test our compliance within the REIT taxation rules to ensure that we are in compliance with the REIT rules on a quarterly and annual basis. We review our distributions and projected distributions each year to ensure we have met and will continue to meet the annual REIT distribution requirements. In 2017, we expect to distribute dividends in excess of our taxable income.

30

As a result of our UPREIT Conversion, our Company and its subsidiaries may be subject to income or franchise taxes in certain states and municipalities. Also, as a result of our UPREIT Conversion, we created five wholly owned subsidiary REITs and added a sixth wholly owned subsidiary REIT as of January 1, 2016, all of which are subject to all of the REIT qualification rules set forth in the Code. We merged five of the wholly owned subsidiary REITs into a single wholly owned subsidiary REIT in December 2015, and then merged the sixth wholly owned subsidiary REIT into our other wholly owned subsidiary REIT in December 2016, which wholly owned subsidiary REIT remains subject to all of the REIT qualification rules set forth in the Code.

Subject to the limitation under the REIT asset test rules, we are permitted to own up to 100% of the stock of one or more taxable REIT subsidiaries (“TRSs”). We have elected for two of our active subsidiaries to be treated as TRSs. One of our TRSs is subject to federal, state and local income taxes at the applicable corporate rates and the other is subject to foreign income taxes. As of March 31, 2017, our TRS that is subject to federal, state and local income taxes at the applicable corporate rates had a net operating loss carry-forward of approximately $0.8 million. The loss carry-forward is fully reserved as of March 31, 2017, with a valuation allowance due to uncertainties regarding realization.

During the first quarter of 2017, we recorded approximately $1.0 million of state and local income tax provision and approximately $0.1 million of tax provision for foreign income taxes included in provision for income taxes on our Consolidated Statement of Operations.

NOTE 12 – STOCK-BASED COMPENSATION

Stock-based compensation expense was $3.7 million and $2.8 million for the three months ended March 31, 2017 and 2016, respectively:

Restricted Stock and Restricted Stock Units

Restricted stock and restricted stock units (“RSUs”) are subject to forfeiture if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change in control of the Company. Prior to vesting, ownership of the shares/units cannot be transferred. Restricted stock has the same dividend and voting rights as our common stock. RSUs accrue dividend equivalents but have no voting rights. Restricted stock and RSUs are valued at the price of our common stock on the date of grant. We expense the cost of these awards ratably over their vesting period. We awarded 140,416 RSUs to employees on January 1, 2017.

Performance Restricted Stock Units and LTIP Units

Performance restricted stock units (“PRSUs”) and long term incentive plan units (“LTIP Units”) are subject to forfeiture if the performance requirements are not achieved or if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change in control of the Company. The PRSUs and the LTIP Units have varying degrees of performance requirements to be earned and vested, and each PRSU and LTIP Units award represents the right to a variable number of shares of common stock or partnership units. Each LTIP Unit once earned and vested is convertible into one Omega OP Unit in Omega OP, subject to certain conditions. The earning requirements are based on either the (i) total shareholder return (“TSR”) of Omega or (ii) Omega’s TSR relative to other real estate investment trusts in the MSCI U.S. REIT Index or FTSE NAREIT Equity Health Care Index TSR (both “Relative TSR”). Vesting in general requires that the employee remain employed by us until the date specified in the applicable PRSU or LTIP agreement, which may be later than the date that the TSR or Relative TSR requirements are satisfied. We expense the cost of these awards ratably over their service period.

31

Prior to vesting and the distribution of shares, ownership of the PRSUs cannot be transferred. Dividend equivalents on the PRSUs accumulate and with respect to PRSUs granted before 2015 are paid when the PRSUs vest and with respect to PRSUs granted in 2015 or later are paid once the PRSUs are earned. While each LTIP Unit is unearned, the employee receives a partnership distribution equal to 10% of the quarterly approved regular periodic distributions per Omega OP Unit. The remaining partnership distributions (which in the case of normal periodic distributions is equal to the total approved quarterly dividend on Omega’s common stock) on the LTIP Units accumulate, and if the LTIP Units are earned, the accumulated distributions are paid.

The number of shares or units earned under the TSR PRSUs or LTIP Units depends generally on the level of achievement of Omega’s TSR over the indicated performance period. We awarded 399,726 LTIP Units to employees on January 1, 2017.

The number of shares earned under the Relative TSR PRSUs depends generally on the level of achievement of Omega’s TSR relative to other real estate investment trusts in the MSCI U.S. REIT Index or FTSE NAREIT Equity Health Care Index TSR over the performance period indicated. We awarded 285,338 Relative TSR PRSUs to employees on January 1, 2017.

32

The following table summarizes our total unrecognized compensation cost as of March 31, 2017 associated with restricted stock, restricted stock units, PRSU awards, and LTIP Unit awards to employees:

	Grant Year		Shares/ Units		Grant Date Average Fair Value Per Unit/ Share		Total Compensation Cost (in millions) (1)		Weighted Average Period of Expense Recognition (in months)		Unrecognized Compensation Cost (in millions)		Performance Period	Vesting Dates
RSUs
3/31/15 RSU		2015		109,985	$	40.57	$	4.5		33	$	1.2	N/A	12/31/2017
4/1/15 RSU		2015		40,464		40.74		1.6		33		0.5	N/A	12/31/2017
Assumed Aviv RSU		2015		7,799		35.08		0.3		33		0.1	N/A	11/1/2017
3/17/16  RSU		2016		130,006		34.78		4.6		33		2.8	N/A	12/31/2018
1/1/2017  RSU		2017		140,416		31.26		4.3		36		4.0	N/A	12/31/2019
Restricted Stock Units Total				428,670	$	35.68	$	15.3			$	8.6
TSR PRSUs and LTIP Units
2016 TSR		2014		135,634	$	8.67	$	1.2		48	$	0.2	1/1/2014-12/31/2016	Quarterly in 2017
3/31/15 2017 LTIP Units		2015		137,249		14.66		2.0		45		0.9	1/1/2015-12/31/2017	Quarterly in 2018
4/1/2015 2017 LTIP Units		2015		54,151		14.80		0.8		45		0.4	1/1/2015-12/31/2017	Quarterly in 2018
3/17/2016 2018 LTIP Units		2016		372,069		13.21		4.9		45		3.6	1/1/2016-12/31/2018	Quarterly in 2019
1/1/2017 2019 LTIP Units		2017		399,726		12.61		5.0		48		4.7	1/1/2017-12/31/2019	Quarterly in 2020
TSR PRSUs & LTIP Total				1,098,829	$	12.69	$	13.9			$	9.8
Relative TSR PRSUs
2016 Relative TSR		2014		135,634	$	14.24	$	1.9		48	$	0.4	1/1/2014-12/31/2016	Quarterly in 2017
3/31/15 2017 Relative TSR		2015		137,249		22.50		3.1		45		1.4	1/1/2015-12/31/2017	Quarterly in 2018
4/1/2015 2017 Relative TSR		2015		54,151		22.91		1.2		45		0.6	1/1/2015-12/31/2017	Quarterly in 2018
3/17/2016 2018 Relative TSR		2016		307,480		16.45		5.1		45		3.7	1/1/2016-12/31/2018	Quarterly in 2019
1/1/2017 2019 Relative TSR		2017		285,338		18.04		5.1		48		4.8	1/1/2017-12/31/2019	Quarterly in 2020
Relative TSR PRSUs Total				919,852	$	17.78	$	16.4			$	10.9
Grand Total				2,447,351	$	18.63	$	45.6			$	29.3

(1) Total compensation costs are net of shares cancelled.

Director Restricted Stock Grants

As of March 31, 2017, we had 51,999 shares of restricted stock outstanding to directors. The directors’ restricted shares are scheduled to vest over the next three years. As of March 31, 2017, the unrecognized compensation cost associated with outstanding director restricted stock grants is approximately $1.1 million.

33

NOTE 13 – BORROWING ACTIVITIES AND ARRANGEMENTS

Secured and Unsecured Borrowings

The following is a summary of our borrowings:

		Annual Interest Rate as of March 31,			March 31,			December 31,
	Maturity	2017			2017			2016
					(in thousands)
Secured borrowings:
HUD mortgages assumed December 2011(1)	2044		3.06	%	$	54,636		$	54,954
Deferred financing costs – net						(584	)		(589	)
Total secured borrowings – net (2)						54,052			54,365
Unsecured borrowings:
Revolving line of credit	2018		2.25	%		123,000			190,000
Tranche A-1 term loan	2019		2.48	%		200,000			200,000
Tranche A-2 term loan	2017		2.44	%		200,000			200,000
Tranche A-3 term loan	2021		2.48	%		350,000			350,000
Omega OP term loan (2)	2017		2.44	%		100,000			100,000
2015 term loan	2022		3.80	%		250,000			250,000
Deferred financing costs – net						(5,125	)		(5,657	)
Total term loans – net						1,094,875			1,094,343
2023 notes	2023		4.375	%		700,000			700,000
2024 notes	2024		5.875	%		400,000			400,000
2024 notes	2024		4.95	%		400,000			400,000
2025 notes	2025		4.50	%		250,000			250,000
2026 notes	2026		5.25	%		600,000			600,000
2027 notes	2027		4.50	%		700,000			700,000
Other	2018		-			3,000			3,000
Subordinated debt	2021		9.00	%		20,000			20,000
Discount - net						(16,669	)		(17,151	)
Deferred financing costs – net						(27,393	)		(27,703	)
Total unsecured borrowings – net						3,028,938			3,028,146
Total secured and unsecured borrowings – net					$	4,300,865		$	4,366,854

⁽¹⁾ Reflects the weighted average annual contractual interest rate on the mortgages at March 31, 2017 excluding a third-party administration fee of approximately 0.5% annually. Secured by real estate assets with a net carrying value of $64.8 million as of March 31, 2017.

⁽²⁾ These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

Certain of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of March 31, 2017 and December 31, 2016, we were in compliance with all affirmative and negative covenants, including financial covenants, for our secured and unsecured borrowings. OHI Holdco and Omega OP, the guarantors of Parent’s outstanding senior notes as of May 25, 2017, do not directly own any substantive assets other than OHI Holdco’s interest in Omega OP and Omega OP’s interest in non-guarantor subsidiaries.

See Note 17 – Subsequent Events for additional details regarding new borrowings, the redemption of the $400 million 5.875% Senior Notes due 2024 and the prepayment of the $200 million senior unsecured incremental term loan facility (the “Tranche A-2 Term Loan Facility”) due 2017.

34

NOTE 14 – FINANCIAL INSTRUMENTS

The carrying amount of cash and cash equivalents, restricted cash and accounts receivable reported in the Consolidated Balance Sheets approximates fair value because of the short maturity of these instruments (i.e., less than 90 days) (Level 1).

At March 31, 2017 and December 31, 2016, the carrying amounts and fair values of our other financial instruments were as follows:

	March 31, 2017					December 31, 2016
	Carrying Amount			Fair Value		Carrying Amount		Fair Value
	(in thousands)
Assets:
Investments in direct financing leases – net	$	604,777		$	601,522	$	601,938	$	598,665
Mortgage notes receivable – net		644,696			652,487		639,343		644,961
Other investments – net		255,899			248,959		256,846		253,385
Total	$	1,505,372		$	1,502,968	$	1,498,127	$	1,497,011
Liabilities:
Revolving line of credit	$	123,000		$	123,000	$	190,000	$	190,000
Tranche A-1 term loan		199,124			200,000		198,830		200,000
Tranche A-2 term loan		200,000			200,000		200,000		200,000
Tranche A-3 term loan		347,605			350,000		347,449		350,000
Omega OP term loan (1)		100,000			100,000		100,000		100,000
2015 term loan		248,145			250,000		248,064		250,000
4.375% notes due 2023 – net		692,598			710,967		692,305		693,505
5.875% notes due 2024 – net		395,236			434,814		395,065		432,938
4.95% notes due 2024 – net		392,922			413,512		392,669		406,361
4.50% notes due 2025 – net		245,953			250,500		245,949		249,075
5.25% notes due 2026 – net		593,792			627,443		593,616		611,461
4.50% notes due 2027 – net		685,418			696,683		685,052		681,978
4.75% notes due 2028 – net		(440	)		—		—		—
HUD debt – net (1)		54,052			52,771		54,365		52,510
Subordinated debt – net		20,460			23,909		20,490		23,944
Other		3,000			3,000		3,000		3,000
Total	$	4,300,865		$	4,436,599	$	4,366,854	$	4,444,772

(1) The amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

Fair value estimates are subjective in nature and are dependent on a number of important assumptions, including estimates of future cash flows, risks, discount rates and relevant comparable market information associated with each financial instrument (see Note 2 – Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2016, as amended). The use of different market assumptions and estimation methodologies may have a material effect on the reported estimated fair value amounts.

The following methods and assumptions were used in estimating fair value disclosures for financial instruments.

· Direct financing leases: The fair value of the investments in direct financing leases are estimated using a discounted cash flow analysis, using interest rates being offered for similar leases to borrowers with similar credit ratings (Level 3).

35

· Mortgage notes receivable: The fair value of the mortgage notes receivables are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3).

· Other investments: Other investments are primarily comprised of notes receivable. The fair values of notes receivable are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3).

· Revolving line of credit and term loans: The fair value of our borrowings under variable rate agreements are estimated using a present value technique based on expected cash flows discounted using the current market rates (Level 3).

· Senior notes and subordinated debt: The fair value of our borrowings under fixed rate agreements are estimated using a present value technique based on inputs from trading activity provided by a third party (Level 2).

· HUD debt: The fair value of our borrowings under HUD debt agreements are estimated using an expected present value technique based on quotes obtained by HUD debt brokers (Level 2).

NOTE 15 – LITIGATION

We are subject to various legal proceedings, claims and other actions arising out of the normal course of business. While any legal proceeding or claim has an element of uncertainty, management believes that the outcome of each lawsuit, claim or legal proceeding that is pending or threatened, or all of them combined, will not have a material adverse effect on our consolidated financial position or results of operations.

NOTE 16 – EARNINGS PER SHARE/UNIT

The computation of basic earnings per share/unit (“EPS” or “EPU”) is computed by dividing net income available to common stockholders/Omega OP Units holders by the weighted-average number of shares of common stock/units outstanding during the relevant period. Diluted EPS/EPU is computed using the treasury stock method, which is net income divided by the total weighted-average number of common outstanding shares/Omega OP Units plus the effect of dilutive common equivalent shares/Omega OP Units during the respective period. Dilutive common shares reflect the assumed issuance of additional common shares/Omega OP Units pursuant to certain of our share-based compensation plans, including stock options, restricted stock and performance restricted stock units and the assumed issuance of additional shares related to Omega OP Units held by outside investors. Dilutive Omega OP Units reflect the assumed issuance of additional Omega OP Units pursuant to certain of our share-based compensation plans, including stock options, restricted stock and performance restricted stock. No per share information was provided for OHI Holdco because the sole stockholder is Omega. OHI Holdco is a wholly owned subsidiary of Omega and has 1,000 shares of $0.01 par value per share common stock outstanding.

36

The following tables set forth the computation of basic and diluted earnings per share/unit:

	Omega						Omega OP
	Three Months Ended March 31,
	2017			2016			2017		2016
	(in thousands, except per share amounts)
Numerator:
Net income	$	109,112		$	58,196		$	109,112	$	58,196
Less: net income attributable to noncontrolling interests		(4,672	)		(2,641	)		—		—
Net income available to common stockholders/Omega OP Unit holders	$	104,440		$	55,555		$	109,112	$	58,196
Denominator:
Denominator for basic earnings per share/unit		197,013			188,228			205,827		197,175
Effect of dilutive securities:
Common stock equivalents/units		347			1,175			347		1,175
Noncontrolling interest – Omega OP Units		8,814			8,947			—		—
Denominator for diluted earnings per share/unit		206,174			198,350			206,174		198,350
Earnings per share - basic:
Net income available to common stockholders/Omega OP Unit holders	$	0.53		$	0.30		$	0.53	$	0.30
Earnings per share/unit – diluted:
Net income	$	0.53		$	0.29		$	0.53	$	0.29

37

NOTE 17 – SUBSEQUENT EVENTS

2017 Omega Credit Facilities

On May 25, 2017, we entered into a credit agreement (the “2017 Omega Credit Agreement”) providing us with a new $1.8 billion senior unsecured revolving and term loan credit facility, consisting of a $1.25 billion senior unsecured multicurrency revolving credit facility (the “2017 Revolving Credit Facility”), a $425 million senior unsecured U.S. Dollar term loan facility (the “2017 U.S. Term Loan Facility”), and a £100 million senior unsecured British Pound Sterling term loan facility (the “2017 Sterling Term Loan Facility” and, together with the 2017 Revolving Credit Facility and the 2017 U.S. Term Loan Facility, collectively, the “2017 Omega Credit Facilities”). The 2017 Omega Credit Agreement contains an accordion feature permitting us, subject to compliance with customary conditions, to increase the maximum aggregate commitments under the 2017 Omega Credit Facilities to $2.5 billion.

The 2017 Omega Credit Facilities replace the previous $1.25 billion senior unsecured 2014 revolving credit facility, the previous $200 million Tranche A-1 senior unsecured term loan facility, and the previous $350 million Tranche A-3 senior unsecured incremental term loan facility established under our 2014 credit agreement, which has been terminated (the “2014 Omega Credit Agreement”).

The 2017 Revolving Credit Facility bears interest at LIBOR plus an applicable percentage (with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2017 Revolving Credit Facility matures on May 25, 2021, subject to an option by us to extend such maturity date for two, six month periods. The 2017 Omega Credit Agreement provides for the 2017 Revolving Credit Facility to be drawn in Euros, British Pounds Sterling, Canadian Dollars (collectively, “Alternative Currencies”) or U.S. Dollars, with a $900 million tranche available in U.S. Dollars and a $350 million tranche available in U.S. Dollars or Alternative Currencies. For purposes of the 2017 Omega Credit Facilities, references to LIBOR include the Canadian dealer offered rates for amounts offered in Canadian Dollars and any other Alternative Currency rate approved in accordance with the terms of the 2017 Omega Credit Agreement for amounts offered in any other non-London interbank offered rate quoted currency, as applicable.

The 2017 U.S. Term Loan Facility and the 2017 Sterling Term Loan Facility bear interest at LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2017 U.S. Term Loan Facility and the 2017 Sterling Term Loan Facility each mature on May 25, 2022.

In April 2017, we repaid and terminated the $200 million Tranche A-2 senior unsecured term loan facility established under the 2014 Omega Credit Agreement.

For the three month period ending June 30, 2017, we recorded a one-time, non-cash charge of approximately $5.5 million relating to the write-off of deferred financing costs associated with the termination of the 2014 Omega Credit Facilities.

2017 Omega OP Term Loan Facility

On May 25, 2017, Omega OP entered into a credit agreement (the “2017 Omega OP Credit Agreement”) providing it with a new $100 million senior unsecured term loan facility (the “2017 Omega OP Term Loan Facility”). The 2017 Omega OP Credit Agreement replaces the $100 million senior unsecured term loan facility obtained in 2015 (the “2015 Omega OP Term Loan Facility”) and the related credit agreement (the “2015 Omega OP Credit Agreement”). The 2017 Omega OP Term Loan Facility bears interest at LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2017 Omega OP Term Loan Facility matures on May 25, 2022.

38

Omega OP’s obligations in connection with the 2017 Omega OP Term Loan Facility are not currently guaranteed, but will be jointly and severally guaranteed by any domestic subsidiary of Omega OP that provides a guaranty of any unsecured indebtedness of Omega or Omega OP for borrowed money evidenced by bonds, debentures, notes or other similar instruments in an amount of at least $50 million individually or in the aggregate.

$550 Million 4.75% Senior Notes and $150 Million 4.5% Senior Notes

On April 4, 2017, we issued (i) $550 million aggregate principal amount of our 4.75% Senior Notes due 2028 (the “2028 Notes”) and (ii) an additional $150 million aggregate principal amount of our existing 4.50% Senior Notes due 2025 (the “2025 Notes”, and together with the 2028 Notes collectively, the “Notes”). The 2028 Notes mature on January 15, 2028 and the 2025 Notes mature on January 15, 2025.

The 2028 Notes were sold at an issue price of 98.978% of their face value before the underwriters’ discount and the 2025 Notes were sold at an issue price of 99.540% of their face value before the underwriters’ discount. Our net proceeds from the Notes offering, after deducting underwriting discounts and expenses, were approximately $690.7 million. The net proceeds from the Notes offering were used to (i) redeem all of our outstanding $400 million aggregate principal amount of 5.875% Senior Notes due 2024 (the “5.875% Notes”) on April 28, 2017, (ii) prepay the $200 million Tranche A-2 Term Loan Facility on April 5, 2017 that otherwise would have become due on June 27, 2017, and (iii) repay outstanding borrowings under our revolving credit facility.

$400 Million 5.875% Senior Notes Redemption

On April 28, 2017, we redeemed all of our outstanding 5.875% Notes. As a result of the redemption, during the second quarter of 2017, we recorded approximately $16.5 million in redemption related costs and write-offs, including $11.8 million for the call premium and $4.7 million in net write-offs associated with unamortized deferred financing costs.

39

Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements, Reimbursement Issues and Other Factors Affecting Future Results

The following discussion should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this document, including statements regarding potential future changes in reimbursement. This document contains forward-looking statements within the meaning of the federal securities laws. These statements relate to our expectations, beliefs, intentions, plans, objectives, goals, strategies, future events, performance and underlying assumptions and other statements other than statements of historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology including, but not limited to, terms such as “may,” “will,” “anticipates,” “expects,” “believes,” “intends,” “should” or comparable terms or the negative thereof. These statements are based on information available on the date of this filing and only speak as to the date hereof and no obligation to update such forward-looking statements should be assumed. Our actual results may differ materially from those reflected in the forward-looking statements contained herein as a result of a variety of factors, including, among other things:

(i) those items discussed under “Risk Factors” in Part I, Item 1A to our annual report on Form 10-K for the year ended December 31, 2016, as amended and in Part II, Item 1A of this report, as amended (if any);

(ii) uncertainties relating to the business operations of the operators of our assets, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels;

(iii) the ability of any operators in bankruptcy to reject unexpired lease obligations, modify the terms of our mortgages and impede our ability to collect unpaid rent or interest during the process of a bankruptcy proceeding and retain security deposits for the debtors’ obligations;

(iv) our ability to sell closed or foreclosed assets on a timely basis and on terms that allow us to realize the carrying value of these assets;

(v) our ability to manage, re-lease or sell any owned and operated facilities;

(vi) the availability and cost of capital to us;

(vii) changes in our credit ratings and the ratings of our debt securities;

(viii) competition in the financing of healthcare facilities;

(ix) regulatory and other changes in the healthcare sector;

(x) changes in the financial position of our operators;

(xi) the effect of economic and market conditions generally and, particularly, in the healthcare industry;

(xii) changes in interest rates;

(xiii) the amount and yield of any additional investments;

(xiv) changes in tax laws and regulations affecting real estate investment trusts (“REITs”);

(xv) the potential impact of changes in the skilled nursing facility (“SNF”) and assisted living facility (“ALF”) market or local real estate conditions on our ability to dispose of assets held for sale for the anticipated proceeds or on a timely basis, or to redeploy the proceeds therefrom on favorable terms; and

(xvi) our ability to maintain our status as a real estate investment trust.

Overview

Omega Healthcare Investors, Inc. (“Omega”) was formed as a real estate investment trust (“REIT”) and incorporated in the State of Maryland on March 31, 1992. All of Omega's assets are owned directly or indirectly, and all of Omega's operations are conducted directly or indirectly, through its subsidiaries, OHI Healthcare Properties Holdco, Inc. (“OHI Holdco”), a direct wholly owned subsidiary of Omega, and OHI Healthcare Properties Limited Partnership (“Omega OP”). OHI Holdco was formed as a corporation and incorporated in the State of Delaware on October 22, 2014. Omega OP was formed as a limited partnership and organized in the State of Delaware on October 24, 2014. No substantive assets or activity occurred in either of these entities until the merger with Aviv REIT, Inc. on April 1, 2015. Unless stated otherwise or the context otherwise requires, the terms the “Company,” “we,” “our” and “us” means Omega, OHI Holdco and Omega OP, collectively.

40

The Company has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Our core business is to provide financing and capital to the long-term healthcare industry with a particular focus on SNFs and, to a lesser extent, ALFs, independent living facilities and rehabilitation and acute care facilities. Our core portfolio consists of long-term leases and mortgage agreements. All of our leases are “triple-net” leases, which require the tenants to pay all property-related expenses. Our mortgage revenue derives from fixed rate mortgage loans, which are secured by first mortgage liens on the underlying real estate and personal property of the mortgagor.

In April 2015, Aviv REIT Inc., a Maryland corporation (“Aviv”), merged (the “Aviv Merger”) with and into a wholly owned subsidiary of Omega, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of October 30, 2014 (the “Merger Agreement”), by and among Omega, Aviv, OHI Holdco, Omega OP and Aviv Healthcare Properties Limited Partnership, a Delaware limited partnership (the “Aviv OP”).

Prior to April 1, 2015 and in accordance with the Merger Agreement, Omega restructured the manner in which it holds its assets by converting to an umbrella partnership real estate investment trust structure (the “UPREIT Conversion”). As a result of the UPREIT Conversion and following the consummation of the Aviv Merger, all of Omega’s assets are held by Omega OP, through its equity interests in its subsidiaries.

Omega OP is governed by the Second Amended and Restated Agreement of Limited Partnership of OHI Healthcare Properties Limited Partnership, dated as of April 1, 2015 (the “Partnership Agreement”). Pursuant to the Partnership Agreement, Omega and OHI Holdco are the general partners of Omega OP, and have exclusive control over Omega OP’s day-to-day management. As of March 31, 2017, Omega and OHI Holdco together owned approximately 96% of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and investors owned approximately 4% of the Omega OP Units.

Our portfolio of real estate investments at March 31, 2017, consisted of 985 healthcare facilities, located in 42 states and the United Kingdom and operated by 77 third party operators. Our gross investment in these facilities, net of impairments and before reserve for uncollectible loans, totaled approximately $8.9 billion at March 31, 2017, with approximately 99% of our real estate investments related to long-term care facilities. Our portfolio is made up of: (i) 808 SNFs, (ii) 101 ALFs, (iii) 16 specialty facilities, (iv) one medical office building, (v) fixed rate mortgages on 44 SNFs and four ALFs and (vi) 11 facilities that are closed/held-for-sale. At March 31, 2017, we also held miscellaneous investments of approximately $255.9 million, consisting primarily of secured loans to third-party operators of our facilities.

As of March 31, 2017 and December 31, 2016 we do not have any material properties or operators with facilities that are not materially occupied.

Our consolidated financial statements include the accounts of (i) Omega, (ii) OHI Holdco, (iii) Omega OP, and (iv) all direct and indirect wholly owned subsidiaries of Omega. All intercompany transactions and balances have been eliminated in consolidation, and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.

Taxation

OHI Holdco is a wholly owned subsidiary of Omega and is a qualified REIT subsidiary for United States federal income tax purposes, and Omega OP is a pass through entity for United States federal income tax purposes.

Since our inception, we have elected to be taxed as a REIT under the applicable provisions of the Internal Revenue Code (“Code”). A REIT is generally not subject to federal income tax on that portion of its REIT taxable income which is distributed to its stockholders, provided that at least 90% of such taxable income is distributed each tax year and certain other requirements are met, including asset and income tests. So long as we qualify as a REIT under the Code, we generally will not be subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions.

41

If the Company fails to qualify as a REIT in any taxable year, the Company will be subject to federal income taxes on its taxable income at regular corporate rates and dividends paid to our stockholders will not be deductible by us in computing taxable income. Further, we will not be permitted to qualify for treatment as a REIT for federal income tax purposes for four years following the year in which qualification is denied, unless the Internal Revenue Service grants us relief under certain statutory provisions. Failing to qualify as a REIT could materially and adversely affect the Company’s net income; however, we believe we are organized and operate in such a manner as to qualify for treatment as a REIT. We test our compliance within the REIT taxation rules to ensure that we are in compliance with the REIT rules on a quarterly and annual basis. We review our distributions and projected distributions each year to ensure we have met and will continue to meet the annual REIT distribution requirements. In 2017, we expect to distribute dividends in excess of our taxable income.

As a result of our UPREIT Conversion, our Company and its subsidiaries may be subject to income or franchise taxes in certain states and municipalities. Also, as a result of our UPREIT Conversion, we created five wholly owned subsidiary REITs and added a sixth wholly owned subsidiary REIT as of January 1, 2016, all of which are subject to all of the REIT qualification rules set forth in the Code. We merged five of the wholly owned subsidiary REITs into a single wholly owned subsidiary REIT in December 2015, and then merged the sixth wholly owned subsidiary REIT into our other wholly owned subsidiary REIT in December 2016, which wholly owned subsidiary REIT remains subject to all of the REIT qualification rules set forth in the Code.

Subject to the limitation under the REIT asset test rules, we are permitted to own up to 100% of the stock of one or more taxable REIT subsidiaries (“TRSs”). We have elected for two of our active subsidiaries to be treated as TRSs. One of our TRSs is subject to federal, state and local income taxes at the applicable corporate rates and the other is subject to foreign income taxes. As of March 31, 2017, our TRS that is subject to federal, state and local income taxes at the applicable corporate rates had a net operating loss carry-forward of approximately $0.8 million. The loss carry-forward is fully reserved as of March 31, 2017, with a valuation allowance due to uncertainties regarding realization.

During the first quarter of 2017, we recorded approximately $1.0 million of state and local income tax provision and approximately $0.1 million of tax provision for foreign income taxes included in provision for income taxes on our Consolidated Statement of Operations.

Government Regulation and Reimbursement

The healthcare industry is heavily regulated. Our operators are subject to extensive and complex federal, state and local healthcare laws and regulations. These laws and regulations are subject to frequent and substantial changes resulting from the adoption of new legislation, rules and regulations, and administrative and judicial interpretations of existing law. The ultimate timing or effect of these changes, which may be applied retroactively, cannot be predicted. Changes in laws and regulations impacting our operators, in addition to regulatory non-compliance by our operators, can have a significant effect on the operations and financial condition of our operators, which in turn may adversely impact us. The following is a discussion of certain laws and regulations generally applicable to our operators, and in certain cases, to us.

Healthcare Reform. A substantial amount of rules and regulations have been issued under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education and Reconciliation Act of 2010 (collectively referred to as the “Healthcare Reform Law”). We expect additional rules, regulations and interpretations under the Healthcare Reform Law to be issued that may materially affect our operators’ financial condition and operations. For example, the new administration and certain members of Congress have affirmatively indicated that they will pursue repeal of, or significant amendment to, the Healthcare Reform Law. Even if the Healthcare Reform Law is not amended or repealed, the new administration could propose changes impacting implementation of the Healthcare Reform Law. The ultimate composition and timing of any legislation enacted under the new administration that would impact the current implementation of the Healthcare Reform Law remains uncertain. Given the complexity of the Healthcare Reform Law and the substantial requirements for regulation thereunder, the impact of the Healthcare Reform Law on our operators or their ability to meet their obligations to us cannot be predicted, whether in its current form or as amended or repealed.

42

Reform Requirements for Long-Term Care Facilities. On October 4, 2016, the Centers for Medicare and Medicaid Services (“CMS”) issued a final rule modifying the conditions of participation in Medicare and Medicaid for SNFs. CMS stated that the regulations, last updated in 1991, were “necessary to reflect the substantial advances that had been made over the past several years in the theory and practice of service delivery and safety” within long-term care. The extensive modifications require SNFs to implement new processes; make changes to current practices; and create new policies and procedures within a short timeframe to remain in compliance with their conditions for participation. Changes include provisions related to staff training, discharge planning, infection prevention and control programs, and pharmacy services, among others. While many of the regulations become effective on November 28, 2016, some of the regulations become effective in Phase 2, beginning on November 28, 2017, with others becoming effective in Phase 3, beginning on November 28, 2019. According to CMS, it is estimated that the average cost for a SNF to implement the new regulations is estimated to be $62,900 the first year and $55,000 each year thereafter.

Reimbursement Generally. A significant portion of our operators’ revenue is derived from government-funded reimbursement programs, consisting primarily of Medicare and Medicaid. As federal and state governments continue to focus on healthcare reform initiatives, and as the federal government and many states face significant current and future budget deficits, efforts to reduce costs by government payors will likely continue, which may result in reductions in reimbursement at both the federal and state levels. Additionally, new and evolving payor and provider programs, including but not limited to Medicare Advantage, dual eligible, accountable care organizations, and bundled payments could adversely impact our tenants’ and operators’ liquidity, financial condition or results of operations.

We currently believe that our operator coverage ratios are adequate and that our operators can absorb moderate reimbursement rate reductions and still meet their obligations to us. However, significant limits on the scope of services reimbursed and/or reductions of reimbursement rates could have a material adverse effect on our operators’ results of operations and financial condition, which could adversely affect our operators’ ability to meet their obligations to us.

Medicaid. State budgetary concerns, coupled with the implementation of rules under the Healthcare Reform Law, or prospective changes to the Healthcare Reform Law under the new administration, may result in significant changes in healthcare spending at the state level. Many states are currently focusing on the reduction of expenditures under their state Medicaid programs, which may result in a reduction in reimbursement rates for our operators. The need to control Medicaid expenditures by the states may be exacerbated by the potential for increased enrollment in Medicaid due to unemployment and declines in family incomes. Since our operators’ profit margins on Medicaid patients are generally relatively low, more than modest reductions in Medicaid reimbursement or an increase in the number of Medicaid patients could adversely affect our operators’ results of operations and financial condition, which in turn could negatively impact us.

The Healthcare Reform Law provided for Medicaid coverage to be expanded to all individuals under age 65 with incomes up to 133% of the federal poverty level, beginning January 1, 2014. While the federal government committed to paying the entire cost for Medicaid coverage for newly eligible beneficiaries from 2014 through 2016, the federal share declines to 95% in 2017, 94% in 2018, 93% in 2019, and 90% in 2020 and subsequent years. Although the Supreme Court ruled on June 28, 2012 that states could not be required to expand Medicaid or risk losing federal funding of their existing Medicaid programs, as of March 31, 2017, thirty-one (31) states and the District of Columbia have expanded Medicaid eligibility with additional states continuing to consider expansion.

Medicare. On July 29, 2016, CMS issued a final rule regarding the fiscal year (“FY”) 2017 Medicare payment rates and quality programs for SNFs, which continues the trend of shifting Medicare payments from volume to value. Aggregate payments to SNFs effective October 1, 2016 for FY 2017 were expected to increase by $920 million, or 2.4%, over FY 2016 payments. This reimbursement increase is attributable to a 2.7% market basket increase, reduced by 0.3% in accordance with the multifactor productivity adjustment required by law.

43

In addition to FY 2017 Medicare payment rates, SNFs continue to be impacted by the “Bipartisan Budget Act of 2015” (“BBA”) signed on November 2, 2015 which provided $80 billion in discretionary spending sequestration relief over two years, and extended Medicare sequestration, which generally cuts Medicare provider and plan payments by 2% across the board, for an additional year, through 2025. The FY 2025 sequestration will be “front loaded,” such that a 4% reduction will apply during the first six months of the fiscal year and no reduction will be imposed during the second half of the fiscal year.

Furthermore, the “Medicare Access and CHIP Reauthorization Act of 2015” continues to have the potential to negatively impact Medicare revenues through the extension of the Medicare therapy cap exceptions process through December 31, 2017; modification of the requirement for manual medical review for services over the $3,700 therapy thresholds; and extension of the application of therapy caps, and related provisions, to outpatient hospitals until January 1, 2018. The statutory Medicare Part B outpatient cap for occupational therapy is $1,980 for 2017, with the combined cap for physical therapy and speech therapy also set at $1,980 for 2017. While the caps do not apply to therapy services covered under Medicare Part A for SNFs and the exception process permits medically necessary therapy services beyond the cap limits, the caps apply in most other circumstances involving patients in SNFs or long-term care facilities who receive therapy services covered under Medicare Part B. Expiration of the therapy cap exceptions process in the future could have a material adverse effect on our operators’ financial condition and operations, which could adversely impact their ability to meet their obligations to us.

As indicated above, reimbursement methodology reforms, such as value-based purchasing, continue to be increasingly prevalent and attempt to hold providers accountable for the cost and quality of care provided by redistributing a portion of a provider or facility’s reimbursement based on the relative performance on designated economic, clinical quality, and patient satisfaction metrics. These reimbursement methodologies and similar programs are expected to expand, both in public and commercial health plans.

For example, the “Protecting Access to Medicare Act of 2014” called for the U.S. Department of Health and Human Services (“HHS”) to develop a value based purchasing program for SNFs aimed at tying a reimbursement adjustment to lower readmission rates effective October 1, 2018, and on April 26, 2015, CMS announced its goal to have 30% of Medicare payments for quality and value through alternative payment models such as accountable care organizations or bundled payments by the end of 2016 and up to 50% by the end of 2018. In March 2016, CMS announced that its 30% target for 2016 had already been reached.

Additionally, CMS’s bundled payment program for Lower Extremity Joint Replacement (“CJR”) procedures went into effect on April 1, 2016, and is mandatory for all hospitals paid under the Medicare Inpatient Prospective Payment System that are located in the 67 selected metropolitan statistical areas. Through this bundled payment model, hospitals in the 67 selected metropolitan areas receive additional payments if quality and costs exceed defined parameters or, if not, must repay Medicare for a portion of the spending. On July 25, 2016, CMS proposed rulemaking to extend the CJR bundled payment models effective July 1, 2017 for both hip/femur fracture surgeries in the same 67 metropolitan as well as additional bundled payment models for heart attacks and bypass surgeries in 98 randomly selected metropolitan statistical areas. SNFs receiving Medicare revenues related to hospital discharges subject to CJR bundled payment programs in the identified geographic areas could be either positively or negatively affected by the CJR bundled payment program. CMS delayed the applicability date of the expanded CJR bundled payment pilot from July 1, 2017 until October 1, 2017 through an interim final rule with comment period published in the Federal Register on March 21, 2017. The interim final rule also modified the final rule entitled, “Advancing Care Coordination Through Episode Payment Models (EPMs); Cardiac Rehabilitation Incentive Payment Model; and Changes to the Comprehensive Care for Joint Replacement Model” published on January 3, 2017 until May 20, 2017.

Quality of Care Initiatives. In addition to quality or value based reimbursement reforms, CMS has implemented a number of initiatives focused on the quality of care provided by long term care facilities that could affect our operators. On December 2008, CMS released quality ratings for all of the nursing homes that participate in Medicare or Medicaid under its “Five Star Quality Rating System.” Facility rankings, ranging from five stars (“much above average”) to one star (“much below average”) are updated on a monthly basis. SNFs are required to provide information for the CMS Nursing Home Compare website regarding staffing and quality measures. Based on this data and the results of state health inspections, SNFs are then rated based on the five-star rating system.

44

In August 2016, CMS announced a modification to the Five Star Quality Rating System through the introduction of new quality measures based primarily on Medicare claims data submitted by hospitals, including: (1) percentage of short-stay residents who were successfully discharged to the community; (2) percentage of short-stay residents who have had an outpatient emergency department visit; (3) percentage of short-stay residents who were re-hospitalized after a nursing home admission; (4) percentage of short-stay residents who made improvements in function; and (5) percentage of long-stay residents whose ability to move independently worsened. These ratings were incorporated into the nursing home rating system in July 2016 and were phased in through January 2017. Effective September 1, 2016, SNFs that received a Five Star Quality Indicators Survey deficiency cited at a Scope and Severity level J or higher are automatically and immediately assessed civil monetary penalties by CMS, with no opportunity to correct the deficiencies to avoid the heightened and costly monetary penalties. It is possible that this or any other ranking system could lead to future reimbursement policies that reward or penalize facilities on the basis of the reported quality of care parameters.

Office of the Inspector General Activities. The Office of Inspector General’s (the “OIG”) Work Plan for government fiscal year 2017, which describes projects that the OIG plans to address during the fiscal year, includes seven projects related specifically to nursing homes: (1) determining to what extent State agencies investigate serious nursing home complaints within the required timeframes; (2) unreported incidents of potential abuse and neglect in SNFs; (3) review of SNF Medicare reimbursement documentation (determine if it meets requirements for each particular resource utilization group); (4) the SNF Adverse Event Screening Tool, which will disseminate practical information about the SNF Adverse Event Trigger Tool; (5) review of the National Background Check Program for long-term care employees; (6) compliance with the SNF prospective payment system requirement related to a three-day qualifying inpatient hospital stay; and (7) review of potentially avoidable hospitalizations of Medicare and Medicaid-Eligible nursing facility residents and prevention and detection services provided by nursing homes.

Department of Justice. SNFs are under intense scrutiny for the quality of care being rendered to residents and appropriate billing practices. The Department of Justice launched ten regional Elder Justice Task Forces in 2016 which are coordinating and enhancing efforts to pursue SNFs that provide grossly substandard care to their residents. They are also focusing on therapy billing issues. These Task Forces are composed of representatives from the U.S. Attorneys’ Offices, State Medicaid Fraud Control Units, state and local prosecutors’ offices, HHS, State Adult Protective Services agencies, Long Term Care Ombudsmen programs, and law enforcement.

Fraud and Abuse. There are various federal and state civil and criminal laws and regulations governing a wide array of healthcare provider referrals, relationships and arrangements, including laws and regulations prohibiting fraud by healthcare providers. Many of these complex laws raise issues that have not been clearly interpreted by the relevant governmental authorities and courts.

These laws include: (i) federal and state false claims acts, which, among other things, prohibit providers from filing false claims or making false statements to receive payment from Medicare, Medicaid or other federal or state healthcare programs; (ii) federal and state anti-kickback and fee-splitting statutes, including the Medicare and Medicaid Anti-kickback statute, which prohibit the payment or receipt of remuneration to induce referrals or recommendations of healthcare items or services, such as services provided in a SNF; (iii) federal and state physician self-referral laws (commonly referred to as the Stark Law), which generally prohibit referrals by physicians to entities for designated health services (some of which are provided in SNFs) with which the physician or an immediate family member has a financial relationship; (iv) the federal Civil Monetary Penalties Law, which prohibits, among other things, the knowing presentation of a false or fraudulent claim for certain healthcare services and (v) federal and state privacy laws, including the privacy and security rules contained in the Health Insurance Portability and Accountability Act of 1996, which provide for the privacy and security of personal health information.

45

Violations of healthcare fraud and abuse laws carry civil, criminal and administrative sanctions, including punitive sanctions, monetary penalties, imprisonment, denial of Medicare and Medicaid reimbursement and potential exclusion from Medicare, Medicaid or other federal or state healthcare programs. Additionally, there are criminal provisions that prohibit filing false claims or making false statements to receive payment or certification under Medicare and Medicaid, as well as failing to refund overpayments or improper payments. Violation of the Anti-kickback statute or Stark Law may form the basis for a federal False Claims Act violation. These laws are enforced by a variety of federal, state and local agencies and can also be enforced by private litigants through, among other things, federal and state false claims acts, which allow private litigants to bring qui tam or whistleblower actions, which have become more frequent in recent years. A few of our operators have responded to subpoenas and other requests for information regarding their operations in connection with inquiries by the U.S. Department of Justice or other regulatory agencies.

Privacy. Our operators are subject to various federal, state and local laws and regulations designed to protect the confidentiality and security of patient health information, including the federal Health Insurance Portability and Accountability Act of 1996, as amended, the Health Information Technology for Economic and Clinical Health Act (“HITECH”), and the corresponding regulations promulgated thereunder (collectively referred to herein as “HIPAA”). The HITECH Act expanded the scope of these provisions by mandating individual notification in instances of breaches of protected health information, providing enhanced penalties for HIPAA violations, and granting enforcement authority to states’ Attorneys General in addition to the HHS Office for Civil Rights. HHS continued its auditing program in 2016 to assess compliance efforts by covered entities and business associates. Through a second phase of audits, which commenced for covered entities in July 2016, HHS focused on a review of policies and procedures adopted and employed by covered entities and their business associates to meet selected standards and implementation specifications of the HIPAA Privacy, Security, and Breach Notification Rules. Covered entities and business associates selected for a desk audit in 2016 have the potential to be selected for an on-site audit in 2017.

Various states have similar laws and regulations that govern the maintenance and safeguarding of patient records, charts and other information generated in connection with the provision of professional medical services. These laws and regulations require our operators to expend the requisite resources to secure protected health information, including the funding of costs associated with technology upgrades. Operators found in violation of HIPAA or any other privacy law or regulation may face large penalties. In addition, compliance with an operator’s notification requirements in the event of a breach of unsecured protected health information could cause reputational harm to an operator’s business.

Licensing and Certification. Our operators and facilities are subject to various federal, state and local licensing and certification laws and regulations, including laws and regulations under Medicare and Medicaid requiring operators of SNFs and ALFs to comply with extensive standards governing operations. Governmental agencies administering these laws and regulations regularly inspect our operators’ facilities and investigate complaints. Our operators and their managers receive notices of observed violations and deficiencies from time to time, and sanctions have been imposed from time to time on facilities operated by them. In addition, many states require certain healthcare providers to obtain a certificate of need, which requires prior approval for the construction, expansion or closure of certain healthcare facilities, which has the potential to impact some of our operators’ abilities to expand or change their businesses.

Americans with Disabilities Act (the “ADA”). Our properties must comply with the ADA and any similar state or local laws to the extent that such properties are public accommodations as defined in those statutes. The ADA may require removal of barriers to access by persons with disabilities in certain public areas of our properties where such removal is readily achievable. Should barriers to access by persons with disabilities be discovered at any of our properties, we may be directly or indirectly responsible for additional costs that may be required to make facilities ADA-compliant. Noncompliance with the ADA could result in the imposition of fines or an award of damages to private litigants. Our commitment to make readily achievable accommodations pursuant to the ADA is ongoing, and we continue to assess our properties and make modifications as appropriate in this respect.

46

Other Laws and Regulations. Additional federal, state and local laws and regulations affect how our operators conduct their operations, including laws and regulations protecting consumers against deceptive practices and otherwise generally affecting our operators’ management of their property and equipment and the conduct of their operations (including laws and regulations involving fire, health and safety; quality of services, including care and food service; residents’ rights, including abuse and neglect laws; and the health standards set by the federal Occupational Safety and Health Administration).

General and Professional Liability. Although arbitration agreements have been effective in limiting general and professional liabilities for SNF and long term care providers, there have been numerous lawsuits challenging the validity of arbitration agreements in long term care settings. As set forth in the recent conditions of participation final rule issued on October 4, 2016, CMS prohibited pre-dispute arbitration agreements between SNFs and residents effective November 28, 2016, thereby increasing potential liabilities for SNFs and long-term care providers. However, the authority of CMS to restrict the rights of these parties to arbitrate is continuing to be challenged by litigation in various jurisdictions, and enforcement by CMS has been suspended until a preliminary injunction issued by the U.S. District Court for the Northern District of Mississippi banning such enforcement by CMS is lifted.

Critical Accounting Policies and Estimates

Our financial statements are prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States, and a summary of our significant accounting policies is included in Note 2 – Summary of Significant Accounting Policies to our Annual Report on Form 10-K for the year ended December 31, 2016, as amended. Our preparation of the financial statements requires us to make estimates and assumptions about future events that affect the amounts reported in our financial statements and accompanying footnotes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment. Actual results inevitably will differ from those estimates, and such differences may be material to the consolidated financial statements. We have described our most critical accounting policies in our 2016 Annual Report on Form 10-K for the year ended December 31, 2016, as amended, in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations.

There have been no changes to our critical accounting policies or estimates since December 31, 2016. See Note 2 – Summary of Significant Accounting Policies to our Annual Report on Form 10-K for the year ended December 31, 2016, as amended.

Accounting Pronouncement Adopted in 2017

In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Compensation-Stock Compensation (Topic 718) (“ASU 2016-09”). ASU 2016-09 amends the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2016. We adopted this accounting standard on January 1, 2017, at which time the Company began prospectively accounting for excess tax benefits or tax deficiencies as an adjustment to income tax expense in our Consolidated Statements of Operations as opposed to the prior requirement that these excess tax benefits be recognized in additional paid-in capital and tax deficiencies be recognized either as an offset to accumulated excess tax benefits, if any, or in the income statement. The Company will continue to account for forfeitures as they occur and present employee taxes paid as a financing activity on our Consolidated Statements of Cash Flows. The adoption of this accounting standard did not have a material impact on our consolidated financial statements.

47

Recent Accounting Pronouncements - Pending Adoption

In 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment. ASU 2014-09 is effective for the Company beginning January 1, 2018. In addition, the FASB has begun to issue targeted updates to clarify specific implementation issues of ASU 2014-09. These updates include ASU 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016-10, Identifying Performance Obligations and Licensing, and ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. The Company is currently evaluating the provisions of ASU 2014-09 and its related updates and will be closely monitoring developments and additional guidance to determine the potential impact of the new standard. The Company intends to adopt ASU 2014-09 and its subsequent updates in accordance with the modified retrospective approach. We do not expect the adoption of ASU 2014-09 and its updates to have a significant impact on our consolidated financial statements, as a substantial portion of our revenue consists of rental income from leasing arrangements and interest income from loan arrangements, both of which are specifically excluded from ASU 2014-09.

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective for the Company beginning January 1, 2019. Early adoption of ASU 2016-02 as of its issuance is permitted. The new standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact of adopting ASU 2016-02 on our consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) (“ASU 2016-13”), which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. ASU 2016-13 is effective for annual and interim periods beginning after December 15, 2019 and early adoption is permitted for annual and interim periods beginning after December 15, 2018. We are currently evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements.

Results of Operations

The following is our discussion of the consolidated results of operations, financial position and liquidity and capital resources, which should be read in conjunction with our unaudited consolidated financial statements and accompanying notes.

Three Months Ended March 31, 2017 and 2016

Operating Revenues

Our operating revenues for the three months ended March 31, 2017, totaled $231.7 million, an increase of $18.9 million over the same period in 2016. The $18.9 million increase was primarily the result of: (i) $15.8 million of rental income associated with acquisitions and lease amendments made throughout 2016 and (ii) a $3.5 million increase in other investment income primarily related to new notes and additional funding to existing operators made throughout 2016 and 2017.

Operating Expenses

Operating expenses for the three months ended March 31, 2017, totaled $92.5 million, a decrease of approximately $23.8 million over the same period in 2016. The decrease was primarily due to: (i) a $26.9 million decrease in provision for impairment losses due to fewer facilities impaired in the first quarter of 2017 compared to the same period in 2016, (ii) a $3.8 million decrease in acquisition costs due to a fewer acquisitions in the first quarter of 2017 compared to the same period in 2016 and (iii) a $2.7 million decrease in provision for uncollectible accounts, offset by a $7.6 million increase in depreciation and amortization expense related to acquisitions completed in 2016.

48

Other Income (Expense)

For the three months ended March 31, 2017, total other expenses were $37.1 million, a decrease of approximately $2.6 million over the same period in 2016. The decrease was primarily related to a one-time $10.4 million contractual settlement with an unrelated third party related to a contingent liability obligation that originated in 2012 and was resolved in the first quarter of 2017. The income from the contractual settlement was offset by a $7.8 million increase in interest expense primarily related to higher debt balances outstanding to fund new investments.

National Association of Real Estate Investment Trusts Funds From Operations

Our funds from operations (“NAREIT FFO”) for the three months ended March 31, 2017 was $181.0 million compared to $153.6 million for the same period in 2016.

We calculate and report NAREIT FFO in accordance with the definition of Funds from Operations and interpretive guidelines issued by the National Association of Real Estate Investment Trusts (“NAREIT”), and, consequently, NAREIT FFO is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairment on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures. Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect funds from operations on the same basis. We believe that NAREIT FFO is an important supplemental measure of our operating performance. Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions. NAREIT FFO was designed by the real estate industry to address this issue. NAREIT FFO herein is not necessarily comparable to NAREIT FFO of other REITs that do not use the same definition or implementation guidelines or interpret the standards differently from us.

NAREIT FFO is a non-GAAP financial measure. We use NAREIT FFO as one of several criteria to measure the operating performance of our business. We further believe that by excluding the effect of depreciation, amortization, impairment on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, NAREIT FFO can facilitate comparisons of operating performance between periods and between other REITs. We offer this measure to assist the users of our financial statements in evaluating our financial performance under GAAP, and NAREIT FFO should not be considered a measure of liquidity, an alternative to net income or an indicator of any other performance measure determined in accordance with GAAP. Investors and potential investors in our securities should not rely on this measure as a substitute for any GAAP measure, including net income.

49

The following table presents our NAREIT FFO results for the three months ended March 31, 2017 and 2016:

	Three Months Ended
	March 31,
	2017			2016
	(in thousands)
Net income	$	109,112		$	58,196
Deduct gain from real estate dispositions		(7,420	)		(1,571	)
		101,692			56,625
Elimination of non-cash items included in net income:
Depreciation and amortization		69,993			62,433
Depreciation – unconsolidated joint venture		1,658			—
Add back impairments on real estate properties		7,638			34,558
NAREIT FFO (a)	$	180,981		$	153,616

(a)       Includes amounts allocated to Omega stockholders and Omega OP Unit holders.

Portfolio and Recent Developments

The following table summarizes the significant acquisitions that occurred in the first quarter of 2017:

Number of Facilities				Country/	Total Investment		Land		Building & Site Improvements		Furniture & Fixtures		Initial Annual Cash
SNF		ALF		State	(in millions)								Yield (%)
	-		1	VA	$	7.6	$	0.5	$	6.8	$	0.3		7.50

Asset Sales, Impairments and Other

During the first quarter of 2017, we sold 15 facilities for approximately $45.8 million in net proceeds recognizing a gain of approximately $7.4 million. Eleven of the sold facilities were previously classified as held for sale. In addition, we recorded a provision for impairment of approximately $7.6 million on three facilities, one of which was reclassified to held for sale on March 31, 2017. We reduced the net book value of the impaired facilities to their estimated fair values or, with respect to the facility reclassified to held for sale, to its estimated fair value less costs to sell. To estimate the fair value of the facilities, we utilized a market approach and Level 3 inputs (which generally consist of non-binding offers from unrelated third parties). Our recorded impairments were primarily the result of a decision to exit certain non-strategic facilities and/or operators.

Liquidity and Capital Resources

At March 31, 2017, we had total assets of $8.8 billion, total equity of $4.2 billion and debt of $4.3 billion, representing approximately 50.5% of total capitalization.

Financing Activities and Borrowing Arrangements

Certain of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of March 31, 2017 and December 31, 2016, we were in compliance with all affirmative and negative covenants, including financial covenants, for our secured and unsecured borrowings.

50

$500 Million Equity Shelf Program

For the three months ended March 31, 2017, we issued 0.2 million shares of common stock at an average price of $29.71 per share, net of issuance costs, generating net proceeds of $6.8 million under our $500 million Equity Shelf Program.

Dividend Reinvestment and Common Stock Purchase Plan

For the three months ended March 31, 2017, approximately 0.2 million shares of our common stock at an average price of $30.67 per share were issued through our Dividend Reinvestment and Common Stock Purchase Program for gross proceeds of approximately $7.3 million.

Subsequent Events

2017 Omega Credit Facilities

On May 25, 2017, we entered into a credit agreement (the “2017 Omega Credit Agreement”) providing us with a new $1.8 billion senior unsecured revolving and term loan credit facility, consisting of a $1.25 billion senior unsecured multicurrency revolving credit facility (the “2017 Revolving Credit Facility”), a $425 million senior unsecured U.S. Dollar term loan facility (the “2017 U.S. Term Loan Facility”), and a £100 million senior unsecured British Pound Sterling term loan facility (the “2017 Sterling Term Loan Facility” and, together with the 2017 Revolving Credit Facility and the 2017 U.S. Term Loan Facility, collectively, the “2017 Omega Credit Facilities”). The 2017 Omega Credit Agreement contains an accordion feature permitting us, subject to compliance with customary conditions, to increase the maximum aggregate commitments under the 2017 Omega Credit Facilities to $2.5 billion.

The 2017 Omega Credit Facilities replace the previous $1.25 billion senior unsecured 2014 revolving credit facility, the previous $200 million Tranche A-1 senior unsecured term loan facility, and the previous $350 million Tranche A-3 senior unsecured incremental term loan facility established under our 2014 credit agreement, which has been terminated (the “2014 Omega Credit Agreement”).

The 2017 Revolving Credit Facility bears interest at LIBOR plus an applicable percentage (with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2017 Revolving Credit Facility matures on May 25, 2021, subject to an option by us to extend such maturity date for two, six month periods. The 2017 Omega Credit Agreement provides for the 2017 Revolving Credit Facility to be drawn in Euros, British Pounds Sterling, Canadian Dollars (collectively, “Alternative Currencies”) or U.S. Dollars, with a $900 million tranche available in U.S. Dollars and a $350 million tranche available in U.S. Dollars or Alternative Currencies. For purposes of the 2017 Omega Credit Facilities, references to LIBOR include the Canadian dealer offered rates for amounts offered in Canadian Dollars and any other Alternative Currency rate approved in accordance with the terms of the 2017 Omega Credit Agreement for amounts offered in any other non-London interbank offered rate quoted currency, as applicable.

The 2017 U.S. Term Loan Facility and the 2017 Sterling Term Loan Facility bear interest at LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2017 U.S. Term Loan Facility and the 2017 Sterling Term Loan Facility each mature on May 25, 2022.

In April 2017, we repaid and terminated the $200 million Tranche A-2 senior unsecured term loan facility established under the 2014 Omega Credit Agreement.

For the three month period ending June 30, 2017, we recorded a one-time, non-cash charge of approximately $5.5 million relating to the write-off of deferred financing costs associated with the termination of the 2014 Omega Credit Facilities.

51

2017 Omega OP Term Loan Facility

On May 25, 2017, Omega OP entered into a credit agreement (the “2017 Omega OP Credit Agreement”) providing it with a new $100 million senior unsecured term loan facility (the “2017 Omega OP Term Loan Facility”). The 2017 Omega OP Credit Agreement replaces the $100 million senior unsecured term loan facility obtained in 2015 (the “2015 Omega OP Term Loan Facility”) and the related credit agreement (the “2015 Omega OP Credit Agreement”). The 2017 Omega OP Term Loan Facility bears interest at LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2017 Omega OP Term Loan Facility matures on May 25, 2022.

Omega OP’s obligations in connection with the 2017 Omega OP Term Loan Facility are not currently guaranteed, but will be jointly and severally guaranteed by any domestic subsidiary of Omega OP that provides a guaranty of any unsecured indebtedness of Omega or Omega OP for borrowed money evidenced by bonds, debentures, notes or other similar instruments in an amount of at least $50 million individually or in the aggregate.

$550 Million 4.75% Senior Notes and $150 Million 4.5% Senior Notes

On April 4, 2017, we issued (i) $550 million aggregate principal amount of our 4.75% Senior Notes due 2028 (the “2028 Notes”) and (ii) an additional $150 million aggregate principal amount of our existing 4.50% Senior Notes due 2025 (the “2025 Notes”, and together with the 2028 Notes collectively, the “Notes”). The 2028 Notes mature on January 15, 2028 and the 2025 Notes mature on January 15, 2025.

The 2028 Notes were sold at an issue price of 98.978% of their face value before the underwriters’ discount and the 2025 Notes were sold at an issue price of 99.540% of their face value before the underwriters’ discount. Our net proceeds from the Notes offering, after deducting underwriting discounts and expenses, were approximately $690.7 million. The net proceeds from the Notes offering were used to (i) redeem all of our outstanding $400 million aggregate principal amount of 5.875% Senior Notes due 2024 (the “5.875% Notes”) on April 28, 2017, (ii) prepay the $200 million Tranche A-2 Term Loan Facility on April 5, 2017 that otherwise would have become due on June 27, 2017, and (iii) repay outstanding borrowings under our revolving credit facility.

$400 Million 5.875% Senior Notes Redemption

On April 28, 2017, we redeemed all of our outstanding 5.875% Notes. As a result of the redemption, during the second quarter of 2017, we recorded approximately $16.5 million in redemption related costs and write-offs, including $11.8 million for the call premium and $4.7 million in net write-offs associated with unamortized deferred financing costs.

Dividends

In order to qualify as a REIT, we are required to distribute dividends (other than capital gain dividends) to our stockholders in an amount at least equal to (A) the sum of (i) 90% of our “REIT taxable income” (computed without regard to the dividends paid deduction and our net capital gain), and (ii) 90% of the net income (after tax), if any, from foreclosure property, minus (B) the sum of certain items of non-cash income. In addition, if we dispose of any built-in gain asset during a recognition period, we will be required to distribute at least 90% of the built-in gain (after tax), if any, recognized on the disposition of such asset. Such distributions must be paid in the taxable year to which they relate, or in the following taxable year if declared before we timely file our tax return for such year and paid on or before the first regular dividend payment after such declaration. In addition, such distributions are required to be made pro rata, with no preference to any share of stock as compared with other shares of the same class, and with no preference to one class of stock as compared with another class except to the extent that such class is entitled to such a preference. To the extent that we do not distribute all of our net capital gain or do distribute at least 90%, but less than 100% of our “REIT taxable income” as adjusted, we will be subject to tax thereon at regular ordinary and capital gain corporate tax rates.

52

For the three months ended March 31, 2017, we paid dividends of approximately $122 million to our common stockholders. The Omega OP Unit holders received the same distributions per unit as those paid to the common stockholders of Omega.

Liquidity

We believe our liquidity and various sources of available capital, including cash from operations, our existing availability under our Omega Credit Facilities and expected proceeds from mortgage payoffs are adequate to finance operations, meet recurring debt service requirements and fund future investments through the next twelve months.

We regularly review our liquidity needs, the adequacy of cash flow from operations, and other expected liquidity sources to meet these needs. We believe our principal short-term liquidity needs are to fund:

· normal recurring expenses;

· debt service payments;

· capital improvement programs;

· common stock dividends; and

· growth through acquisitions of additional properties.

The primary source of liquidity is our cash flows from operations. Operating cash flows have historically been determined by: (i) the number of facilities we lease or have mortgages on; (ii) rental and mortgage rates; (iii) our debt service obligations; and (iv) general and administrative expenses. The timing, source and amount of cash flows provided by or used in financing activities and in investing activities are sensitive to the capital markets environment, especially to changes in interest rates. Changes in the capital markets environment may impact the availability of cost-effective capital and affect our plans for acquisition and disposition activity.

Cash and cash equivalents totaled $40.3 million as of March 31, 2017, a decrease of $53.3 million as compared to the balance at December 31, 2016. The following is a discussion of changes in cash and cash equivalents due to operating, investing and financing activities, which are presented in our Consolidated Statements of Cash Flows.

Operating Activities – Operating activities generated $113.9 million of net cash flow for the three months ended March 31, 2017, as compared to $127.2 million for the same period in 2016, a decrease of $13.2 million which is primarily due to the timing of collection of contractual receivables.

Investing Activities – Net cash flow from investing activities was an inflow of $16.4 million for the three months ended March 31, 2017, as compared to an outflow of $673.8 million for the same period in 2016. The $690.1 million increase in cash flow from investing activities related primarily to (i) a $408.5 million reduction in acquisitions of real estate, (ii) a $113.8 million cash deposit to acquire 10 care homes in the United Kingdom completed in the prior year, (iii) $115.6 million from other investments – net primarily related to funding fewer other investments in 2017, (iv) a $43.5 million increase in proceeds from the sale of real estate investments in 2017, as compared to the same period in 2016 and (v) an increase of $8.6 million in distributions from our unconsolidated joint venture in 2017, as compared to the same period of 2016.

53

Financing Activities – Net cash flow from financing activities was an outflow of $183.8 million for the three months ended March 31, 2017, as compared to an inflow of $550.7 million for the same period in 2016. The $734.5 million increase in cash outflow from financing activities was primarily related to (i) a net decrease in cash provided by our credit facility of $367.0 million, in 2016 our credit facility provided $300.0 million in cash as compared to a use of $67.0 million in cash in 2017, (ii) a decrease of $350 million in long-term borrowings resulting from the $350 million senior unsecured incremental term loan facility obtained in January 2016, (iii) an increase of $14.8 million in dividends paid, (iv) a decrease in net proceeds of $12.3 million from our dividend reinvestment plan in 2017, as compared to the same period in 2016. Offsetting these outflows was a $6.8 million increase in cash proceeds from the issuance of common stock in 2017, as compared to the same period in 2016.

Item 3 – Quantitative and Qualitative Disclosures about Market Risk

During the quarter ended March 31, 2017, there were no material changes in our primary market risk exposures or how those exposures are managed from the information disclosed under Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2016, as amended.

Item 4 – Controls and Procedures

Disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

In connection with the preparation of this Form 10-Q/A, management evaluated the effectiveness of the design and operation of the disclosure controls and procedures of Omega, OHI Holdco, and Omega OP (for purposes of this Item 4 the “Companies”) as of March 31, 2017. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer of each of the Companies concluded that the disclosure controls and procedures of the Companies were not effective at the reasonable assurance level as of March 31, 2017 due to the failure to prepare and file separate guarantor financial statements in Omega’s quarterly report on Form 10-Q filed with the SEC on May 5, 2017 as contemplated by Regulation S-X.

Pursuant to Regulation S-X Rule 3-10, companies are required to include in their Form 10-K and 10-Q filings the financial statements required for a registrant by Regulation S-X for subsidiary guarantors of outstanding securities previously registered under the Securities Act of 1933, as amended, unless (i) each subsidiary guarantor is 100% owned by the parent company issuer, (ii) the guarantees are full and unconditional and joint and several, and (iii) certain condensed consolidating financial statements conforming to Rule 3-10 are included in a note to the issuer’s financial statements. The Parent company has outstanding senior notes that are fully and unconditionally guaranteed, jointly and severally by subsidiary guarantors. While the guarantees on the senior notes are full and unconditional and joint and several, and the condensed consolidating financial statements contemplated by Regulation S-X Rule 3-10 were provided, separate guarantor financial statements were required to be filed because Omega OP was not 100% owned by Omega within the meaning of Rule 3-10. We note that for purposes of Rule 3-10, a subsidiary in corporate form is “100% owned” if all of its outstanding voting shares are owned, either directly or indirectly, by its parent company, but a subsidiary not in corporate form is only “100% owned” if the sum of all interests are owned, either directly or indirectly, by its parent company. Because Omega OP is a partnership and Omega directly or indirectly holds approximately 96% of the outstanding interests (including all of the general partner interests which have full control over the activities of Omega OP) in Omega OP, Omega has determined that the presentation of separate guarantor financial statements under Rule 3-10 is appropriate.

The inclusion of OHI Holdco’s and Omega OP’s financial statements in this Form 10-Q/A has no impact or effect on Omega's consolidated financial condition and results of operations.

Internal Control Over Financial Reporting

There were no changes in the Companies’ internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2017 identified in connection with the evaluation of their disclosure controls and procedures described above that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting.

54

PART II – OTHER INFORMATION

Item 1 – Legal Proceedings

See Note 15 – Litigation to the Consolidated Financial Statements in Part I, Item 1 hereto, which is hereby incorporated by reference in response to this item.

Item 1A – Risk Factors

There have been no material changes to our risk factors as previously disclosed in Item 1A contained in Part I of Amendment No.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and filed with the Securities and Exchange Commission (“SEC”) on August 9, 2017.

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds

During the quarterly period ended March 31, 2017, Omega issued an aggregate of 46,858 shares of Omega common stock, in exchange for an equivalent number of Omega OP Units tendered to Omega OP for redemption in accordance with the provisions of the Partnership Agreement. The Company issued these shares of Omega common stock in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, based upon factual representations received from the limited partners who received the Omega common stock.

55

Item 6–Exhibits

Exhibit No.
4.1	Nineteenth Supplemental Indenture, dated as of March 17, 2017, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.875% Senior Notes due 2024, including the Form of 5.875% Senior Notes and Form of Subsidiary Guarantee related thereto.#
4.2	Twelfth Supplemental Indenture, dated as of March 17, 2017, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.950% Senior Notes due 2024, including the Form of 4.950% Senior Notes and Form of Subsidiary Guarantee related thereto.#
4.3	Eleventh Supplemental Indenture, dated as of March 17, 2017, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.50% Senior Notes due 2025, including the Form of 4.50% Senior Notes and Form of Subsidiary Guarantee related thereto.#
4.4	Eighth Supplemental Indenture, dated as of March 17, 2017, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.500% Senior Notes due 2027, including the Form of 4.500% Senior Notes and Form of Subsidiary Guarantee related thereto.#
4.5	Sixth Supplemental Indenture, dated as of March 17, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 5.250% Senior Notes due 2026, including the Form of 5.250% Senior Notes and Form of Subsidiary Guarantee related thereto.#
4.6	Third Supplemental Indenture, dated as of March 17, 2017, among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein and U.S. Bank National Association, as trustee, related to the 4.375% Senior Notes due 2023, including the Form of 4.375% Senior Notes and Form of Subsidiary Guarantee related thereto.#
4.7	Indenture, dated as of April 4, 2017, by and among Omega Healthcare Investors, Inc., each of the subsidiary guarantors listed therein, and U.S. Bank National Association, as trustee (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on April 4, 2017).
10.1	Form of 2017 Employment Agreement Amendments (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 13, 2017) for the Company’s executive officers.+
12.1	Ratio of Earnings to Fixed Charges.#
31.1	Rule 13a-14(a)/15d-14(a) Certification of the Chief Executive Officer.*
31.2	Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer.*
31.3	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer of OHI Healthcare Properties Holdco, Inc.*
31.4	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer of OHI Healthcare Properties Holdco, Inc.*
31.5	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer of OHI Healthcare Properties Holdco, Inc. , in its capacity as primary general partner of OHI Healthcare Properties Limited Partnership.*

56

31.6	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer of OHI Healthcare Properties Holdco, Inc. , in its capacity as primary general partner of OHI Healthcare Properties Limited Partnership.*
32.1	Section 1350 Certification of the Chief Executive Officer.*
32.2	Section 1350 Certification of the Chief Financial Officer.*
32.3	Section 1350 Certification of the Chief Executive Officer of OHI Healthcare Properties Holdco, Inc.*
32.4	Section 1350 Certification of the Chief Financial Officer of OHI Healthcare Properties Holdco, Inc.*
32.5	Section 1350 Certification of the Chief Executive Officer of OHI Healthcare Properties Holdco, Inc., as Chief Financial Officer of the primary general partner of OHI Healthcare Properties Limited Partnership.*
32.6	Section 1350 Certification of the Chief Financial Officer of OHI Healthcare Properties Holdco, Inc., as Chief Financial Officer of the primary general partner of OHI Healthcare Properties Limited Partnership.*
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.

* Exhibits that are filed herewith.

+ Management contract or compensatory plan, contract or arrangement.

# Previously filed or furnished, as applicable, as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 5, 2017.

57

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

OMEGA HEALTHCARE INVESTORS, INC.

Registrant

Date:	August 9, 2017	By:	/S/ C. TAYLOR PICKETT
			C. Taylor Pickett
			Chief Executive Officer
Date:	August 9, 2017	By:	/S/ ROBERT O. STEPHENSON
			Robert O. Stephenson
			Chief Financial Officer

OHI HEALTHCARE PROPERTIES HOLDCO, INC.

Co-Registrant

Date:	August 9, 2017	By:	/S/ C. TAYLOR PICKETT
			C. Taylor Pickett
			Chief Executive Officer
Date:	August 9, 2017	By:	/S/ ROBERT O. STEPENSON
			Robert O. Stephenson
			Chief Financial Officer

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

Co-Registrant

By: OHI Healthcare Properties Holdco, Inc., its Primary General Partner

Date:	August 9, 2017	By:	/S/ C. TAYLOR PICKETT
			C. Taylor Pickett
			Chief Executive Officer
Date:	August 9, 2017	By:	/S/ ROBERT O. STEPHENSON
			Robert O. Stephenson
			Chief Financial Officer

58

EX-31.1

Exhibit 31.1

RULE 13a-14(a)/15d-14(a) CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Certification

I, C. Taylor Pickett, certify that:

1. I have reviewed this Amendment No. 1 to the Quarterly Report on Form 10-Q of Omega Healthcare Investors, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2017

/S/ C. TAYLOR PICKETT

C. Taylor Pickett

Chief Executive Officer

EX-31.2

Exhibit 31.2

RULE 13a-14(a)/15d-14(a) CERTIFICATION OF CHIEF FINANCIAL OFFICER

Certifications

I, Robert O. Stephenson, certify that:

1. I have reviewed this Amendment No. 1 to the Quarterly Report on Form 10-Q of Omega Healthcare Investors, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2017

/S/ ROBERT O. STEPHENSON

Robert O. Stephenson

Chief Financial Officer

EX-31.3

Exhibit 31.3

RULE 13a-14(a)/15d-14(a) CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Certification

I, C. Taylor Pickett, certify that:

1. I have reviewed this Amendment No. 1 to the Quarterly Report on Form 10-Q of OHI Healthcare Properties Holdco, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2017

/S/ C. TAYLOR PICKETT

C. Taylor Pickett

Chief Executive Officer

EX-31.4

Exhibit 31.4

RULE 13a-14(a)/15d-14(a) CERTIFICATION OF CHIEF FINANCIAL OFFICER

Certifications

I, Robert O. Stephenson, certify that:

1. I have reviewed this Amendment No. 1 to the Quarterly Report on Form 10-Q of OHI Healthcare Properties Holdco, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2017

/S/ ROBERT O. STEPHENSON

Robert O. Stephenson

Chief Financial Officer

EX-31.5

Exhibit 31.5

RULE 13a-14(a)/15d-14(a) CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Certification

I, C. Taylor Pickett, certify that:

1. I have reviewed this Amendment No. 1 to the Quarterly Report on to Form 10-Q of OHI Healthcare Properties Limited Partnership;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2017

/S/ C. TAYLOR PICKETT

C. Taylor Pickett

Chief Executive Officer of

OHI Healthcare Properties Holdco., Inc.

the Primary General partner

EX-31.6

Exhibit 31.6

RULE 13a-14(a)/15d-14(a) CERTIFICATION OF CHIEF FINANCIAL OFFICER

Certifications

I, Robert O. Stephenson, certify that:

1. I have reviewed this Amendment No. 1 to the Quarterly Report on Form 10-Q of OHI Healthcare Properties Limited Partnership;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2017

/S/ ROBERT O. STEPHENSON

Robert O. Stephenson

Chief Financial Officer of

OHI Healthcare Properties Holdco, Inc.,

the Primary General Partner

EX-32.1

Exhibit 32.1

SECTION 1350 CERTIFICATION

OF THE CHIEF EXECUTIVE OFFICER

I, C. Taylor Pickett, Chief Executive Officer of Omega Healthcare Investors, Inc. (the “Company”), hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to the best of my knowledge:

(1) Amendment No. 1 to the Quarterly Report on Form 10-Q of the Company for the three months ended March 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2017

/S/ C. TAYLOR PICKETT

C. Taylor Pickett

Chief Executive Officer

EX-32.2

Exhibit 32.2

SECTION 1350 CERTIFICATION

OF THE CHIEF FINANCIAL OFFICER

I, Robert O. Stephenson, Chief Financial Officer of Omega Healthcare Investors, Inc. (the “Company”), hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:

(1) Amendment No. 1 to the Quarterly Report on Form 10-Q of the Company for the three months ended March 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2017

/S/ ROBERT O. STEPHENSON

Robert O. Stephenson

Chief Financial Officer

EX-32.3

Exhibit 32.3

SECTION 1350 CERTIFICATION

OF THE CHIEF EXECUTIVE OFFICER

I, C. Taylor Pickett, Chief Executive Officer of OHI Healthcare Properties Holdco, Inc. (the “Company”), hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to the best of my knowledge:

(1) Amendment No. 1 to the Quarterly Report on Form 10-Q of the Company for the three months ended March 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2017

/S/ C. TAYLOR PICKETT

C. Taylor Pickett

Chief Executive Officer

EX-32.4

Exhibit 32.4

SECTION 1350 CERTIFICATION

OF THE CHIEF FINANCIAL OFFICER

I, Robert O. Stephenson, Chief Financial Officer of OHI Healthcare Properties Holdco, Inc. (the “Company”), hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:

(1) Amendment No. 1 to the Quarterly Report on Form 10-Q of the Company for the three months ended March 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2017

/S/ ROBERT O. STEPHENSON

Robert O. Stephenson

Chief Financial Officer

EX-32.5

Exhibit 32.5

SECTION 1350 CERTIFICATION

OF THE CHIEF EXECUTIVE OFFICER

I, C. Taylor Pickett, Chief Executive Officer of OHI Healthcare Properties Holdco, Inc., the primary general partner of OHI Healthcare Properties Limited Partnership (the “Company”), hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to the best of my knowledge:

(1) Amendment No. 1 to the Quarterly Report on Form 10-Q of the Company for the three months ended March 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2017

/S/ C. TAYLOR PICKETT

C. Taylor Pickett

Chief Executive Officer of

OHI Healthcare Properties Holdco, Inc.

the Primary General Partner

EX-32.6

Exhibit 32.6

SECTION 1350 CERTIFICATION

OF THE CHIEF FINANCIAL OFFICER

I, Robert O. Stephenson, Chief Financial Officer of OHI Healthcare Properties Holdco, Inc., the primary general partner of OHI Healthcare Properties Limited Partnership (the “Company”), hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:

(1) Amendment No. 1 to the Quarterly Report on Form 10-Q of the Company for the three months ended March 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2017

/S/ ROBERT O. STEPHENSON

Robert O. Stephenson

Chief Financial Officer of

OHI Healthcare Properties Holdco, Inc.

the Primary General partner

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Aug. 02, 2017
Document And Entity Information [Line Items]
Entity Registrant Name	OMEGA HEALTHCARE INVESTORS INC
Entity Central Index Key	0000888491
Trading Symbol	ohi
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock Shares Outstanding		197,241,081
Document Type	10-Q/A
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
OHI Healthcare Properties Holdco, Inc.
Document And Entity Information [Line Items]
Entity Registrant Name	OHI Healthcare Properties Holdco, Inc.
Entity Central Index Key	0001639311
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock Shares Outstanding		1,000
Document Type	10-Q/A
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
OHI Healthcare Properties Limited Partnership
Document And Entity Information [Line Items]
Entity Registrant Name	OHI Healthcare Properties Limited Partnership
Entity Central Index Key	0001639315
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock Shares Outstanding		0
Document Type	10-Q/A
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1

XML

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Mar. 31, 2017	Dec. 31, 2016
Real estate properties
Real estate investments (see Note 2)		$ 7,581,665	$ 7,566,358
Less accumulated depreciation		(1,306,084)	(1,240,336)
Real estate investments - net		6,275,581	6,326,022
Investments in direct financing leases - net		604,777	601,938
Mortgage notes receivable - net		644,696	639,343
Total		7,525,054	7,567,303
Other investments - net		255,899	256,846
Investment in unconsolidated joint venture		40,152	48,776
Assets held for sale - net		23,245	52,868
Total investments		7,844,350	7,925,793
Cash and cash equivalents		40,349	93,687
Restricted cash		12,198	13,589
Accounts receivable - net		272,506	240,035
Goodwill		643,692	643,474
Other assets		29,023	32,682
Total assets		8,842,118	8,949,260
LIABILITIES AND OWNERS' EQUITY
Revolving line of credit		123,000	190,000
Term loans - net		1,094,875	1,094,343
Secured borrowings - net	[1]	54,052	54,365
Unsecured borrowings - net		3,028,938	3,028,146
Accrued expenses and other liabilities		316,985	360,514
Deferred income taxes		9,746	9,906
Total liabilities		4,627,596	4,737,274
Equity:
Common stock $.10 par value authorized - 350,000 shares, issued and outstanding - 196,761 shares as of March 31, 2017 and 196,142 as of December 31, 2016		19,676	19,614
Common stock - additional paid-in capital		4,878,637	4,861,408
Cumulative net earnings		1,843,377	1,738,937
Cumulative dividends paid		(2,829,718)	(2,707,387)
Accumulated other comprehensive loss		(48,478)	(53,827)
Total stockholders' equity		3,863,494	3,858,745
Noncontrolling interest		351,028	353,241
Total equity		4,214,522	4,211,986
Owners' Equity:
Total liabilities and owners' equity		8,842,118	8,949,260
OHI Healthcare Properties Holdco, Inc.
Real estate properties
Real estate investments (see Note 2)		7,581,665	7,566,358
Less accumulated depreciation		(1,306,084)	(1,240,336)
Real estate investments - net		6,275,581	6,326,022
Investments in direct financing leases - net		604,777	601,938
Mortgage notes receivable - net		644,696	639,343
Total		7,525,054	7,567,303
Other investments - net		255,899	256,846
Investment in unconsolidated joint venture		40,152	48,776
Assets held for sale - net		23,245	52,868
Total investments		7,844,350	7,925,793
Cash and cash equivalents		40,349	93,687
Restricted cash		12,198	13,589
Accounts receivable - net		272,506	240,035
Goodwill		643,692	643,474
Other assets		29,023	32,682
Total assets		8,842,118	8,949,260
LIABILITIES AND OWNERS' EQUITY
Term loans - net		100,000	100,000
Secured borrowings - net		54,052	54,365
Accrued expenses and other liabilities		275,899	302,959
Deferred income taxes		9,746	9,906
Intercompany payable		4,187,899	4,270,044
Total liabilities		4,627,596	4,737,274
Equity:
Common stock - additional paid-in capital		923,218	923,218
Cumulative net earnings		149,360	126,187
Cumulative dividends paid		(202,391)	(175,289)
Accumulated other comprehensive loss		(11,253)	(12,439)
Total stockholders' equity		858,934	861,677
Noncontrolling interest		3,355,588	3,350,309
Total equity		4,214,522	4,211,986
Owners' Equity:
Total liabilities and owners' equity		8,842,118	8,949,260
OHI Healthcare Properties Limited Partnership
Real estate properties
Real estate investments (see Note 2)		7,581,665	7,566,358
Less accumulated depreciation		(1,306,084)	(1,240,336)
Real estate investments - net		6,275,581	6,326,022
Investments in direct financing leases - net		604,777	601,938
Mortgage notes receivable - net		644,696	639,343
Total		7,525,054	7,567,303
Other investments - net		255,899	256,846
Investment in unconsolidated joint venture		40,152	48,776
Assets held for sale - net		23,245	52,868
Total investments		7,844,350	7,925,793
Cash and cash equivalents		40,349	93,687
Restricted cash		12,198	13,589
Accounts receivable - net		272,506	240,035
Goodwill		643,692	643,474
Other assets		29,023	32,682
Total assets		8,842,118	8,949,260
LIABILITIES AND OWNERS' EQUITY
Term loans - net		100,000	100,000
Secured borrowings - net		54,052	54,365
Accrued expenses and other liabilities		275,899	302,959
Deferred income taxes		9,746	9,906
Intercompany payable		4,187,899	4,270,044
Total liabilities		4,627,596	4,737,274
Equity:
Accumulated other comprehensive loss		(50,780)
Owners' Equity:
General partners' equity		3,863,494	3,858,745
Limited partners' equity		351,028	353,241
Total owners' equity		4,214,522	4,211,986
Total liabilities and owners' equity		$ 8,842,118	$ 8,949,260

[1] These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

XML

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares shares in Thousands	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized	350,000	350,000
Common stock, shares issued	196,761	196,142
Common stock, shares outstanding	196,761	196,142

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue
Rental income	$ 192,537	$ 176,703
Income from direct financing leases	15,646	15,442
Mortgage interest income	15,956	16,606
Other investment income - net	6,914	3,431
Miscellaneous income	691	697
Total operating revenues	231,744	212,879
Expenses
Depreciation and amortization	69,993	62,433
General and administrative	12,524	10,455
Acquisition costs	(41)	3,771
Impairment loss on real estate properties	7,638	34,558
Provision for uncollectible accounts	2,404	5,124
Total operating expenses	92,518	116,341
Income before other income and expense	139,226	96,538
Other income (expense)
Interest income	4	8
Interest expense	(45,041)	(37,222)
Interest - amortization of deferred financing costs	(2,502)	(2,132)
Interest - refinancing costs		(298)
Contractual settlement	10,412
Realized gain (loss) on foreign exchange	61	(22)
Total other expense	(37,066)	(39,666)
Income before gain on assets sold	102,160	56,872
Gain on assets sold - net	7,420	1,571
Income from continuing operations	109,580	58,443
Income tax expense	(1,100)	(247)
Income from unconsolidated joint venture	632
Net income	109,112	58,196
Net income attributable to noncontrolling interest	(4,672)	(2,641)
Net income available to common stockholders	$ 104,440	$ 55,555
Basic:
Net income available to common stockholders (in dollars per share)	$ 0.53	$ 0.30
Diluted:
Net income (in dollars per share)	0.53	0.29
Diluted:
Dividends declared per common share (in dollars per share)	$ 0.62	$ 0.57
Weighted-average shares outstanding, basic (in shares)	197,013	188,228
Weighted-average shares outstanding, diluted (in shares)	206,174	198,350
OHI Healthcare Properties Holdco, Inc.
Revenue
Rental income	$ 192,537	$ 176,703
Income from direct financing leases	15,646	15,442
Mortgage interest income	15,956	16,606
Other investment income - net	6,914	3,431
Miscellaneous income	691	697
Total operating revenues	231,744	212,879
Expenses
Depreciation and amortization	69,993	62,433
General and administrative	12,524	10,455
Acquisition costs	(41)	3,771
Impairment loss on real estate properties	7,638	34,558
Provision for uncollectible accounts	2,404	5,124
Total operating expenses	92,518	116,341
Income before other income and expense	139,226	96,538
Other income (expense)
Interest income	4	8
Interest expense	(45,041)	(37,222)
Interest - amortization of deferred financing costs	(2,502)	(2,132)
Interest - refinancing costs		(298)
Contractual settlement	10,412
Realized gain (loss) on foreign exchange	61	(22)
Total other expense	(37,066)	(39,666)
Income before gain on assets sold	102,160	56,872
Gain on assets sold - net	7,420	1,571
Income from continuing operations	109,580	58,443
Income tax expense	(1,100)	(247)
Income from unconsolidated joint venture	632
Net income	109,112	58,196
Net income attributable to noncontrolling interest	(85,939)	(45,294)
Net income available to common stockholders	23,173	12,902
OHI Healthcare Properties Limited Partnership
Revenue
Rental income	192,537	176,703
Income from direct financing leases	15,646	15,442
Mortgage interest income	15,956	16,606
Other investment income - net	6,914	3,431
Miscellaneous income	691	697
Total operating revenues	231,744	212,879
Expenses
Depreciation and amortization	69,993	62,433
General and administrative	12,524	10,455
Acquisition costs	(41)	3,771
Impairment loss on real estate properties	7,638	34,558
Provision for uncollectible accounts	2,404	5,124
Total operating expenses	92,518	116,341
Income before other income and expense	139,226	96,538
Other income (expense)
Interest income	4	8
Interest expense	(45,041)	(37,222)
Interest - amortization of deferred financing costs	(2,502)	(2,132)
Interest - refinancing costs		(298)
Contractual settlement	10,412
Realized gain (loss) on foreign exchange	61	(22)
Total other expense	(37,066)	(39,666)
Income before gain on assets sold	102,160	56,872
Gain on assets sold - net	7,420	1,571
Income from continuing operations	109,580	58,443
Income tax expense	(1,100)	(247)
Income from unconsolidated joint venture	632
Net income	109,112	58,196
Net income attributable to noncontrolling interest
Net income available to common stockholders	$ 109,112	$ 58,196
Basic:
Net income (in dollars per share)	$ 0.53	$ 0.30
Diluted:
Net income (in dollars per share)	0.53	0.29
Dividends declared per common share (in dollars per share)	$ 0.62	$ 0.57
Weighted-average Omega OP Units outstanding, basic (in shares)	205,827	197,175
Weighted-average Omega OP Units outstanding, diluted (in shares)	206,174	198,350

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net income	$ 109,112	$ 58,196
Other comprehensive income (loss)
Foreign currency translation	4,334	(4,730)
Cash flow hedges	1,254	(8,876)
Total other comprehensive income (loss)	5,588	(13,606)
Comprehensive income	114,700	44,590
Comprehensive income attributable to noncontrolling interest	(4,911)	(2,025)
Comprehensive income attributable to common stockholders	109,789	42,565
OHI Healthcare Properties Holdco, Inc.
Net income	109,112	58,196
Other comprehensive income (loss)
Foreign currency translation	4,334	(4,730)
Cash flow hedges	1,254	(8,876)
Total other comprehensive income (loss)	5,588	(13,606)
Comprehensive income	114,700	44,590
Comprehensive income attributable to noncontrolling interest	(90,340)	(34,705)
Comprehensive income attributable to common stockholders	24,360	9,885
OHI Healthcare Properties Limited Partnership
Net income	109,112	58,196
Other comprehensive income (loss)
Foreign currency translation	4,334	(4,730)
Cash flow hedges	1,254	(8,876)
Total other comprehensive income (loss)	5,588	(13,606)
Comprehensive income	$ 114,700	$ 44,590

XML

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited) - 3 months ended Mar. 31, 2017 - USD ($) shares in Thousands, $ in Thousands	Common Stock Par Value	Additional Paid-in Capital	Cumulative Net Earnings	Cumulative Dividends Paid	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity	Noncontrolling Interest	Total	OHI Healthcare Properties Holdco, Inc. Common stock - additional paid-in capital	OHI Healthcare Properties Holdco, Inc. Cumulative Net Earnings	OHI Healthcare Properties Holdco, Inc. Cumulative Dividends Paid	OHI Healthcare Properties Holdco, Inc. Accumulated Other Comprehensive Income (Loss)	OHI Healthcare Properties Holdco, Inc. Total Stockholders' Equity	OHI Healthcare Properties Holdco, Inc. Noncontrolling Interest	OHI Healthcare Properties Holdco, Inc.	OHI Healthcare Properties Limited Partnership General Partners	OHI Healthcare Properties Limited Partnership Limited Partners	OHI Healthcare Properties Limited Partnership
Balance (196,142 common shares & 8,862 Omega OP Units, 43,714 shares) at Dec. 31, 2016	$ 19,614	$ 4,861,408	$ 1,738,937	$ (2,707,387)	$ (53,827)	$ 3,858,745	$ 353,241	$ 4,211,986	$ 923,218	$ 126,187	$ (175,289)	$ (12,439)	$ 861,677	$ 3,350,309	$ 4,211,986
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Stock-based compensation expense		3,744				3,744		3,744
Vesting/exercising of equity compensation plan, net of tax withholdings (103 shares)	10	(2,130)				(2,120)		(2,120)
Dividend reinvestment and stock purchase plan (239 shares at an average of $30.67 per share)	24	7,311				7,335		7,335
Grant of stock as payment of directors fees (2 shares at an average of $31.19 per share)		75				75		75
Deferred compensation directors		(16)				(16)		(16)
Equity Shelf Program (228 shares at $29.71 per share, net of issuance costs)	23	6,736				6,759		6,759
Common dividends declared ($0.62 per share)				(122,331)		(122,331)		(122,331)
Conversion of Omega OP Units to common stock (47 shares at $32.30 per share)	5	1,509				1,514		1,514
Redemption of Omega OP Units (48 units)							(1,570)	(1,570)
Omega OP Unit distributions							(5,554)	(5,554)
Contributions														17,291	17,291
Distributions											(27,102)		(27,102)	(102,353)	(129,455)
Foreign currency translation					4,149	4,149	185	4,334				920	920	3,414	4,334	$ 4,149	$ 185	$ 4,334
Cash flow hedges					1,200	1,200	54	1,254				266	266	988	1,254	1,200	54	1,254
Net income			104,440			104,440	4,672	109,112		23,173			23,173	85,939	109,112	104,440	4,672	109,112
Balance (196,761 shares & 8,814 Omega OP Units,43,714 shares) at Mar. 31, 2017	$ 19,676	$ 4,878,637	1,843,377	$ (2,829,718)	(48,478)	3,863,494	351,028	4,214,522	$ 923,218	149,360	$ (202,391)	(11,253)	858,934	3,355,588	4,214,522
Balance at Dec. 31, 2016																$ 3,858,745	$ 353,241	$ 4,211,986
Balance (in shares) at Dec. 31, 2016																196,142	8,862	205,004
Increase (Decrease) in Partners' Capital [Roll Forward]
Contributions from partners																$ 17,291		$ 17,291
Contributions from partners (in shares)																619		619
Distributions to partners																$ (122,331)	$ (5,554)	$ (127,885)
Omega OP Unit redemptions																	$ (1,570)	$ (1,570)
Omega OP Unit redemptions (in shares)																	(48)	(48)
Foreign currency translation					4,149	4,149	185	4,334				920	920	3,414	4,334	4,149	$ 185	$ 4,334
Cash flow hedges					$ 1,200	1,200	54	1,254				$ 266	266	988	1,254	1,200	54	1,254
Net income			$ 104,440			$ 104,440	$ 4,672	$ 109,112		$ 23,173			$ 23,173	$ 85,939	$ 109,112	104,440	4,672	109,112
Balance at Mar. 31, 2017																$ 3,863,494	$ 351,028	$ 4,214,522
Balance (in shares) at Mar. 31, 2017																196,761	8,814	205,575

XML

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited) (Parentheticals) - $ / shares shares in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Balance (in shares)	196,142
Vesting/exercising of equity compensation plan (in shares)	103
Shares issued under dividend reinvestment (in shares)	239
Dividend reinvestment and stock purchase plan (in dollars per share)	$ 30.67
Grant of stock as payment of fees (in shares)	2
Grant of stock as payment of fees (in dollars per share)	$ 31.19
Equity shelf program (in shares)	228
Equity shelf program, (in dollars per share)	$ 29.71
Common dividends, (in dollars per share)	$ 0.62
Conversion of OP Units to Common stock (in shares)	47
Conversion of OP Units to Common stock (in dollars per share)	$ 32.30
Redemption of OP Units (in units)	48
Balance (in shares)	196,761	196,142
Balance (in units)	8,814	8,862
OHI Healthcare Properties Holdco, Inc.
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Balance (in shares)	1
Balance (in shares)	1	1

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities
Net income	$ 109,112	$ 58,196
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	69,993	62,433
Impairment loss on real estate properties	7,638	34,558
Provision for uncollectible accounts	2,404	5,124
Refinancing costs and amortization of deferred financing costs	2,502	2,430
Accretion of direct financing leases	(3,016)	(2,921)
Stock-based compensation expense	3,744	2,778
Gain on assets sold - net	(7,420)	(1,571)
Amortization of acquired in-place leases - net	(3,096)	(4,300)
Effective yield receivable on mortgage notes	(593)	(819)
Change in operating assets and liabilities - net:
Accounts receivable	(21,377)	560
Straight-line rent receivables	(11,747)	(9,947)
Lease inducements	447	647
Other operating assets and liabilities	(34,653)	(19,989)
Net cash provided by operating activities	113,938	127,179
Cash flows from investing activities
Acquisition of real estate	(7,574)	(416,104)
Investments in construction in progress	(15,703)	(16,316)
Investments in direct financing leases	(2,229)
Deposit to acquire real estate		(113,816)
Placement of mortgage loans	(5,749)	(6,162)
Distributions from unconsolidated joint venture	8,587
Proceeds from sale of real estate investments	45,848	2,392
Capital improvements to real estate investments	(8,199)	(9,544)
Proceeds from other investments	23,181	1,461
Investments in other investments	(22,144)	(116,003)
Collection of mortgage principal	333	312
Net cash provided by (used in) investing activities	16,351	(673,780)
Cash flows from financing activities
Proceeds from credit facility borrowings	148,000	670,000
Payments on credit facility borrowings	(215,000)	(370,000)
Receipts of other long-term borrowings		350,000
Payments of other long-term borrowings	(318)	(309)
Payments of financing related costs	(563)	(3,576)
Receipts from dividend reinvestment plan	7,335	19,596
Payments for exercised options and restricted stock	(2,120)	(2,381)
Net proceeds from issuance of common stock	6,759
Dividends paid	(122,272)	(107,500)
Redemption of Omega OP Units	(56)	(10)
Distributions to Omega OP Unit Holders	(5,554)	(5,131)
Net cash (used in) provided by financing activities	(183,789)	550,689
Effect of foreign currency translation on cash and cash equivalents	162	(105)
(Decrease) increase in cash and cash equivalents	(53,338)	3,983
Cash and cash equivalents at beginning of period	93,687	5,424
Cash and cash equivalents at end of period	40,349	9,407
Supplemental disclosures of cash flow information:
Interest paid during the period, net of amounts capitalized	61,832	36,597
Taxes paid during the period	1,173	141
Non cash financing activities
Change in fair value of cash flow hedges	(1,291)	8,876
OHI Healthcare Properties Holdco, Inc.
Cash flows from operating activities
Net income	109,112	58,196
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	69,993	62,433
Impairment loss on real estate properties	7,638	34,558
Provision for uncollectible accounts	2,404	5,124
Refinancing costs and amortization of deferred financing costs	2,502	2,430
Accretion of direct financing leases	(3,016)	(2,921)
Stock-based compensation expense	3,744	2,778
Gain on assets sold - net	(7,420)	(1,571)
Amortization of acquired in-place leases - net	(3,096)	(4,300)
Effective yield receivable on mortgage notes	(593)	(819)
Change in operating assets and liabilities - net:
Accounts receivable	(21,377)	560
Straight-line rent receivables	(11,747)	(9,947)
Lease inducements	447	647
Other operating assets and liabilities	(34,653)	(19,989)
Net cash provided by operating activities	113,938	127,179
Cash flows from investing activities
Acquisition of real estate	(7,574)	(416,104)
Investments in construction in progress	(15,703)	(16,316)
Investments in direct financing leases	(2,229)
Deposit to acquire real estate		(113,816)
Placement of mortgage loans	(5,749)	(6,162)
Distributions from unconsolidated joint venture	8,587
Proceeds from sale of real estate investments	45,848	2,392
Capital improvements to real estate investments	(8,199)	(9,544)
Proceeds from other investments	23,181	1,461
Investments in other investments	(22,144)	(116,003)
Collection of mortgage principal	333	312
Net cash provided by (used in) investing activities	16,351	(673,780)
Cash flows from financing activities
Proceeds from intercompany loans from Omega	148,000	1,020,000
Repayment of intercompany loans to Omega	(215,318)	(370,309)
Payment of financing related costs incurred by Omega	(563)	(3,576)
Distributions to limited partner	(100,780)	(87,725)
Dividends paid	(27,102)	(24,916)
Contribution from noncontrolling interest	11,974	17,215
Net cash (used in) provided by financing activities	(183,789)	550,689
Effect of foreign currency translation on cash and cash equivalents	162	(105)
(Decrease) increase in cash and cash equivalents	(53,338)	3,983
Cash and cash equivalents at beginning of period	93,687	5,424
Cash and cash equivalents at end of period	40,349	9,407
Supplemental disclosures of cash flow information:
Interest paid during the period, net of amounts capitalized	61,832	36,597
Taxes paid during the period	1,173	141
Non cash financing activities
Change in fair value of cash flow hedges	(1,291)	8,876
OHI Healthcare Properties Limited Partnership
Cash flows from operating activities
Net income	109,112	58,196
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	69,993	62,433
Impairment loss on real estate properties	7,638	34,558
Provision for uncollectible accounts	2,404	5,124
Refinancing costs and amortization of deferred financing costs	2,502	2,430
Accretion of direct financing leases	(3,016)	(2,921)
Stock-based compensation expense	3,744	2,778
Gain on assets sold - net	(7,420)	(1,571)
Amortization of acquired in-place leases - net	(3,096)	(4,300)
Effective yield receivable on mortgage notes	(593)	(819)
Change in operating assets and liabilities - net:
Accounts receivable	(21,377)	560
Straight-line rent receivables	(11,747)	(9,947)
Lease inducements	447	647
Other operating assets and liabilities	(34,653)	(19,989)
Net cash provided by operating activities	113,938	127,179
Cash flows from investing activities
Acquisition of real estate	(7,574)	(416,104)
Investments in construction in progress	(15,703)	(16,316)
Investments in direct financing leases	(2,229)
Deposit to acquire real estate		(113,816)
Placement of mortgage loans	(5,749)	(6,162)
Distributions from unconsolidated joint venture	8,587
Proceeds from sale of real estate investments	45,848	2,392
Capital improvements to real estate investments	(8,199)	(9,544)
Proceeds from other investments	23,181	1,461
Investments in other investments	(22,144)	(116,003)
Collection of mortgage principal	333	312
Net cash provided by (used in) investing activities	16,351	(673,780)
Cash flows from financing activities
Proceeds from intercompany loans from Omega	148,000	1,020,000
Repayment of intercompany loans to Omega	(215,318)	(370,309)
Payment of financing related costs incurred by Omega	(563)	(3,576)
Equity contribution of general partner	11,974	17,215
Distribution to general partner	(122,272)	(107,500)
Distributions to limited partner	(5,554)	(5,131)
Redemption of Omega OP Units	(56)	(10)
Net cash (used in) provided by financing activities	(183,789)	550,689
Effect of foreign currency translation on cash and cash equivalents	162	(105)
(Decrease) increase in cash and cash equivalents	(53,338)	3,983
Cash and cash equivalents at beginning of period	93,687	5,424
Cash and cash equivalents at end of period	40,349	9,407
Supplemental disclosures of cash flow information:
Interest paid during the period, net of amounts capitalized	61,832	36,597
Taxes paid during the period	1,173	141
Non cash financing activities
Change in fair value of cash flow hedges	$ (1,291)	$ 8,876

XML

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Business Overview and Organization

Omega Healthcare Investors, Inc. (“Omega”) was formed as a real estate investment trust (“REIT”) and incorporated in the State of Maryland on March 31, 1992. All of Omega's assets are owned directly or indirectly, and all of Omega's operations are conducted directly or indirectly, through its subsidiaries, OHI Healthcare Properties Holdco, Inc. (“OHI Holdco”), a direct wholly owned subsidiary of Omega, and OHI Healthcare Properties Limited Partnership (“Omega OP”). OHI Holdco was formed as a corporation and incorporated in the State of Delaware on October 22, 2014. Omega OP was formed as a limited partnership and organized in the State of Delaware on October 24, 2014. No substantive assets or activity occurred in either of these entities until the merger with Aviv REIT, Inc. on April 1, 2015. Unless stated otherwise or the context otherwise requires, the terms the “Company,” “we,” “our” and “us” means Omega, OHI Holdco and Omega OP, collectively.

The Company has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States (“U.S.”) and the United Kingdom (“U.K.”). Our core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (“SNFs”) and, to a lesser extent, assisted living facilities (“ALFs”), independent living facilities and rehabilitation and acute care facilities. Our core portfolio consists of long-term leases and mortgage agreements. All of our leases are “triple-net” leases, which require the tenants to pay all property-related expenses. Our mortgage revenue derives from fixed rate mortgage loans, which are secured by first mortgage liens on the underlying real estate and personal property of the mortgagor.

In April 2015, Aviv REIT, Inc., a Maryland corporation (“Aviv”), merged (the “Aviv Merger”) with and into a wholly owned subsidiary of Omega, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of October 30, 2014 (the “Merger Agreement”), by and among Omega, Aviv, OHI Holdco, Omega OP, and Aviv Healthcare Properties Limited Partnership, a Delaware limited partnership.

Prior to April 1, 2015 and in accordance with the Merger Agreement, Omega restructured the manner in which it holds its assets by converting to an umbrella partnership real estate investment trust structure (the “UPREIT Conversion”). As a result of the UPREIT Conversion and following the consummation of the Aviv Merger, all of Omega’s assets are held by Omega OP, through its equity interests in its subsidiaries.

Omega OP is governed by the Second Amended and Restated Agreement of Limited Partnership of OHI Healthcare Properties Limited Partnership, dated as of April 1, 2015 (the “Partnership Agreement”). Pursuant to the Partnership Agreement, Omega and OHI Holdco are the general partners of Omega OP, and have exclusive control over Omega OP’s day-to-day management. As of March 31, 2017, Omega and OHI Holdco together owned approximately 96% of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and investors owned approximately 4% of the Omega OP Units.

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods reported herein are not necessarily indicative of results to be expected for the full year. These unaudited consolidated financial statements should be read in conjunction with the financial statements and the footnotes thereto included in our Form 10-K/A filed with the SEC on August 9, 2017.

Our consolidated financial statements include the accounts of (i) Omega, (ii) OHI Holdco (iii) Omega OP and (iv) all direct and indirect wholly owned subsidiaries of Omega. All intercompany transactions and balances have been eliminated in consolidation, and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.

Asset Impairment

Management evaluates our real estate investments for impairment indicators at each reporting period, including the evaluation of our assets’ useful lives. The judgment regarding the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance, legal structure, as well as our intent with respect to holding or disposing of the asset. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to the future undiscounted cash flows of the underlying facilities. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows based on our intended use of the property are determined to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the real estate investments for the excess of carrying value over fair value. The fair value of the real estate investment is determined by market research, which includes valuing the property as a nursing home as well as other alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset. Management’s impairment evaluation process, and when applicable, impairment calculations involve estimation of the future cash flows from management’s intended use of the property. Changes in the facts and circumstances that drive management’s assumptions may result in an impairment of the Company’s assets in a future period that could be material to the Company’s results of operations.

If we decide to sell real estate properties or land holdings, we evaluate the recoverability of the carrying amounts of the assets. If the evaluation indicates that the carrying value is not recoverable from estimated net sales proceeds, the property is written down to estimated fair value less costs to sell. Our estimates of cash flows and fair values of the properties are based on current market conditions and consider matters such as rental rates and occupancies for comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers or prospective purchasers.

For the three months ended March 31, 2017 and 2016, we recognized impairment losses of $7.6 million and $34.6 million, respectively. For additional information see Note 2 – Properties and Investments and Note 7 – Assets Held For Sale.

Goodwill Impairment

We assess goodwill for potential impairment during the fourth quarter of each fiscal year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the net assets of the reporting unit. In evaluating goodwill for impairment on an interim basis, we assess qualitative factors such as a significant decline in real estate valuations, current macroeconomic conditions, state of the equity and capital markets and our overall financial and operating performance or a significant decline in the value of our market capitalization, to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of the reporting unit is less than its carrying amount. On an annual basis during the fourth quarter of each fiscal year, or on an interim basis if we conclude it is more likely than not that the fair value of the reporting unit is less than its carrying value, we perform a two-step goodwill impairment test to identify potential impairment and measure the amount of impairment we will recognize, if any.

Noncontrolling Interests

Noncontrolling interests is the portion of equity not attributable to the respective reporting entity. We present the portion of any equity that we do not own in consolidated entities as noncontrolling interests and classify those interests as a component of total equity, separate from total stockholders’ equity, or owners’ equity on our Consolidated Balance Sheets. We include net income attributable to the noncontrolling interests in net income in our Consolidated Statements of Operations.

As our ownership of a controlled subsidiary increases or decreases, any difference between the aggregate consideration paid to acquire the noncontrolling interests and our noncontrolling interest balance is recorded as a component of equity in additional paid-in capital, so long as we maintain a controlling ownership interest.

The noncontrolling interest for Omega represents the outstanding Omega OP Units held by outside investors. The noncontrolling interest for OHI Holdco represents the Omega OP Units held by the Parent and the outstanding Omega OP Units held by outside investors.

Foreign Operations

The U.S. dollar is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound. For our consolidated subsidiaries whose functional currency is not the U.S. dollar, we translate their financial statements into the U.S. dollar. We translate assets and liabilities at the exchange rate in effect as of the financial statement date. Revenue and expense accounts are translated using an average exchange rate for the period. Gains and losses resulting from translation are included in accumulated other comprehensive loss (“AOCL”), as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest.

We and certain of our consolidated subsidiaries may have intercompany and third-party debt that is not denominated in the entity’s functional currency. When the debt is remeasured against the functional currency of the entity, a gain or loss can result. The resulting adjustment is reflected in results of operations, unless it is intercompany debt that is deemed to be long-term in nature and then the adjustments are included in AOCL.

Derivative Instruments

During our normal course of business, we may use certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at the inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with the Company’s related assertions. The Company recognizes all derivative instruments, including embedded derivatives required to be bifurcated, as assets or liabilities in the Consolidated Balance Sheets at their fair value which are determined using a market approach and Level 2 inputs. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in earnings. For derivatives designated as qualifying cash flow hedging relationships, the change in fair value of the effective portion of the derivatives is recognized in AOCL as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest, whereas the change in fair value of the ineffective portion is recognized in earnings. We formally document all relationships between hedging instruments and hedged items, as well as our risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific forecasted transactions as well as recognized obligations or assets in the Consolidated Balance Sheets. We also assess and document, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, we discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the current fair value of the derivative. As a matter of policy, we do not use derivatives for trading or speculative purposes. At March 31, 2017 and December 31, 2016, we had $0.2 million and $1.5 million, respectively, of qualifying cash flow hedges recorded at fair value in accrued expenses and other liabilities on our Consolidated Balance Sheets.

Accounts Receivable

Accounts receivable includes: contractual receivables, effective yield interest receivables, straight-line rent receivables and lease inducements, net of an estimated provision for losses related to uncollectible and disputed accounts. Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception or renewal of the lease, and are amortized as a reduction of rental revenue over the non-cancellable lease term.

On a quarterly basis, we review our accounts receivable to determine their collectability. The determination of collectability of these assets requires significant judgment and is affected by several factors relating to the credit quality of our operators that we regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement environment, (iv) the ability of the tenant to perform under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying collateral of the agreement.  If we determine collectability of any of our contractual receivables is at risk, we estimate the potential uncollectible amounts and provide an allowance. In the case of a lease recognized on a straight-line basis, a mortgage recognized on an effective yield basis or the existence of lease inducements, we generally provide an allowance for straight-line, effective interest, and or lease inducement accounts receivable when certain conditions or indicators of adverse collectability are present. If the accounts receivable balance is subsequently deemed uncollectible, the receivable and allowance for doubtful account balance are written off.

A summary of our net receivables by type is as follows:

	March 31,			December 31,
	2017			2016
	(in thousands)
Contractual receivables	$	34,751		$	13,376
Effective yield interest receivables		10,343			9,749
Straight-line rent receivables		219,821			208,874
Lease inducements		7,946			8,393
Allowance		(355	)		(357	)
Accounts receivable – net	$	272,506		$	240,035

Related Party Transactions

The Company has a policy which generally requires related party transactions to be approved or ratified by the Audit Committee. On February 1, 2016, we acquired 10 SNFs from Laurel Healthcare Holdings, Inc. (“Laurel”) for approximately $169.0 million in cash and leased them to an unrelated existing operator. A former member of the Board of Directors of the Company, together with certain members of his immediate family, beneficially owned approximately 34% of the equity of Laurel prior to the transaction. Immediately following our acquisition, the unrelated existing operator acquired all of the outstanding equity interests of Laurel, including the interests previously held by the former director of the Company and his family.

Accounting Pronouncement Adopted in 2017

In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Compensation-Stock Compensation (Topic 718) (“ASU 2016-09”). ASU 2016-09 amends the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2016. We adopted this accounting standard on January 1, 2017, at which time the Company began prospectively accounting for excess tax benefits or tax deficiencies as an adjustment to income tax expense in our Consolidated Statements of Operations as opposed to the prior requirement that these excess tax benefits be recognized in additional paid-in capital and tax deficiencies be recognized either as an offset to accumulated excess tax benefits, if any, or in the income statement. The Company will continue to account for forfeitures as they occur and present employee taxes paid as a financing activity on our Consolidated Statements of Cash Flows. The adoption of this accounting standard did not have a material impact on our consolidated financial statements.

Recent Accounting Pronouncements - Pending Adoption

In 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment. ASU 2014-09 is effective for the Company beginning January 1, 2018. In addition, the FASB has begun to issue targeted updates to clarify specific implementation issues of ASU 2014-09. These updates include ASU 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016-10, Identifying Performance Obligations and Licensing, and ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. The Company is currently evaluating the provisions of ASU 2014-09 and its related updates and will be closely monitoring developments and additional guidance to determine the potential impact of the new standard. The Company intends to adopt ASU 2014-09 and its subsequent updates in accordance with the modified retrospective approach. We do not expect the adoption of ASU 2014-09 and its updates to have a significant impact on our consolidated financial statements, as a substantial portion of our revenue consists of rental income from leasing arrangements and interest income from loan arrangements, both of which are specifically excluded from ASU 2014-09.

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective for the Company beginning January 1, 2019. Early adoption of ASU 2016-02 as of its issuance is permitted. The new standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact of adopting ASU 2016-02 on our consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) (“ASU 2016-13”), which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. ASU 2016-13 is effective for annual and interim periods beginning after December 15, 2019 and early adoption is permitted for annual and interim periods beginning after December 15, 2018. We are currently evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements.

XML

PROPERTIES AND INVESTMENTS

3 Months Ended

Mar. 31, 2017

Real Estate [Abstract]

PROPERTIES AND INVESTMENTS

NOTE 2 – PROPERTIES AND INVESTMENTS

Leased Property

Our real estate properties, represented by 808 SNFs, 101 ALFs, 16 specialty facilities and one medical office building at March 31, 2017, are leased under provisions of single or master leases with initial terms typically ranging from five to 15 years, plus renewal options. Substantially all of our leases contain provisions for specified annual increases over the rents of the prior year and are generally computed in one of three methods depending on specific provisions of each lease as follows: (i) a specific annual percentage increase over the prior year’s rent, generally between 2.0% and 3.0%; (ii) an increase based on the change in pre-determined formulas from year to year (e.g., increases in the Consumer Price Index (“CPI”)); or (iii) specific dollar increases over prior years. Under the terms of the leases, the lessee is responsible for all maintenance, repairs, taxes and insurance on the leased properties.

A summary of our investment in leased real estate properties is as follows:

	March 31,			December 31,
	2017			2016
	(in thousands)
Buildings	$	5,980,501		$	5,954,771
Land		756,803			759,295
Furniture, fixtures and equipment		454,288			454,760
Site improvements		206,326			206,206
Construction in progress		183,747			191,326
Total real estate investments		7,581,665			7,566,358
Less accumulated depreciation		(1,306,084	)		(1,240,336	)
Real estate investments - net	$	6,275,581		$	6,326,022

The following table summarizes the significant acquisitions that occurred in the first quarter of 2017:

Number of  Facilities				Country/	Total  Investment		Land		Building & Site Improvements		Furniture & Fixtures		Initial Annual Cash
SNF		ALF		State	(in millions)								Yield (%)
	-		1	VA	$	7.6	$	0.5	$	6.8	$	0.3		7.50

Asset Sales, Impairments and Other

During the first quarter of 2017, we sold 15 facilities for approximately $45.8 million in net proceeds recognizing a gain of approximately $7.4 million. Eleven of the sold facilities were previously classified as held for sale. In addition, we recorded a provision for impairment of approximately $7.6 million on three facilities, one of which was reclassified to held for sale on March 31, 2017. We reduced the net book value of the impaired facilities to their estimated fair values or, with respect to the facility reclassified to held for sale, to its estimated fair value less costs to sell. To estimate the fair value of the facilities, we utilized a market approach and Level 3 inputs (which generally consist of non-binding offers from unrelated third parties). Also see Note 7 – Assets Held For Sale for details. Our recorded impairments were primarily the result of a decision to exit certain non-strategic facilities and/or operators.

XML

DIRECT FINANCING LEASES

3 Months Ended

Mar. 31, 2017

Leases, Capital [Abstract]

DIRECT FINANCING LEASES

NOTE 3 – DIRECT FINANCING LEASES

The components of investments in direct financing leases consist of the following:

	March 31,			December 31,
	2017			2016
	(in thousands)
Minimum lease payments receivable	$	4,291,940		$	4,287,069
Less unearned income		(3,684,757	)		(3,685,131	)
Less allowance for loss on direct financing lease		(2,406	)		—
Investment in direct financing leases - net	$	604,777		$	601,938
Properties subject to direct financing leases		58			58

As of March 31, 2017, the following minimum rents are due under our direct financing leases for the next five fiscal years (in thousands):

2018	2019	2020	2021	2022
$51,319	$52,626	$53,917	$55,199	$56,488

New Ark Investment Inc.

On November 27, 2013, we closed an aggregate $529 million purchase/leaseback transaction in connection with the acquisition of Ark Holding Company, Inc. (“Ark Holding”) by 4 West Holdings Inc. At closing, we acquired 55 SNFs and 1 ALF operated by Ark Holding and leased the facilities back to Ark Holding, now known as New Ark Investment Inc. (“New Ark”), pursuant to four 50-year master leases with rental payments yielding 10.6% per annum over the term of the leases. The purchase/leaseback transaction is being accounted for as a direct financing lease.

The lease agreements allow the tenant the right to purchase the facilities for a bargain purchase price plus closing costs at the end of the lease term. In addition, commencing in the 41st year of each lease, the tenant will have the right to prepay the remainder of its obligations thereunder for an amount equal to the sum of the unamortized portion of the original aggregate $529 million investment plus the net present value of the remaining payments under the lease and closing costs. In the event the tenant exercises either of these options, we have the right to purchase the properties for fair value at the time.

The 56 facilities represent 5,623 licensed beds located in 12 states, predominantly in the southeastern U.S. The 56 facilities are separated by region and divided amongst four cross-defaulted master leases. The four regions include the Southeast (39 facilities), the Northwest (7 facilities), Texas (9 facilities) and Indiana (1 facility).

Additionally, we own four facilities and lease them to New Ark under a master lease which expires in 2026. The four facility lease is being accounted for as an operating lease.

In March 2017, we executed sale agreements with two unrelated third parties to sell the 7 Northwest facilities with a carrying value of approximately $36.4 million for $34.0 million. As a result, we recorded an allowance for loss of approximately $2.4 million. For the three months ended March 31, 2017, we recognized approximately $0.8 million of direct financing lease income on a cash basis related to the Northwest facilities lease. The sale of these facilities is expected to close in the second quarter of 2017.

XML

MORTGAGE NOTES RECEIVABLE

3 Months Ended

Mar. 31, 2017

Mortgage Notes Receivable Investments [Abstract]

MORTGAGE NOTES RECEIVABLE

NOTE 4 – MORTGAGE NOTES RECEIVABLE

As of March 31, 2017, mortgage notes receivable relate to 27 fixed rate mortgages on 49 long-term care facilities. The mortgage notes are secured by first mortgage liens on the borrowers’ underlying real estate and personal property. The mortgage notes receivable relate to facilities located in ten states that are operated by eight independent healthcare operating companies. We monitor compliance with mortgages and when necessary have initiated collection, foreclosure and other proceedings with respect to certain outstanding mortgage notes.

Mortgage interest income is recognized as earned over the terms of the related mortgage notes, using the effective yield method. Allowances are provided against earned revenues from mortgage interest when collection of amounts due becomes questionable or when negotiations for restructurings of troubled operators lead to lower expectations regarding ultimate collection. When collection is uncertain, mortgage interest income on impaired mortgage loans is recognized as received after taking into account the application of security deposits.

The outstanding principal amounts of mortgage notes receivable, net of allowances, were as follows:

	March 31,			December 31,
	2017			2016
	(in thousands)
Mortgage note due 2024; interest at 9.98%	$	112,500		$	112,500
Mortgage note due 2029; interest at 9.45%		411,807			412,140
Other mortgage notes outstanding (1)		124,323			118,637
Mortgage notes receivable, gross		648,630			643,277
Allowance for loss on mortgage notes receivable		(3,934	)		(3,934	)
Total mortgages — net	$	644,696		$	639,343

⁽¹⁾ Other mortgage notes outstanding have stated interest rates ranging from 8.35% to 12.0% and maturity dates through 2029.

XML

OTHER INVESTMENTS

3 Months Ended

Mar. 31, 2017

Receivables [Abstract]

OTHER INVESTMENTS

NOTE 5 – OTHER INVESTMENTS

A summary of our other investments is as follows:

	March 31,			December 31,
	2017			2016
	(in thousands)
Other investment note due 2019; interest at 10.73%	$	49,521		$	49,458
Other investment note due 2020; interest at 14.00%		47,856			47,913
Other investment note due 2022, interest at 9.00%		31,987			31,987
Other investment note due 2030; interest at 6.66%		48,705			44,595
Other investment notes outstanding (1)		82,628			87,691
Other investments, gross		260,697			261,644
Allowance for loss on other investments		(4,798	)		(4,798	)
Total other investments	$	255,899		$	256,846

⁽¹⁾ Other investment notes have maturity dates through 2028 and interest rates ranging from 6.50% to 13.0%.

XML

INVESTMENT IN UNCONSOLIDATED JOINT VENTURE

3 Months Ended

Mar. 31, 2017

Equity Method Investments and Joint Ventures [Abstract]

INVESTMENT IN UNCONSOLIDATED JOINT VENTURE

NOTE 6 – INVESTMENT IN UNCONSOLIDATED JOINT VENTURE

On November 1, 2016, we invested approximately $50.0 million for an approximate 15% ownership interest in a joint venture operating as Second Spring Healthcare Investments. The other approximate 85% interest is owned by affiliates of Lindsey Goldberg LLC. We account for the joint venture using the equity method. On November 1, 2016, the joint venture acquired 64 SNFs from Welltower Inc. for approximately $1.1 billion.

We receive asset management fees from the joint venture for services provided. For the three months ended March 31, 2017, we recognized $0.5 million of asset management fees. These fees are included in miscellaneous income in the accompanying Consolidated Statement of Operations. The accounting policies for the unconsolidated joint venture are the same as those of the Company.

XML

ASSETS HELD FOR SALE

3 Months Ended

Mar. 31, 2017

Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]

ASSETS HELD FOR SALE

NOTE 7 – ASSETS HELD FOR SALE

The following is a summary of our assets held for sale:

	Properties Held For Sale
	Number of Properties			Net Book Value (in thousands)
December 31, 2016		20		$	52,868
Properties sold/other (1)		(12	)		(30,023	)
Properties added (2)		1			400
March 31, 2017(3)		9		$	23,245

⁽¹⁾ In the first quarter of 2017, we sold nine SNFs and two ALFs for approximately $29.4 million in net proceeds recognizing a gain on sale of approximately $3.6 million. One SNF classified as an asset held for sale at December 31, 2016 was no longer considered held for sale during the first quarter of 2017 and was reclassified back to leased properties at approximately $5.1 million which represents the facility’s then carrying value adjusted for depreciation that was not recognized while classified as held for sale.

(2)	In the first quarter of 2017, we recorded a $3.5 million impairment to reduce one ALF’s net book value to its estimated fair value less costs to sell before it was reclassified to assets held for sale.
(3)	We plan to sell the nine facilities classified as held for sale at March 31, 2017 over the next several quarters.

XML

INTANGIBLES

3 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLES

NOTE 8 – INTANGIBLES

The following is a summary of our intangibles as of March 31, 2017 and December 31, 2016:

	March 31,			December 31,
	2017			2016
	(in thousands)
Assets:
Goodwill	$	643,692		$	643,474
Above market leases	$	22,443		$	22,476
In-place leases		167			167
Accumulated amortization		(16,180	)		(15,864	)
Net intangible assets	$	6,430		$	6,779
Liabilities:
Below market leases	$	164,735		$	165,028
Accumulated amortization		(74,131	)		(70,738	)
Net intangible liabilities	$	90,604		$	94,290

Above market leases and in-place leases, net of accumulated amortization, are included in other assets on our Consolidated Balance Sheets. Below market leases, net of accumulated amortization, are included in accrued expenses and other liabilities on our Consolidated Balance Sheets. The net amortization related to the above and below market leases is included in our Consolidated Statements of Operations as an adjustment to rental income.

For the three months ended March 31, 2017 and 2016, our net amortization related to intangibles was $3.1 million and $4.3 million, respectively. The estimated net amortization related to these intangibles for the remainder of 2017 and the subsequent four years is as follows: remainder of 2017 – $8.9 million; 2018 – $10.5 million; 2019 – $9.5 million; 2020 – $9.3 million and 2021 – $8.7 million. As of March 31, 2017 the weighted average remaining amortization period of above market leases (inclusive of in-place leases) and below market leases is approximately eight years and nine years, respectively.

The following is a reconciliation of our goodwill as of March 31, 2017:

	(in thousands)
Balance as of December 31, 2016	$	643,474
Add: foreign currency translation		218
Balance as of March 31, 2017	$	643,692

XML

CONCENTRATION OF RISK

3 Months Ended

Mar. 31, 2017

Risks and Uncertainties [Abstract]

CONCENTRATION OF RISK

NOTE 9 – CONCENTRATION OF RISK

As of March 31, 2017, our portfolio of real estate investments consisted of 985 healthcare facilities, located in 42 states and the U.K. and operated by 77 third party operators. Our investment in these facilities, net of impairments and reserve for uncollectible loans, totaled approximately $8.9 billion at March 31, 2017, with approximately 99% of our real estate investments related to long-term care facilities. Our portfolio is made up of 808 SNFs, 101 ALFs, 16 specialty facilities, one medical office building, fixed rate mortgages on 44 SNFs and four ALFs, and 11 facilities that are closed/held-for-sale. At March 31, 2017, we also held other investments of approximately $255.9 million, consisting primarily of secured loans to third-party operators of our facilities.

At March 31, 2017, the three states in which we had our highest concentration of investments were Ohio (10%), Texas (9%) and Florida (9%). No single operator or manager generated more than 10% of our total revenues for the three months ended March 31, 2017.

XML

STOCKHOLDERS'/OWNERS' EQUITY

3 Months Ended

Mar. 31, 2017

Stockholders' Equity Note [Abstract]

STOCKHOLDERS'/OWNERS' EQUITY

NOTE 10 – STOCKHOLDERS’/OWNERS’ EQUITY

On April 13, 2017, the Board of Directors declared a common stock dividend of $0.63 per share, increasing the quarterly common dividend by $0.01 per share over the prior quarter, to be paid May 15, 2017 to common stockholders of record as of the close of business on May 1, 2017.

On January 12, 2017, the Board of Directors declared a common stock dividend of $0.62 per share, increasing the quarterly common dividend by $0.01 per share over the previous quarter. The common dividends were paid February 15, 2017 to common stockholders of record as of the close of business on January 31, 2017.

On the same dates listed above, Omega OP Unit holders received the same distributions per unit as those paid to the common stockholders of Omega.

$500 Million Equity Shelf Program

For the three months ended March 31, 2017, we issued 0.2 million shares of common stock at an average price of $29.71 per share, net of issuance costs, generating net proceeds of $6.8 million under our $500 million Equity Shelf Program.

Dividend Reinvestment and Common Stock Purchase Plan

For the three months ended March 31, 2017, approximately 0.2 million shares of our common stock at an average price of $30.67 per share were issued through our Dividend Reinvestment and Common Stock Purchase Program for gross proceeds of approximately $7.3 million.

Accumulated Other Comprehensive Loss

The following is a summary of our accumulated other comprehensive loss, net of tax where applicable:

	Omega						OHI Holdco						Omega OP
	As of and For the Three Months Ended March 31,
	2017			2016			2017			2016			2017			2016
	(in thousands)
Foreign Currency Translation:
Beginning balance	$	(54,948	)	$	(8,413	)	$	(54,948	)	$	(8,413	)	$	(54,948	)	$	(8,413	)
Translation gain (loss)		4,273			(4,708	)		4,273			(4,708	)		4,273			(4,708	)
Realized gain (loss)		61			(22	)		61			(22	)		61			(22	)
Ending balance		(50,614	)		(13,143	)		(50,614	)		(13,143	)		(50,614	)		(13,143	)
Cash Flow Hedges:
Beginning balance		(1,420	)		(718	)		(1,420	)		(718	)		(1,420	)		(718	)
Unrealized gain (loss)		490			(8,876	)		490			(8,876	)		490			(8,876	)
Realized gain (loss)		764			-			764			-			764			-
Ending balance		(166	)		(9,594	)		(166	)		(9,594	)		(166	)		(9,594	)
Total accumulated other comprehensive loss		(50,780	)		(22,737	)		(50,780	)		(22,737	)		(50,780	)		(22,737	)
Add: portion included in noncontrolling interest		2,302			1,035			39,527			17,681			-			-
Total accumulated other comprehensive loss	$	(48,478	)	$	(21,702	)	$	(11,253	)	$	(5,056	)	$	(50,780	)	$	(22,737	)

XML

TAXES

3 Months Ended

Mar. 31, 2017

Income Tax Disclosure [Abstract]

TAXES

NOTE 11 – TAXES

OHI Holdco is a wholly owned subsidiary of Omega and is a qualified REIT subsidiary for United States federal income tax purposes, and Omega OP is a pass through entity for United States federal income tax purposes.

Since our inception, we have elected to be taxed as a REIT under the applicable provisions of the Internal Revenue Code (“Code”). A REIT is generally not subject to federal income tax on that portion of its REIT taxable income which is distributed to its stockholders, provided that at least 90% of such taxable income is distributed each tax year and certain other requirements are met, including asset and income tests. So long as we qualify as a REIT under the Code, we generally will not be subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions.

If the Company fails to qualify as a REIT in any taxable year, the Company will be subject to federal income taxes on its taxable income at regular corporate rates and dividends paid to our stockholders will not be deductible by us in computing taxable income. Further, we will not be permitted to qualify for treatment as a REIT for federal income tax purposes for four years following the year in which qualification is denied, unless the Internal Revenue Service grants us relief under certain statutory provisions. Failing to qualify as a REIT could materially and adversely affect the Company’s net income; however, we believe we are organized and operate in such a manner as to qualify for treatment as a REIT. We test our compliance within the REIT taxation rules to ensure that we are in compliance with the REIT rules on a quarterly and annual basis. We review our distributions and projected distributions each year to ensure we have met and will continue to meet the annual REIT distribution requirements. In 2017, we expect to distribute dividends in excess of our taxable income.

As a result of our UPREIT Conversion, our Company and its subsidiaries may be subject to income or franchise taxes in certain states and municipalities. Also, as a result of our UPREIT Conversion, we created five wholly owned subsidiary REITs and added a sixth wholly owned subsidiary REIT as of January 1, 2016, all of which are subject to all of the REIT qualification rules set forth in the Code. We merged five of the wholly owned subsidiary REITs into a single wholly owned subsidiary REIT in December 2015, and then merged the sixth wholly owned subsidiary REIT into our other wholly owned subsidiary REIT in December 2016, which wholly owned subsidiary REIT remains subject to all of the REIT qualification rules set forth in the Code.

Subject to the limitation under the REIT asset test rules, we are permitted to own up to 100% of the stock of one or more taxable REIT subsidiaries (“TRSs”). We have elected for two of our active subsidiaries to be treated as TRSs. One of our TRSs is subject to federal, state and local income taxes at the applicable corporate rates and the other is subject to foreign income taxes. As of March 31, 2017, our TRS that is subject to federal, state and local income taxes at the applicable corporate rates had a net operating loss carry-forward of approximately $0.8 million. The loss carry-forward is fully reserved as of March 31, 2017, with a valuation allowance due to uncertainties regarding realization.

During the first quarter of 2017, we recorded approximately $1.0 million of state and local income tax provision and approximately $0.1 million of tax provision for foreign income taxes included in provision for income taxes on our Consolidated Statement of Operations.

XML

STOCK-BASED COMPENSATION

3 Months Ended

Mar. 31, 2017

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

STOCK-BASED COMPENSATION

NOTE 12 – STOCK-BASED COMPENSATION

Stock-based compensation expense was $3.7 million and $2.8 million for the three months ended March 31, 2017 and 2016, respectively:

Restricted Stock and Restricted Stock Units

Restricted stock and restricted stock units (“RSUs”) are subject to forfeiture if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change in control of the Company. Prior to vesting, ownership of the shares/units cannot be transferred. Restricted stock has the same dividend and voting rights as our common stock. RSUs accrue dividend equivalents but have no voting rights. Restricted stock and RSUs are valued at the price of our common stock on the date of grant. We expense the cost of these awards ratably over their vesting period. We awarded 140,416 RSUs to employees on January 1, 2017.

Performance Restricted Stock Units and LTIP Units

Performance restricted stock units (“PRSUs”) and long term incentive plan units (“LTIP Units”) are subject to forfeiture if the performance requirements are not achieved or if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change in control of the Company. The PRSUs and the LTIP Units have varying degrees of performance requirements to be earned and vested, and each PRSU and LTIP Units award represents the right to a variable number of shares of common stock or partnership units. Each LTIP Unit once earned and vested is convertible into one Omega OP Unit in Omega OP, subject to certain conditions. The earning requirements are based on either the (i) total shareholder return (“TSR”) of Omega or (ii) Omega’s TSR relative to other real estate investment trusts in the MSCI U.S. REIT Index or FTSE NAREIT Equity Health Care Index TSR (both “Relative TSR”). Vesting in general requires that the employee remain employed by us until the date specified in the applicable PRSU or LTIP agreement, which may be later than the date that the TSR or Relative TSR requirements are satisfied. We expense the cost of these awards ratably over their service period.

Prior to vesting and the distribution of shares, ownership of the PRSUs cannot be transferred. Dividend equivalents on the PRSUs accumulate and with respect to PRSUs granted before 2015 are paid when the PRSUs vest and with respect to PRSUs granted in 2015 or later are paid once the PRSUs are earned. While each LTIP Unit is unearned, the employee receives a partnership distribution equal to 10% of the quarterly approved regular periodic distributions per Omega OP Unit. The remaining partnership distributions (which in the case of normal periodic distributions is equal to the total approved quarterly dividend on Omega’s common stock) on the LTIP Units accumulate, and if the LTIP Units are earned, the accumulated distributions are paid.

The number of shares or units earned under the TSR PRSUs or LTIP Units depends generally on the level of achievement of Omega’s TSR over the indicated performance period. We awarded 399,726 LTIP Units to employees on January 1, 2017.

The number of shares earned under the Relative TSR PRSUs depends generally on the level of achievement of Omega’s TSR relative to other real estate investment trusts in the MSCI U.S. REIT Index or FTSE NAREIT Equity Health Care Index TSR over the performance period indicated. We awarded 285,338 Relative TSR PRSUs to employees on January 1, 2017.

The following table summarizes our total unrecognized compensation cost as of March 31, 2017 associated with restricted stock, restricted stock units, PRSU awards, and LTIP Unit awards to employees:

	Grant   Year		Shares/ Units		Grant Date  Average  Fair Value  Per Unit/  Share		Total  Compensation  Cost (in millions)  (1)		Weighted   Average  Period of  Expense  Recognition  (in months)		Unrecognized   Compensation  Cost (in  millions)		Performance   Period	Vesting  Dates
RSUs
3/31/15 RSU		2015		109,985	$	40.57	$	4.5		33	$	1.2	N/A	12/31/2017
4/1/15 RSU		2015		40,464		40.74		1.6		33		0.5	N/A	12/31/2017
Assumed Aviv RSU		2015		7,799		35.08		0.3		33		0.1	N/A	11/1/2017
3/17/16 RSU		2016		130,006		34.78		4.6		33		2.8	N/A	12/31/2018
1/1/2017 RSU		2017		140,416		31.26		4.3		36		4.0	N/A	12/31/2019
Restricted Stock Units Total				428,670	$	35.68	$	15.3			$	8.6
TSR PRSUs and LTIP Units
2016 TSR		2014		135,634	$	8.67	$	1.2		48	$	0.2	1/1/2014-12/31/2016	Quarterly in 2017
3/31/15 2017 LTIP Units		2015		137,249		14.66		2.0		45		0.9	1/1/2015-12/31/2017	Quarterly in 2018
4/1/2015 2017 LTIP Units		2015		54,151		14.80		0.8		45		0.4	1/1/2015-12/31/2017	Quarterly in 2018
3/17/2016 2018 LTIP Units		2016		372,069		13.21		4.9		45		3.6	1/1/2016-12/31/2018	Quarterly in 2019
1/1/2017 2019 LTIP Units		2017		399,726		12.61		5.0		48		4.7	1/1/2017-12/31/2019	Quarterly in 2020
TSR PRSUs & LTIP Total				1,098,829	$	12.69	$	13.9			$	9.8
Relative TSR PRSUs
2016 Relative TSR		2014		135,634	$	14.24	$	1.9		48	$	0.4	1/1/2014-12/31/2016	Quarterly in 2017
3/31/15 2017 Relative TSR		2015		137,249		22.50		3.1		45		1.4	1/1/2015-12/31/2017	Quarterly in 2018
4/1/2015 2017 Relative TSR		2015		54,151		22.91		1.2		45		0.6	1/1/2015-12/31/2017	Quarterly in 2018
3/17/2016 2018 Relative TSR		2016		307,480		16.45		5.1		45		3.7	1/1/2016-12/31/2018	Quarterly in 2019
1/1/2017 2019 Relative TSR		2017		285,338		18.04		5.1		48		4.8	1/1/2017-12/31/2019	Quarterly in 2020
Relative TSR PRSUs Total				919,852	$	17.78	$	16.4			$	10.9
Grand Total				2,447,351	$	18.63	$	45.6			$	29.3

(1) Total compensation costs are net of shares cancelled.

Director Restricted Stock Grants

As of March 31, 2017, we had 51,999 shares of restricted stock outstanding to directors. The directors’ restricted shares are scheduled to vest over the next three years. As of March 31, 2017, the unrecognized compensation cost associated with outstanding director restricted stock grants is approximately $1.1 million.

XML

BORROWING ACTIVITIES AND ARRANGEMENTS

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

BORROWING ACTIVITIES AND ARRANGEMENTS

NOTE 13 – BORROWING ACTIVITIES AND ARRANGEMENTS

Secured and Unsecured Borrowings

The following is a summary of our borrowings:

		Annual Interest Rate as of March 31,			March 31,			December 31,
	Maturity	2017			2017			2016
					(in thousands)
Secured borrowings:
HUD mortgages assumed December 2011(1)	2044		3.06	%	$	54,636		$	54,954
Deferred financing costs – net						(584	)		(589	)
Total secured borrowings – net (2)						54,052			54,365
Unsecured borrowings:
Revolving line of credit	2018		2.25	%		123,000			190,000
Tranche A-1 term loan	2019		2.48	%		200,000			200,000
Tranche A-2 term loan	2017		2.44	%		200,000			200,000
Tranche A-3 term loan	2021		2.48	%		350,000			350,000
Omega OP term loan (2)	2017		2.44	%		100,000			100,000
2015 term loan	2022		3.80	%		250,000			250,000
Deferred financing costs – net						(5,125	)		(5,657	)
Total term loans – net						1,094,875			1,094,343
2023 notes	2023		4.375	%		700,000			700,000
2024 notes	2024		5.875	%		400,000			400,000
2024 notes	2024		4.95	%		400,000			400,000
2025 notes	2025		4.50	%		250,000			250,000
2026 notes	2026		5.25	%		600,000			600,000
2027 notes	2027		4.50	%		700,000			700,000
Other	2018		-			3,000			3,000
Subordinated debt	2021		9.00	%		20,000			20,000
Discount - net						(16,669	)		(17,151	)
Deferred financing costs – net						(27,393	)		(27,703	)
Total unsecured borrowings – net						3,028,938			3,028,146
Total secured and unsecured borrowings – net					$	4,300,865		$	4,366,854

⁽¹⁾ Reflects the weighted average annual contractual interest rate on the mortgages at March 31, 2017 excluding a third-party administration fee of approximately 0.5% annually. Secured by real estate assets with a net carrying value of $64.8 million as of March 31, 2017.

⁽²⁾ These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

Certain of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of March 31, 2017 and December 31, 2016, we were in compliance with all affirmative and negative covenants, including financial covenants, for our secured and unsecured borrowings. OHI Holdco and Omega OP, the guarantors of Parent’s outstanding senior notes as of May 25, 2017, do not directly own any substantive assets other than OHI Holdco’s interest in Omega OP and Omega OP’s interest in non-guarantor subsidiaries.

See Note 17 – Subsequent Events for additional details regarding new borrowings, the redemption of the $400 million 5.875% Senior Notes due 2024 and the prepayment of the $200 million senior unsecured incremental term loan facility (the “Tranche A-2 Term Loan Facility”) due 2017.

XML

FINANCIAL INSTRUMENTS

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

FINANCIAL INSTRUMENTS

NOTE 14 – FINANCIAL INSTRUMENTS

The carrying amount of cash and cash equivalents, restricted cash and accounts receivable reported in the Consolidated Balance Sheets approximates fair value because of the short maturity of these instruments (i.e., less than 90 days) (Level 1).

At March 31, 2017 and December 31, 2016, the carrying amounts and fair values of our other financial instruments were as follows:

	March 31, 2017					December 31, 2016
	Carrying Amount			Fair Value		Carrying Amount		Fair Value
	(in thousands)
Assets:
Investments in direct financing leases – net	$	604,777		$	601,522	$	601,938	$	598,665
Mortgage notes receivable – net		644,696			652,487		639,343		644,961
Other investments – net		255,899			248,959		256,846		253,385
Total	$	1,505,372		$	1,502,968	$	1,498,127	$	1,497,011
Liabilities:
Revolving line of credit	$	123,000		$	123,000	$	190,000	$	190,000
Tranche A-1 term loan		199,124			200,000		198,830		200,000
Tranche A-2 term loan		200,000			200,000		200,000		200,000
Tranche A-3 term loan		347,605			350,000		347,449		350,000
Omega OP term loan (1)		100,000			100,000		100,000		100,000
2015 term loan		248,145			250,000		248,064		250,000
4.375% notes due 2023 – net		692,598			710,967		692,305		693,505
5.875% notes due 2024 – net		395,236			434,814		395,065		432,938
4.95% notes due 2024 – net		392,922			413,512		392,669		406,361
4.50% notes due 2025 – net		245,953			250,500		245,949		249,075
5.25% notes due 2026 – net		593,792			627,443		593,616		611,461
4.50% notes due 2027 – net		685,418			696,683		685,052		681,978
4.75% notes due 2028 – net		(440	)		—		—		—
HUD debt – net (1)		54,052			52,771		54,365		52,510
Subordinated debt – net		20,460			23,909		20,490		23,944
Other		3,000			3,000		3,000		3,000
Total	$	4,300,865		$	4,436,599	$	4,366,854	$	4,444,772

(1) The amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

Fair value estimates are subjective in nature and are dependent on a number of important assumptions, including estimates of future cash flows, risks, discount rates and relevant comparable market information associated with each financial instrument (see Note 2 – Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2016, as amended). The use of different market assumptions and estimation methodologies may have a material effect on the reported estimated fair value amounts.

The following methods and assumptions were used in estimating fair value disclosures for financial instruments.

· Direct financing leases: The fair value of the investments in direct financing leases are estimated using a discounted cash flow analysis, using interest rates being offered for similar leases to borrowers with similar credit ratings (Level 3).

· Mortgage notes receivable: The fair value of the mortgage notes receivables are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3).

· Other investments: Other investments are primarily comprised of notes receivable. The fair values of notes receivable are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3).

· Revolving line of credit and term loans: The fair value of our borrowings under variable rate agreements are estimated using a present value technique based on expected cash flows discounted using the current market rates (Level 3).

· Senior notes and subordinated debt: The fair value of our borrowings under fixed rate agreements are estimated using a present value technique based on inputs from trading activity provided by a third party (Level 2).

· HUD debt: The fair value of our borrowings under HUD debt agreements are estimated using an expected present value technique based on quotes obtained by HUD debt brokers (Level 2).

XML

LITIGATION

3 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

LITIGATION

NOTE 15 – LITIGATION

We are subject to various legal proceedings, claims and other actions arising out of the normal course of business. While any legal proceeding or claim has an element of uncertainty, management believes that the outcome of each lawsuit, claim or legal proceeding that is pending or threatened, or all of them combined, will not have a material adverse effect on our consolidated financial position or results of operations.

XML

EARNINGS PER SHARE/UNIT

3 Months Ended

Mar. 31, 2017

Net Income Available To Common Per Share

EARNINGS PER SHARE/UNIT

NOTE 16 – EARNINGS PER SHARE/UNIT

The computation of basic earnings per share/unit (“EPS” or “EPU”) is computed by dividing net income available to common stockholders/Omega OP Units holders by the weighted-average number of shares of common stock/units outstanding during the relevant period. Diluted EPS/EPU is computed using the treasury stock method, which is net income divided by the total weighted-average number of common outstanding shares/Omega OP Units plus the effect of dilutive common equivalent shares/Omega OP Units during the respective period. Dilutive common shares reflect the assumed issuance of additional common shares/Omega OP Units pursuant to certain of our share-based compensation plans, including stock options, restricted stock and performance restricted stock units and the assumed issuance of additional shares related to Omega OP Units held by outside investors. Dilutive Omega OP Units reflect the assumed issuance of additional Omega OP Units pursuant to certain of our share-based compensation plans, including stock options, restricted stock and performance restricted stock. No per share information was provided for OHI Holdco because the sole stockholder is Omega. OHI Holdco is a wholly owned subsidiary of Omega and has 1,000 shares of $0.01 par value per share common stock outstanding.

The following tables set forth the computation of basic and diluted earnings per share/unit:

	Omega						Omega OP
	Three Months Ended March 31,
	2017			2016			2017		2016
	(in thousands, except per share amounts)
Numerator:
Net income	$	109,112		$	58,196		$	109,112	$	58,196
Less: net income attributable to noncontrolling interests		(4,672	)		(2,641	)		—		—
Net income available to common stockholders/Omega OP Unit holders	$	104,440		$	55,555		$	109,112	$	58,196
Denominator:
Denominator for basic earnings per share/unit		197,013			188,228			205,827		197,175
Effect of dilutive securities:
Common stock equivalents/units		347			1,175			347		1,175
Noncontrolling interest – Omega OP Units		8,814			8,947			—		—
Denominator for diluted earnings per share/unit		206,174			198,350			206,174		198,350
Earnings per share - basic:
Net income available to common stockholders/Omega OP Unit holders	$	0.53		$	0.30		$	0.53	$	0.30
Earnings per share/unit – diluted:
Net income	$	0.53		$	0.29		$	0.53	$	0.29

XML

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2017

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 17 – SUBSEQUENT EVENTS

2017 Omega Credit Facilities

On May 25, 2017, we entered into a credit agreement (the “2017 Omega Credit Agreement”) providing us with a new $1.8 billion senior unsecured revolving and term loan credit facility, consisting of a $1.25 billion senior unsecured multicurrency revolving credit facility (the “2017 Revolving Credit Facility”), a $425 million senior unsecured U.S. Dollar term loan facility (the “2017 U.S. Term Loan Facility”), and a £100 million senior unsecured British Pound Sterling term loan facility (the “2017 Sterling Term Loan Facility” and, together with the 2017 Revolving Credit Facility and the 2017 U.S. Term Loan Facility, collectively, the “2017 Omega Credit Facilities”). The 2017 Omega Credit Agreement contains an accordion feature permitting us, subject to compliance with customary conditions, to increase the maximum aggregate commitments under the 2017 Omega Credit Facilities to $2.5 billion.

The 2017 Omega Credit Facilities replace the previous $1.25 billion senior unsecured 2014 revolving credit facility, the previous $200 million Tranche A-1 senior unsecured term loan facility, and the previous $350 million Tranche A-3 senior unsecured incremental term loan facility established under our 2014 credit agreement, which has been terminated (the “2014 Omega Credit Agreement”).

The 2017 Revolving Credit Facility bears interest at LIBOR plus an applicable percentage (with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2017 Revolving Credit Facility matures on May 25, 2021, subject to an option by us to extend such maturity date for two, six month periods. The 2017 Omega Credit Agreement provides for the 2017 Revolving Credit Facility to be drawn in Euros, British Pounds Sterling, Canadian Dollars (collectively, “Alternative Currencies”) or U.S. Dollars, with a $900 million tranche available in U.S. Dollars and a $350 million tranche available in U.S. Dollars or Alternative Currencies. For purposes of the 2017 Omega Credit Facilities, references to LIBOR include the Canadian dealer offered rates for amounts offered in Canadian Dollars and any other Alternative Currency rate approved in accordance with the terms of the 2017 Omega Credit Agreement for amounts offered in any other non-London interbank offered rate quoted currency, as applicable.

The 2017 U.S. Term Loan Facility and the 2017 Sterling Term Loan Facility bear interest at LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2017 U.S. Term Loan Facility and the 2017 Sterling Term Loan Facility each mature on May 25, 2022.

In April 2017, we repaid and terminated the $200 million Tranche A-2 senior unsecured term loan facility established under the 2014 Omega Credit Agreement.

For the three month period ending June 30, 2017, we recorded a one-time, non-cash charge of approximately $5.5 million relating to the write-off of deferred financing costs associated with the termination of the 2014 Omega Credit Facilities.

2017 Omega OP Term Loan Facility

On May 25, 2017, Omega OP entered into a credit agreement (the “2017 Omega OP Credit Agreement”) providing it with a new $100 million senior unsecured term loan facility (the “2017 Omega OP Term Loan Facility”). The 2017 Omega OP Credit Agreement replaces the $100 million senior unsecured term loan facility obtained in 2015 (the “2015 Omega OP Term Loan Facility”) and the related credit agreement (the “2015 Omega OP Credit Agreement”). The 2017 Omega OP Term Loan Facility bears interest at LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2017 Omega OP Term Loan Facility matures on May 25, 2022.

Omega OP’s obligations in connection with the 2017 Omega OP Term Loan Facility are not currently guaranteed, but will be jointly and severally guaranteed by any domestic subsidiary of Omega OP that provides a guaranty of any unsecured indebtedness of Omega or Omega OP for borrowed money evidenced by bonds, debentures, notes or other similar instruments in an amount of at least $50 million individually or in the aggregate.

$550 Million 4.75% Senior Notes and $150 Million 4.5% Senior Notes

On April 4, 2017, we issued (i) $550 million aggregate principal amount of our 4.75% Senior Notes due 2028 (the “2028 Notes”) and (ii) an additional $150 million aggregate principal amount of our existing 4.50% Senior Notes due 2025 (the “2025 Notes”, and together with the 2028 Notes collectively, the “Notes”). The 2028 Notes mature on January 15, 2028 and the 2025 Notes mature on January 15, 2025.

The 2028 Notes were sold at an issue price of 98.978% of their face value before the underwriters’ discount and the 2025 Notes were sold at an issue price of 99.540% of their face value before the underwriters’ discount. Our net proceeds from the Notes offering, after deducting underwriting discounts and expenses, were approximately $690.7 million. The net proceeds from the Notes offering were used to (i) redeem all of our outstanding $400 million aggregate principal amount of 5.875% Senior Notes due 2024 (the “5.875% Notes”) on April 28, 2017, (ii) prepay the $200 million Tranche A-2 Term Loan Facility on April 5, 2017 that otherwise would have become due on June 27, 2017, and (iii) repay outstanding borrowings under our revolving credit facility.

$400 Million 5.875% Senior Notes Redemption

On April 28, 2017, we redeemed all of our outstanding 5.875% Notes. As a result of the redemption, during the second quarter of 2017, we recorded approximately $16.5 million in redemption related costs and write-offs, including $11.8 million for the call premium and $4.7 million in net write-offs associated with unamortized deferred financing costs.

XML

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods reported herein are not necessarily indicative of results to be expected for the full year. These unaudited consolidated financial statements should be read in conjunction with the financial statements and the footnotes thereto included in our Form 10-K/A filed with the SEC on August 9, 2017.

Our consolidated financial statements include the accounts of (i) Omega, (ii) OHI Holdco (iii) Omega OP and (iv) all direct and indirect wholly owned subsidiaries of Omega. All intercompany transactions and balances have been eliminated in consolidation, and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests.

Asset Impairment

Asset Impairment

Management evaluates our real estate investments for impairment indicators at each reporting period, including the evaluation of our assets’ useful lives. The judgment regarding the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance, legal structure, as well as our intent with respect to holding or disposing of the asset. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to the future undiscounted cash flows of the underlying facilities. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows based on our intended use of the property are determined to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the real estate investments for the excess of carrying value over fair value. The fair value of the real estate investment is determined by market research, which includes valuing the property as a nursing home as well as other alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset. Management’s impairment evaluation process, and when applicable, impairment calculations involve estimation of the future cash flows from management’s intended use of the property. Changes in the facts and circumstances that drive management’s assumptions may result in an impairment of the Company’s assets in a future period that could be material to the Company’s results of operations.

If we decide to sell real estate properties or land holdings, we evaluate the recoverability of the carrying amounts of the assets. If the evaluation indicates that the carrying value is not recoverable from estimated net sales proceeds, the property is written down to estimated fair value less costs to sell. Our estimates of cash flows and fair values of the properties are based on current market conditions and consider matters such as rental rates and occupancies for comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers or prospective purchasers.

For the three months ended March 31, 2017 and 2016, we recognized impairment losses of $7.6 million and $34.6 million, respectively. For additional information see Note 2 – Properties and Investments and Note 7 – Assets Held For Sale.

Goodwill Impairment

Goodwill Impairment

We assess goodwill for potential impairment during the fourth quarter of each fiscal year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the net assets of the reporting unit. In evaluating goodwill for impairment on an interim basis, we assess qualitative factors such as a significant decline in real estate valuations, current macroeconomic conditions, state of the equity and capital markets and our overall financial and operating performance or a significant decline in the value of our market capitalization, to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of the reporting unit is less than its carrying amount. On an annual basis during the fourth quarter of each fiscal year, or on an interim basis if we conclude it is more likely than not that the fair value of the reporting unit is less than its carrying value, we perform a two-step goodwill impairment test to identify potential impairment and measure the amount of impairment we will recognize, if any.

Noncontrolling Interests

Noncontrolling Interests

Noncontrolling interests is the portion of equity not attributable to the respective reporting entity. We present the portion of any equity that we do not own in consolidated entities as noncontrolling interests and classify those interests as a component of total equity, separate from total stockholders’ equity, or owners’ equity on our Consolidated Balance Sheets. We include net income attributable to the noncontrolling interests in net income in our Consolidated Statements of Operations.

As our ownership of a controlled subsidiary increases or decreases, any difference between the aggregate consideration paid to acquire the noncontrolling interests and our noncontrolling interest balance is recorded as a component of equity in additional paid-in capital, so long as we maintain a controlling ownership interest.

The noncontrolling interest for Omega represents the outstanding Omega OP Units held by outside investors. The noncontrolling interest for OHI Holdco represents the Omega OP Units held by the Parent and the outstanding Omega OP Units held by outside investors.

Foreign Operations

Foreign Operations

The U.S. dollar is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound. For our consolidated subsidiaries whose functional currency is not the U.S. dollar, we translate their financial statements into the U.S. dollar. We translate assets and liabilities at the exchange rate in effect as of the financial statement date. Revenue and expense accounts are translated using an average exchange rate for the period. Gains and losses resulting from translation are included in accumulated other comprehensive loss (“AOCL”), as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest.

We and certain of our consolidated subsidiaries may have intercompany and third-party debt that is not denominated in the entity’s functional currency. When the debt is remeasured against the functional currency of the entity, a gain or loss can result. The resulting adjustment is reflected in results of operations, unless it is intercompany debt that is deemed to be long-term in nature and then the adjustments are included in AOCL.

Derivative Instruments

Derivative Instruments

During our normal course of business, we may use certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at the inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with the Company’s related assertions. The Company recognizes all derivative instruments, including embedded derivatives required to be bifurcated, as assets or liabilities in the Consolidated Balance Sheets at their fair value which are determined using a market approach and Level 2 inputs. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in earnings. For derivatives designated as qualifying cash flow hedging relationships, the change in fair value of the effective portion of the derivatives is recognized in AOCL as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest, whereas the change in fair value of the ineffective portion is recognized in earnings. We formally document all relationships between hedging instruments and hedged items, as well as our risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific forecasted transactions as well as recognized obligations or assets in the Consolidated Balance Sheets. We also assess and document, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, we discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the current fair value of the derivative. As a matter of policy, we do not use derivatives for trading or speculative purposes. At March 31, 2017 and December 31, 2016, we had $0.2 million and $1.5 million, respectively, of qualifying cash flow hedges recorded at fair value in accrued expenses and other liabilities on our Consolidated Balance Sheets.

Accounts Receivable

Accounts Receivable

Accounts receivable includes: contractual receivables, effective yield interest receivables, straight-line rent receivables and lease inducements, net of an estimated provision for losses related to uncollectible and disputed accounts. Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception or renewal of the lease, and are amortized as a reduction of rental revenue over the non-cancellable lease term.

On a quarterly basis, we review our accounts receivable to determine their collectability. The determination of collectability of these assets requires significant judgment and is affected by several factors relating to the credit quality of our operators that we regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement environment, (iv) the ability of the tenant to perform under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying collateral of the agreement.  If we determine collectability of any of our contractual receivables is at risk, we estimate the potential uncollectible amounts and provide an allowance. In the case of a lease recognized on a straight-line basis, a mortgage recognized on an effective yield basis or the existence of lease inducements, we generally provide an allowance for straight-line, effective interest, and or lease inducement accounts receivable when certain conditions or indicators of adverse collectability are present. If the accounts receivable balance is subsequently deemed uncollectible, the receivable and allowance for doubtful account balance are written off.

A summary of our net receivables by type is as follows:

	March 31,			December 31,
	2017			2016
	(in thousands)
Contractual receivables	$	34,751		$	13,376
Effective yield interest receivables		10,343			9,749
Straight-line rent receivables		219,821			208,874
Lease inducements		7,946			8,393
Allowance		(355	)		(357	)
Accounts receivable – net	$	272,506		$	240,035

Related Party Transactions

Related Party Transactions

The Company has a policy which generally requires related party transactions to be approved or ratified by the Audit Committee. On February 1, 2016, we acquired 10 SNFs from Laurel Healthcare Holdings, Inc. (“Laurel”) for approximately $169.0 million in cash and leased them to an unrelated existing operator. A former member of the Board of Directors of the Company, together with certain members of his immediate family, beneficially owned approximately 34% of the equity of Laurel prior to the transaction. Immediately following our acquisition, the unrelated existing operator acquired all of the outstanding equity interests of Laurel, including the interests previously held by the former director of the Company and his family.

Accounting Pronouncement Adopted in 2017

Accounting Pronouncement Adopted in 2017

In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Compensation-Stock Compensation (Topic 718) (“ASU 2016-09”). ASU 2016-09 amends the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2016. We adopted this accounting standard on January 1, 2017, at which time the Company began prospectively accounting for excess tax benefits or tax deficiencies as an adjustment to income tax expense in our Consolidated Statements of Operations as opposed to the prior requirement that these excess tax benefits be recognized in additional paid-in capital and tax deficiencies be recognized either as an offset to accumulated excess tax benefits, if any, or in the income statement. The Company will continue to account for forfeitures as they occur and present employee taxes paid as a financing activity on our Consolidated Statements of Cash Flows. The adoption of this accounting standard did not have a material impact on our consolidated financial statements.

Recent Accounting Pronouncements - Pending Adoption

Recent Accounting Pronouncements - Pending Adoption

In 2014, the FASBissued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment. ASU 2014-09 is effective for the Company beginning January 1, 2018. In addition, the FASB has begun to issue targeted updates to clarify specific implementation issues of ASU 2014-09. These updates include ASU 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016-10, Identifying Performance Obligations and Licensing, and ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. The Company is currently evaluating the provisions of ASU 2014-09 and its related updates and will be closely monitoring developments and additional guidance to determine the potential impact of the new standard. The Company intends to adopt ASU 2014-09 and its subsequent updates in accordance with the modified retrospective approach. We do not expect the adoption of ASU 2014-09 and its updates to have a significant impact on our consolidated financial statements, as a substantial portion of our revenue consists of rental income from leasing arrangements and interest income from loan arrangements, both of which are specifically excluded from ASU 2014-09.

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective for the Company beginning January 1, 2019. Early adoption of ASU 2016-02 as of its issuance is permitted. The new standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. We are currently evaluating the impact of adopting ASU 2016-02 on our consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) (“ASU 2016-13”), which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. ASU 2016-13 is effective for annual and interim periods beginning after December 15, 2019 and early adoption is permitted for annual and interim periods beginning after December 15, 2018. We are currently evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements.

XML

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Schedule of summary of net receivables

	March 31,			December 31,
	2017			2016
	(in thousands)
Contractual receivables	$	34,751		$	13,376
Effective yield interest receivables		10,343			9,749
Straight-line rent receivables		219,821			208,874
Lease inducements		7,946			8,393
Allowance		(355	)		(357	)
Accounts receivable – net	$	272,506		$	240,035

XML

PROPERTIES AND INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2017

Real Estate [Abstract]

Schedule of investment in leased real estate properties

	March 31,			December 31,
	2017			2016
	(in thousands)
Buildings	$	5,980,501		$	5,954,771
Land		756,803			759,295
Furniture, fixtures and equipment		454,288			454,760
Site improvements		206,326			206,206
Construction in progress		183,747			191,326
Total real estate investments		7,581,665			7,566,358
Less accumulated depreciation		(1,306,084	)		(1,240,336	)
Real estate investments - net	$	6,275,581		$	6,326,022

Schedule of summary of significant acquisitions

Number of  Facilities				Country/	Total  Investment		Land		Building & Site Improvements		Furniture & Fixtures		Initial Annual Cash
SNF		ALF		State	(in millions)								Yield (%)
	-		1	VA	$	7.6	$	0.5	$	6.8	$	0.3		7.50

XML

DIRECT FINANCING LEASES (Tables)

3 Months Ended

Mar. 31, 2017

Leases, Capital [Abstract]

Schedule of components of investment in direct financing leases

	March 31,			December 31,
	2017			2016
	(in thousands)
Minimum lease payments receivable	$	4,291,940		$	4,287,069
Less unearned income		(3,684,757	)		(3,685,131	)
Less allowance for loss on direct financing lease		(2,406	)		—
Investment in direct financing leases - net	$	604,777		$	601,938
Properties subject to direct financing leases		58			58

Schedule of minimum rents due under direct financing lease for the next five years

2018	2019	2020	2021	2022
$51,319	$52,626	$53,917	$55,199	$56,488

XML

MORTGAGE NOTES RECEIVABLE (Tables)

3 Months Ended

Mar. 31, 2017

Mortgage Notes Receivable Investments [Abstract]

Schedule of outstanding principal amounts of mortgage notes receivable, net of allowances

	March 31,			December 31,
	2017			2016
	(in thousands)
Mortgage note due 2024; interest at 9.98%	$	112,500		$	112,500
Mortgage note due 2029; interest at 9.45%		411,807			412,140
Other mortgage notes outstanding (1)		124,323			118,637
Mortgage notes receivable, gross		648,630			643,277
Allowance for loss on mortgage notes receivable		(3,934	)		(3,934	)
Total mortgages — net	$	644,696		$	639,343

⁽¹⁾ Other mortgage notes outstanding have stated interest rates ranging from 8.35% to 12.0% and maturity dates through 2029.

XML

OTHER INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2017

Receivables [Abstract]

Schedule of other investments

	March 31,			December 31,
	2017			2016
	(in thousands)
Other investment note due 2019; interest at 10.73%	$	49,521		$	49,458
Other investment note due 2020; interest at 14.00%		47,856			47,913
Other investment note due 2022, interest at 9.00%		31,987			31,987
Other investment note due 2030; interest at 6.66%		48,705			44,595
Other investment notes outstanding (1)		82,628			87,691
Other investments, gross		260,697			261,644
Allowance for loss on other investments		(4,798	)		(4,798	)
Total other investments	$	255,899		$	256,846

⁽¹⁾ Other investment notes have maturity dates through 2028 and interest rates ranging from 6.50% to 13.0%.

XML

ASSETS HELD FOR SALE (Tables)

3 Months Ended

Mar. 31, 2017

Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]

Schedule of properties held-for-sale

	Properties Held For Sale
	Number of Properties			Net Book Value (in thousands)
December 31, 2016		20		$	52,868
Properties sold/other (1)		(12	)		(30,023	)
Properties added (2)		1			400
March 31, 2017(3)		9		$	23,245

⁽¹⁾ In the first quarter of 2017, we sold nine SNFs and two ALFs for approximately $29.4 million in net proceeds recognizing a gain on sale of approximately $3.6 million. One SNF classified as an asset held for sale at December 31, 2016 was no longer considered held for sale during the first quarter of 2017 and was reclassified back to leased properties at approximately $5.1 million which represents the facility’s then carrying value adjusted for depreciation that was not recognized while classified as held for sale.

(2)	In the first quarter of 2017, we recorded a $3.5 million impairment to reduce one ALF’s net book value to its estimated fair value less costs to sell before it was reclassified to assets held for sale.
(3)	We plan to sell the nine facilities classified as held for sale at March 31, 2017 over the next several quarters.

XML

INTANGIBLES (Tables)

3 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangibles

	March 31,			December 31,
	2017			2016
	(in thousands)
Assets:
Goodwill	$	643,692		$	643,474
Above market leases	$	22,443		$	22,476
In-place leases		167			167
Accumulated amortization		(16,180	)		(15,864	)
Net intangible assets	$	6,430		$	6,779
Liabilities:
Below market leases	$	164,735		$	165,028
Accumulated amortization		(74,131	)		(70,738	)
Net intangible liabilities	$	90,604		$	94,290

Schedule of reconciliation of goodwill

	(in thousands)
Balance as of December 31, 2016	$	643,474
Add: foreign currency translation		218
Balance as of March 31, 2017	$	643,692

XML

STOCKHOLDERS'/OWNERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2017

Stockholders' Equity Note [Abstract]

Schedule of accumulated other comprehensive loss

	Omega						OHI Holdco						Omega OP
	As of and For the Three Months Ended March 31,
	2017			2016			2017			2016			2017			2016
	(in thousands)
Foreign Currency Translation:
Beginning balance	$	(54,948	)	$	(8,413	)	$	(54,948	)	$	(8,413	)	$	(54,948	)	$	(8,413	)
Translation gain (loss)		4,273			(4,708	)		4,273			(4,708	)		4,273			(4,708	)
Realized gain (loss)		61			(22	)		61			(22	)		61			(22	)
Ending balance		(50,614	)		(13,143	)		(50,614	)		(13,143	)		(50,614	)		(13,143	)
Cash Flow Hedges:
Beginning balance		(1,420	)		(718	)		(1,420	)		(718	)		(1,420	)		(718	)
Unrealized gain (loss)		490			(8,876	)		490			(8,876	)		490			(8,876	)
Realized gain (loss)		764			-			764			-			764			-
Ending balance		(166	)		(9,594	)		(166	)		(9,594	)		(166	)		(9,594	)
Total accumulated other comprehensive loss		(50,780	)		(22,737	)		(50,780	)		(22,737	)		(50,780	)		(22,737	)
Add: portion included in noncontrolling interest		2,302			1,035			39,527			17,681			-			-
Total accumulated other comprehensive loss	$	(48,478	)	$	(21,702	)	$	(11,253	)	$	(5,056	)	$	(50,780	)	$	(22,737	)

XML

STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2017

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Schedule of unrecognized compensation cost associated with outstanding restricted stock and PRSU awards and LTIP Unit awards

	Grant   Year		Shares/ Units		Grant Date  Average  Fair Value  Per Unit/  Share		Total  Compensation  Cost (in millions)  (1)		Weighted   Average  Period of  Expense  Recognition  (in months)		Unrecognized   Compensation  Cost (in  millions)		Performance   Period	Vesting  Dates
RSUs
3/31/15 RSU		2015		109,985	$	40.57	$	4.5		33	$	1.2	N/A	12/31/2017
4/1/15 RSU		2015		40,464		40.74		1.6		33		0.5	N/A	12/31/2017
Assumed Aviv RSU		2015		7,799		35.08		0.3		33		0.1	N/A	11/1/2017
3/17/16 RSU		2016		130,006		34.78		4.6		33		2.8	N/A	12/31/2018
1/1/2017 RSU		2017		140,416		31.26		4.3		36		4.0	N/A	12/31/2019
Restricted Stock Units Total				428,670	$	35.68	$	15.3			$	8.6
TSR PRSUs and LTIP Units
2016 TSR		2014		135,634	$	8.67	$	1.2		48	$	0.2	1/1/2014-12/31/2016	Quarterly in 2017
3/31/15 2017 LTIP Units		2015		137,249		14.66		2.0		45		0.9	1/1/2015-12/31/2017	Quarterly in 2018
4/1/2015 2017 LTIP Units		2015		54,151		14.80		0.8		45		0.4	1/1/2015-12/31/2017	Quarterly in 2018
3/17/2016 2018 LTIP Units		2016		372,069		13.21		4.9		45		3.6	1/1/2016-12/31/2018	Quarterly in 2019
1/1/2017 2019 LTIP Units		2017		399,726		12.61		5.0		48		4.7	1/1/2017-12/31/2019	Quarterly in 2020
TSR PRSUs & LTIP Total				1,098,829	$	12.69	$	13.9			$	9.8
Relative TSR PRSUs
2016 Relative TSR		2014		135,634	$	14.24	$	1.9		48	$	0.4	1/1/2014-12/31/2016	Quarterly in 2017
3/31/15 2017 Relative TSR		2015		137,249		22.50		3.1		45		1.4	1/1/2015-12/31/2017	Quarterly in 2018
4/1/2015 2017 Relative TSR		2015		54,151		22.91		1.2		45		0.6	1/1/2015-12/31/2017	Quarterly in 2018
3/17/2016 2018 Relative TSR		2016		307,480		16.45		5.1		45		3.7	1/1/2016-12/31/2018	Quarterly in 2019
1/1/2017 2019 Relative TSR		2017		285,338		18.04		5.1		48		4.8	1/1/2017-12/31/2019	Quarterly in 2020
Relative TSR PRSUs Total				919,852	$	17.78	$	16.4			$	10.9
Grand Total				2,447,351	$	18.63	$	45.6			$	29.3

(1) Total compensation costs are net of shares cancelled.

XML

BORROWING ACTIVITIES AND ARRANGEMENTS (Tables)

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Schedule of long-term borrowings

		Annual Interest Rate as of March 31,			March 31,			December 31,
	Maturity	2017			2017			2016
					(in thousands)
Secured borrowings:
HUD mortgages assumed December 2011(1)	2044		3.06	%	$	54,636		$	54,954
Deferred financing costs – net						(584	)		(589	)
Total secured borrowings – net (2)						54,052			54,365
Unsecured borrowings:
Revolving line of credit	2018		2.25	%		123,000			190,000
Tranche A-1 term loan	2019		2.48	%		200,000			200,000
Tranche A-2 term loan	2017		2.44	%		200,000			200,000
Tranche A-3 term loan	2021		2.48	%		350,000			350,000
Omega OP term loan (2)	2017		2.44	%		100,000			100,000
2015 term loan	2022		3.80	%		250,000			250,000
Deferred financing costs – net						(5,125	)		(5,657	)
Total term loans – net						1,094,875			1,094,343
2023 notes	2023		4.375	%		700,000			700,000
2024 notes	2024		5.875	%		400,000			400,000
2024 notes	2024		4.95	%		400,000			400,000
2025 notes	2025		4.50	%		250,000			250,000
2026 notes	2026		5.25	%		600,000			600,000
2027 notes	2027		4.50	%		700,000			700,000
Other	2018		-			3,000			3,000
Subordinated debt	2021		9.00	%		20,000			20,000
Discount - net						(16,669	)		(17,151	)
Deferred financing costs – net						(27,393	)		(27,703	)
Total unsecured borrowings – net						3,028,938			3,028,146
Total secured and unsecured borrowings – net					$	4,300,865		$	4,366,854

⁽¹⁾ Reflects the weighted average annual contractual interest rate on the mortgages at March 31, 2017 excluding a third-party administration fee of approximately 0.5% annually. Secured by real estate assets with a net carrying value of $64.8 million as of March 31, 2017.

⁽²⁾ These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

XML

FINANCIAL INSTRUMENTS (Tables)

3 Months Ended

Mar. 31, 2017

Fair Value Disclosures [Abstract]

Schedule of the carrying amounts and fair values of financial instruments

	March 31, 2017					December 31, 2016
	Carrying Amount			Fair Value		Carrying Amount		Fair Value
	(in thousands)
Assets:
Investments in direct financing leases – net	$	604,777		$	601,522	$	601,938	$	598,665
Mortgage notes receivable – net		644,696			652,487		639,343		644,961
Other investments – net		255,899			248,959		256,846		253,385
Total	$	1,505,372		$	1,502,968	$	1,498,127	$	1,497,011
Liabilities:
Revolving line of credit	$	123,000		$	123,000	$	190,000	$	190,000
Tranche A-1 term loan		199,124			200,000		198,830		200,000
Tranche A-2 term loan		200,000			200,000		200,000		200,000
Tranche A-3 term loan		347,605			350,000		347,449		350,000
Omega OP term loan (1)		100,000			100,000		100,000		100,000
2015 term loan		248,145			250,000		248,064		250,000
4.375% notes due 2023 – net		692,598			710,967		692,305		693,505
5.875% notes due 2024 – net		395,236			434,814		395,065		432,938
4.95% notes due 2024 – net		392,922			413,512		392,669		406,361
4.50% notes due 2025 – net		245,953			250,500		245,949		249,075
5.25% notes due 2026 – net		593,792			627,443		593,616		611,461
4.50% notes due 2027 – net		685,418			696,683		685,052		681,978
4.75% notes due 2028 – net		(440	)		—		—		—
HUD debt – net (1)		54,052			52,771		54,365		52,510
Subordinated debt – net		20,460			23,909		20,490		23,944
Other		3,000			3,000		3,000		3,000
Total	$	4,300,865		$	4,436,599	$	4,366,854	$	4,444,772

(1) The amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

XML

EARNINGS PER SHARE/UNIT (Tables)

3 Months Ended

Mar. 31, 2017

Net Income Available To Common Per Share

Schedule of computation of basic and diluted earnings per share

	Omega						Omega OP
	Three Months Ended March 31,
	2017			2016			2017		2016
	(in thousands, except per share amounts)
Numerator:
Net income	$	109,112		$	58,196		$	109,112	$	58,196
Less: net income attributable to noncontrolling interests		(4,672	)		(2,641	)		—		—
Net income available to common stockholders/Omega OP Unit holders	$	104,440		$	55,555		$	109,112	$	58,196
Denominator:
Denominator for basic earnings per share/unit		197,013			188,228			205,827		197,175
Effect of dilutive securities:
Common stock equivalents/units		347			1,175			347		1,175
Noncontrolling interest – Omega OP Units		8,814			8,947			—		—
Denominator for diluted earnings per share/unit		206,174			198,350			206,174		198,350
Earnings per share - basic:
Net income available to common stockholders/Omega OP Unit holders	$	0.53		$	0.30		$	0.53	$	0.30
Earnings per share/unit – diluted:
Net income	$	0.53		$	0.29		$	0.53	$	0.29

XML

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Contractual receivables	$ 34,751	$ 13,376
Effective yield interest receivables	10,343	9,749
Straight-line rent receivables	219,821	208,874
Lease inducements	7,946	8,393
Allowance	(355)	(357)
Accounts receivable - net	$ 272,506	$ 240,035

XML

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Detail)	3 Months Ended
	Mar. 31, 2017 Segment
Accounting Policies [Abstract]
Number of reportable segment	1

XML

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Detail 1)		3 Months Ended
	Feb. 01, 2016 USD ($) Facility	Mar. 31, 2017 USD ($) Facility Healthcare_facility	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)
Basis Of Presentation And Significant Accounting Policies [Line Items]
Impairment losses recognized		$ 7,638,000	$ 34,558,000
Number of leased real estate properties | Healthcare_facility		985
SNF's
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of leased real estate properties | Facility		808
Cash flow hedges
Basis Of Presentation And Significant Accounting Policies [Line Items]
Cash flow hedges recorded at fair value in accrued expenses and other liabilities		$ 200,000		$ 1,500,000
Omega OP Units
Basis Of Presentation And Significant Accounting Policies [Line Items]
Percentage of limited partnership interests owned		96.00%
Other Investors | Omega OP Units
Basis Of Presentation And Significant Accounting Policies [Line Items]
Percentage of limited partnership interests owned		4.00%
Laurel | SNF's
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of leased real estate properties | Facility	10
Purchase price of buildings acquired paid in cash	$ 169,000,000
Percentage of ownership interest	34.00%

XML

PROPERTIES AND INVESTMENTS - Investment in leased real estate properties (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Total real estate investments	$ 7,581,665	$ 7,566,358
Less accumulated depreciation	(1,306,084)	(1,240,336)
Real estate investments - net	6,275,581	6,326,022
Buildings
Property, Plant and Equipment [Line Items]
Total real estate investments	5,980,501	5,954,771
Land
Property, Plant and Equipment [Line Items]
Total real estate investments	756,803	759,295
Furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Total real estate investments	454,288	454,760
Site improvements
Property, Plant and Equipment [Line Items]
Total real estate investments	206,326	206,206
Construction in progress
Property, Plant and Equipment [Line Items]
Total real estate investments	$ 183,747	$ 191,326

XML

PROPERTIES AND INVESTMENTS - Significant acquisitions occurred in first quarter of 2017 (Detail 1) $ in Millions	3 Months Ended
	Mar. 31, 2017 USD ($) Facility Healthcare_facility
Real Estate Properties [Line Items]
Number of Facilities | Healthcare_facility	985
SNF's
Real Estate Properties [Line Items]
Number of Facilities | Facility	808
ALFs
Real Estate Properties [Line Items]
Number of Facilities | Facility	101
Q1 | VA
Real Estate Properties [Line Items]
Total Investment	$ 7.6
Initial Annual Cash Yield (%)	7.50%
Q1 | VA | Land
Real Estate Properties [Line Items]
Total Investment	$ 0.5
Q1 | VA | Building and site improvements
Real Estate Properties [Line Items]
Total Investment	6.8
Q1 | VA | Furniture and fixtures
Real Estate Properties [Line Items]
Total Investment	$ 0.3
Q1 | ALFs | VA
Real Estate Properties [Line Items]
Number of Facilities | Facility	1

XML

PROPERTIES AND INVESTMENTS - Leased Property (Narrative) (Detail)	3 Months Ended
	Mar. 31, 2017 Facility Healthcare_facility
Real Estate Properties [Line Items]
Number of real estate properties | Healthcare_facility	985
Property available for operating lease | Minimum
Real Estate Properties [Line Items]
Lease term	5 years
Increase in the specific annual percentage over the prior year's rent	2.00%
Property available for operating lease | Maximum
Real Estate Properties [Line Items]
Lease term	15 years
Increase in the specific annual percentage over the prior year's rent	3.00%
SNF's
Real Estate Properties [Line Items]
Number of real estate properties	808
ALFs
Real Estate Properties [Line Items]
Number of real estate properties	101
Specialty facilities
Real Estate Properties [Line Items]
Number of real estate properties	16
Medical office building
Real Estate Properties [Line Items]
Number of real estate properties	1

XML

PROPERTIES AND INVESTMENTS - Assets Sold or Held for Sale (Narrative) (Detail 2) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($) Facility	Mar. 31, 2016 USD ($)
Real Estate [Abstract]
Number of facilities sold	15
Total cash proceeds | $	$ 45,800
Amount of gain (loss) from sale of facilities | $	$ 7,400
Number of previously classified as held for sale	11
Provision for impairment on real estate properties | $	$ 7,638	$ 34,558
Number of facilities with impairment charges	3
Number of facilities with impairment charges classified as held for sale	1

XML

DIRECT FINANCING LEASES (Detail) $ in Thousands	Mar. 31, 2017 USD ($) Property	Dec. 31, 2016 USD ($) Property
Leases, Capital [Abstract]
Minimum lease payments receivable	$ 4,291,940	$ 4,287,069
Less unearned income	(3,684,757)	(3,685,131)
Less allowance for loss on direct financing lease	(2,406)
Investment in direct financing leases - net	$ 604,777	$ 601,938
Properties subject to direct financing leases | Property	58	58

XML

DIRECT FINANCING LEASES (Detail 1) $ in Thousands	Mar. 31, 2017 USD ($)
Leases, Capital [Abstract]
2018	$ 51,319
2019	52,626
2020	53,917
2021	55,199
2022	$ 56,488

XML

DIRECT FINANCING LEASES (Narrative) (Detail) $ in Thousands	1 Months Ended		3 Months Ended
	Mar. 31, 2017 USD ($) Healthcare_facility State	Nov. 27, 2013 USD ($) Facility Lease Bed State	Mar. 31, 2017 USD ($) Healthcare_facility State	Mar. 31, 2016 USD ($)
Capital Leased Assets [Line Items]
Number of facilities owned | Healthcare_facility	985		985
Number of states | State	42		42
Income from direct financing leases | $			$ 15,646	$ 15,442
Northwest | Direct financing leases | Sales Agreement
Capital Leased Assets [Line Items]
Carrying amount of facility | $	$ 36,400		$ 36,400
Proceeds from sale of facility | $	34,000
Allowance for loss under direct financing leases | $	2,400
Income from direct financing leases | $	$ 800
New Ark Investment Inc.
Capital Leased Assets [Line Items]
Purchase price of beds acquired paid in cash | $		$ 529,000
Number of lease | Lease		4
Master lease term		50 years
Interest on lease per annum		10.60%
Number of facilities owned		56
Number of licensed beds | Bed		5,623
Number of states | State		12
New Ark Investment Inc. | Southeast
Capital Leased Assets [Line Items]
Number of additional facility owned		39
New Ark Investment Inc. | Northwest
Capital Leased Assets [Line Items]
Number of additional facility owned		7
New Ark Investment Inc. | Texas
Capital Leased Assets [Line Items]
Number of additional facility owned		9
New Ark Investment Inc. | Indiana
Capital Leased Assets [Line Items]
Number of additional facility owned		1
SNF's | New Ark Investment Inc. | Direct financing leases
Capital Leased Assets [Line Items]
Number of facilities owned		55
ALFs | New Ark Investment Inc. | Direct financing leases
Capital Leased Assets [Line Items]
Number of facilities owned		1

XML

MORTGAGE NOTES RECEIVABLE (Details) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
		Mar. 31, 2017	Dec. 31, 2016
Mortgage Loans on Real Estate [Line Items]
Mortgage notes receivable, gross		$ 648,630	$ 643,277
Allowance for loss on mortgage notes receivable		(3,934)	(3,934)
Total mortgages - net		644,696	639,343
Mortgage note due 2024; interest at 9.98%
Mortgage Loans on Real Estate [Line Items]
Mortgage notes receivable, gross		$ 112,500	$ 112,500
Mortgage loans on real estate, interest rate		9.98%	9.98%
Mortgage note due 2029; interest at 9.45%
Mortgage Loans on Real Estate [Line Items]
Mortgage notes receivable, gross		$ 411,807	$ 412,140
Mortgage loans on real estate, interest rate		9.45%	9.45%
Other mortgage notes outstanding
Mortgage Loans on Real Estate [Line Items]
Mortgage notes receivable, gross	[1]	$ 124,323	$ 118,637

[1] Other mortgage notes outstanding have stated interest rates ranging from 8.35% to 12.0% and maturity dates through 2029.

XML

MORTGAGE NOTES RECEIVABLE (Parentheticals) (Details) - Other mortgage notes outstanding	3 Months Ended
	Mar. 31, 2017
Minimum
Mortgage Loans on Real Estate [Line Items]
Mortgage loans on real estate, interest rate	8.35%
Maximum
Mortgage Loans on Real Estate [Line Items]
Mortgage loans on real estate, interest rate	12.00%
Maturity year	2029

XML

MORTGAGE NOTES RECEIVABLE (Narrative) (Detail)	3 Months Ended
	Mar. 31, 2017 Facility State Mortgage Entity
Mortgage Loans on Real Estate [Line Items]
Number of states	42
Mortgage loans
Mortgage Loans on Real Estate [Line Items]
Number of fixed rate mortgages | Mortgage	27
Number of long term care facilities | Facility	49
Number of states	10
Number of independent healthcare operating companies | Entity	8

XML

OTHER INVESTMENTS (Details) - USD ($) $ in Thousands		Mar. 31, 2017	Dec. 31, 2016
Schedule of Investments [Line Items]
Other investments, gross		$ 260,697	$ 261,644
Allowance for loss on other investments		(4,798)	(4,798)
Total other investments		255,899	256,846
Other investment note due 2019; interest at 10.73%
Schedule of Investments [Line Items]
Other investments, gross		$ 49,521	$ 49,458
Interest rate		10.73%	10.73%
Other investment note due 2020; interest at 14.00%
Schedule of Investments [Line Items]
Other investments, gross		$ 47,856	$ 47,913
Interest rate		14.00%	14.00%
Other investment note due 2022, interest at 9.00%
Schedule of Investments [Line Items]
Other investments, gross		$ 31,987	$ 31,987
Interest rate		9.00%	9.00%
Other investment note due 2030; interest at 6.66%
Schedule of Investments [Line Items]
Other investments, gross		$ 48,705	$ 44,595
Interest rate		6.66%	6.66%
Other investment notes outstanding
Schedule of Investments [Line Items]
Other investments, gross	[1]	$ 82,628	$ 87,691

[1] Other investment notes have maturity dates through 2028 and interest rates ranging from 6.50% to 13.0%.

XML

OTHER INVESTMENTS (Parentheticals) (Details) - Other investment notes outstanding	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Minimum
Schedule of Investments [Line Items]
Interest rate	6.50%	6.50%
Maximum
Schedule of Investments [Line Items]
Interest rate	13.00%	13.00%
Maturity year	2028

XML

INVESTMENT IN UNCONSOLIDATED JOINT VENTURE (Details) $ in Thousands		3 Months Ended
	Nov. 01, 2016 USD ($) Facility	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Schedule of Equity Method Investments [Line Items]
Investment in unconsolidated joint venture		$ 40,152	$ 48,776
Assets management fees recognized		$ 500
Second Spring Healthcare Investments
Schedule of Equity Method Investments [Line Items]
Investment in unconsolidated joint venture	$ 50,000
Percentage of ownership interest	15.00%
Second Spring Healthcare Investments | Affiliates of Lindsey Goldberg LLC
Schedule of Equity Method Investments [Line Items]
Percentage of ownership interest	85.00%
Second Spring Healthcare Investments | Welltower Inc | SNF's
Schedule of Equity Method Investments [Line Items]
Number of properties acquired | Facility	64
Payments to acquire facilities	$ 1,100,000

XML

ASSETS HELD FOR SALE (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($) Property
Number Of Properties
Beginning Balance | Property	20
Properties sold/other | Property	(12)	[1]
Properties added | Property	1	[2]
Ending balance | Property	9	[3]
Net Book Value
Beginning Balance | $	$ 52,868
Properties sold/other | $	(30,023)	[1]
Properties added | $	400	[2]
Ending balance | $	$ 23,245	[3]

[1] In the first quarter of 2017, we sold nine SNFs and two ALFs for approximately $29.4 million in net proceeds recognizing a gain on sale of approximately $3.6 million. One SNF classified as an asset held for sale at December 31, 2016 was no longer considered held for sale during the first quarter of 2017 and was reclassified back to leased properties at approximately $5.1 million which represents the facility's then carrying value adjusted for depreciation that was not recognized while classified as held for sale.

[2] In the first quarter of 2017, we recorded a $3.5 million impairment to reduce one ALF's net book value to its estimated fair value less costs to sell before it was reclassified to assets held for sale.

[3] We plan to sell the nine facilities classified as held for sale at March 31, 2017 over the next several quarters.

XML

ASSETS HELD FOR SALE (Parentheticals) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2017 USD ($) Facility Property
Real Estate Properties [Line Items]
Net proceeds from sale of facilities held for sale | $	$ 29.4
Gain from sale of facilities | $	$ 3.6
Number of facilities with impairment charges	1
Number of facility classified as held for sale to sell	9
SNF's
Real Estate Properties [Line Items]
Number of facilities held for sale sold	9
Number of property reclassified | Property	1
Carrying value for property reclassified | $	$ 5.1
ALFs
Real Estate Properties [Line Items]
Number of facilities held for sale sold	2
Impairment charges | $	$ 3.5
Number of facilities with impairment charges	1

XML

INTANGIBLES - Summary of our intangibles (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Assets:
Goodwill	$ 643,692	$ 643,474
Accumulated amortization	(16,180)	(15,864)
Net intangible assets	6,430	6,779
Liabilities:
Below market leases	164,735	165,028
Accumulated amortization	(74,131)	(70,738)
Net intangible liabilities	90,604	94,290
Above market leases
Assets:
Gross intangible assets	22,443	22,476
In-place leases
Assets:
Gross intangible assets	$ 167	$ 167

XML

INTANGIBLES - Reconciliation of goodwill (Details 1) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($)
Goodwill [Roll Forward]
Balance as of December 31, 2016	$ 643,474
Add: foreign currency translation	218
Balance as of March 31, 2017	$ 643,692

XML

INTANGIBLES (Narrative) (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 3.1	$ 4.3
Remainder of 2017	8.9
2018	10.5
2019	9.5
2020	9.3
2021	$ 8.7

XML

INTANGIBLES (Narrative) (Detail 1)	3 Months Ended
	Mar. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Below market leases, weighted average remaining amortization	9 years
Above market lease intangibles
Finite-Lived Intangible Assets [Line Items]
Weighted average remaining amortization	8 years

XML

CONCENTRATION OF RISK (Narrative) (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($) Facility Healthcare_facility State Operator	Dec. 31, 2016 USD ($)
Concentration Risk [Line Items]
Number of facilities owned | Healthcare_facility	985
Number of states | State	42
Number of operators | Operator	77
Gross investment in facilities, net of impairments and before reserve for uncollectible loans | $	$ 8,900,000
Percentage share of real estate investments related to long-term care facilities	99.00%
Number of facilities held-for-sale/closed	11
Miscellaneous investments, net | $	$ 255,899	$ 256,846
Concentration risk, benchmark description	No single operator or manager generated more than 10% of our total revenues for the three months ended March 31, 2017.
Ohio
Concentration Risk [Line Items]
Concentration percent by state	10.00%
Texas
Concentration Risk [Line Items]
Concentration percent by state	9.00%
Florida
Concentration Risk [Line Items]
Concentration percent by state	9.00%
SNF's
Concentration Risk [Line Items]
Number of facilities owned	808
Number of facilities under fixed rate mortgage loan	44
ALFs
Concentration Risk [Line Items]
Number of facilities owned	101
Number of facilities under fixed rate mortgage loan	4
Specialty facilities
Concentration Risk [Line Items]
Number of facilities owned	16
Medical office building
Concentration Risk [Line Items]
Number of facilities owned	1

XML

STOCKHOLDERS'/OWNERS' EQUITY (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Cumulative Translation Adjustment Summary [Roll Forward]
Total accumulated other comprehensive loss	$ (50,780)	$ (22,737)
Add: portion included in noncontrolling interest	2,302	1,035
Total accumulated other comprehensive loss	(48,478)	(21,702)	$ (53,827)
Foreign Currency Translation
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance	(54,948)	(8,413)
Translation gain (loss)	4,273	(4,708)
Realized gain (loss)	61	(22)
Ending balance	(50,614)	(13,143)
Cash Flow Hedges
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance	(1,420)	(718)
Unrealized gain (loss)	490	(8,876)
Realized gain (loss)	764
Ending balance	(166)	(9,594)
OHI Holdco
Cumulative Translation Adjustment Summary [Roll Forward]
Total accumulated other comprehensive loss	(50,780)	(22,737)
Add: portion included in noncontrolling interest	39,527	17,681
Total accumulated other comprehensive loss	(11,253)	(5,056)	$ (12,439)
OHI Holdco | Foreign Currency Translation
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance	(54,948)	(8,413)
Translation gain (loss)	4,273	(4,708)
Realized gain (loss)	61	(22)
Ending balance	(50,614)	(13,143)
OHI Holdco | Cash Flow Hedges
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance	(1,420)	(718)
Unrealized gain (loss)	490	(8,876)
Realized gain (loss)	764
Ending balance	(166)	(9,594)
Omega OP
Cumulative Translation Adjustment Summary [Roll Forward]
Total accumulated other comprehensive loss	(50,780)	(22,737)
Total accumulated other comprehensive loss	(50,780)	(22,737)
Omega OP | Foreign Currency Translation
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance	(54,948)	(8,413)
Translation gain (loss)	4,273	(4,708)
Realized gain (loss)	61	(22)
Ending balance	(50,614)	(13,143)
Omega OP | Cash Flow Hedges
Cumulative Translation Adjustment Summary [Roll Forward]
Beginning balance	(1,420)	(718)
Unrealized gain (loss)	490	(8,876)
Realized gain (loss)	764
Ending balance	$ (166)	$ (9,594)

XML

STOCKHOLDERS'/OWNERS' EQUITY (Narrative) (Detail) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	Apr. 13, 2017	Jan. 12, 2017	Mar. 31, 2017	Mar. 31, 2016
Dividend [Line Items]
Dividends declared per common share			$ 0.62	$ 0.57
Issuance of common stock (in shares)			228,000
Dividend reinvestment plan (in shares)			239,000
Gross proceeds from issuance of common stock			$ 6,759
Board of Directors
Dividend [Line Items]
Dividends declared per common share		$ 0.62
Nature of common stock dividend payable		Quarterly
Increasing the quarterly common dividend		0.01
Dividends declared, date of declaration		Jan. 12, 2017
Dividends declared, date of payment		Feb. 15, 2017
Dividends declared, date of record		Jan. 31, 2017
500 Million Equity Shelf Program
Dividend [Line Items]
Issuance of common stock (in shares)			228,000
Issuance of common stock, average price per share			$ 29.71
Gross proceeds from issuance of common stock			$ 6,800
Sales price, equity distribution agreement			$ 500,000
Dividend Reinvestment and Common Stock Purchase Plan
Dividend [Line Items]
Dividend reinvestment plan (in shares)			239,000
Issuance of common stock, average price per share			$ 30.67
Gross proceeds from issuance of common stock			$ 7,335
Subsequent Event | Board of Directors
Dividend [Line Items]
Dividends declared per common share	$ 0.63
Nature of common stock dividend payable	Quarterly
Increasing the quarterly common dividend	0.01
Dividends declared, date of declaration	Apr. 13, 2017
Dividends declared, date of payment	May 15, 2017
Dividends declared, date of record	May 01, 2017

XML

TAXES (Narrative) (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2017 USD ($)
Income Tax Disclosure [Abstract]
Percentage of minimum taxable income is distributed	90.00%
Permitted ownership of a taxable REIT subsidiary ("TRS"), maximum percentage	100.00%
Net operating loss carry-forward	$ 0.8
State and local income tax provision	1.0
Provision (benefit) for foreign income taxes	$ 0.1

XML

STOCK-BASED COMPENSATION (Details ) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2017 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/Units | shares	2,447,351
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 18.63
Total Compensation Cost	$ 45.6	[1]
Unrecognized Compensation Cost	$ 29.3
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/Units | shares	428,670
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 35.68
Total Compensation Cost	$ 15.3	[1]
Unrecognized Compensation Cost	$ 8.6
RSUs | 3/31/15 RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2015
Shares/Units | shares	109,985
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 40.57
Total Compensation Cost	$ 4.5	[1]
Weighted Average Period of Expense Recognition	33 months
Unrecognized Compensation Cost	$ 1.2
Vesting Dates	12/31/2017
RSUs | 4/1/15 RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2015
Shares/Units | shares	40,464
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 40.74
Total Compensation Cost	$ 1.6	[1]
Weighted Average Period of Expense Recognition	33 years
Unrecognized Compensation Cost	$ 0.5
Vesting Dates	12/31/2017
RSUs | Assumed Aviv RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2015
Shares/Units | shares	7,799
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 35.08
Total Compensation Cost	$ 0.3	[1]
Weighted Average Period of Expense Recognition	33 years
Unrecognized Compensation Cost	$ 0.1
Vesting Dates	11/1/2017
RSUs | 3/17/16 RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2016
Shares/Units | shares	130,006
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 34.78
Total Compensation Cost	$ 4.6	[1]
Weighted Average Period of Expense Recognition	33 years
Unrecognized Compensation Cost	$ 2.8
Vesting Dates	12/31/2018
RSUs | 1/1/2017 RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2017
Shares/Units | shares	140,416
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 31.26
Total Compensation Cost	$ 4.3	[1]
Weighted Average Period of Expense Recognition	36 months
Unrecognized Compensation Cost	$ 4.0
Vesting Dates	12/31/2019
TSR PRSUs and LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/Units | shares	1,098,829
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 12.69
Total Compensation Cost	$ 13.9	[1]
Unrecognized Compensation Cost	$ 9.8
TSR PRSUs and LTIP Units | 2016 TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2014
Shares/Units | shares	135,634
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 8.67
Total Compensation Cost	$ 1.2	[1]
Weighted Average Period of Expense Recognition	48 months
Unrecognized Compensation Cost	$ 0.2
Performance Period	1/1/2014-12/31/2016
Vesting Dates	Quarterly in 2017
TSR PRSUs and LTIP Units | 3/31/15 2017 LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2015
Shares/Units | shares	137,249
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 14.66
Total Compensation Cost	$ 2.0	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 0.9
Performance Period	1/1/2015-12/31/2017
Vesting Dates	Quarterly in 2018
TSR PRSUs and LTIP Units | 4/1/2015 2017 LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2015
Shares/Units | shares	54,151
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 14.80
Total Compensation Cost	$ 0.8	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 0.4
Performance Period	1/1/2015-12/31/2017
Vesting Dates	Quarterly in 2018
TSR PRSUs and LTIP Units | 3/17/16 2018 LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2016
Shares/Units | shares	372,069
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 13.21
Total Compensation Cost	$ 4.9	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 3.6
Performance Period	1/1/2016-12/31/2018
Vesting Dates	Quarterly in 2019
TSR PRSUs and LTIP Units | 1/1/2017 2019 LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2017
Shares/Units | shares	399,726
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 12.61
Total Compensation Cost	$ 5.0	[1]
Weighted Average Period of Expense Recognition	48 months
Unrecognized Compensation Cost	$ 4.7
Performance Period	1/1/2017-12/31/2019
Vesting Dates	Quarterly in 2020
Relative TSR PRSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/Units | shares	919,852
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 17.78
Total Compensation Cost	$ 16.4	[1]
Unrecognized Compensation Cost	$ 10.9
Relative TSR PRSUs | 2016 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2014
Shares/Units | shares	135,634
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 14.24
Total Compensation Cost	$ 1.9	[1]
Weighted Average Period of Expense Recognition	48 months
Unrecognized Compensation Cost	$ 0.4
Performance Period	1/1/2014-12/31/2016
Vesting Dates	Quarterly in 2017
Relative TSR PRSUs | 3/31/15 2017 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2015
Shares/Units | shares	137,249
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 22.50
Total Compensation Cost	$ 3.1	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 1.4
Performance Period	1/1/2015-12/31/2017
Vesting Dates	Quarterly in 2018
Relative TSR PRSUs | 4/1/2015 2017 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2015
Shares/Units | shares	54,151
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 22.91
Total Compensation Cost	$ 1.2	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 0.6
Performance Period	1/1/2015-12/31/2017
Vesting Dates	Quarterly in 2018
Relative TSR PRSUs | 3/17/16 2018 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2016
Shares/Units | shares	307,480
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 16.45
Total Compensation Cost	$ 5.1	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 3.7
Performance Period	1/1/2016-12/31/2018
Vesting Dates	Quarterly in 2019
Relative TSR PRSUs | 1/1/2017 2019 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2017
Shares/Units | shares	285,338
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 18.04
Total Compensation Cost	$ 5.1	[1]
Weighted Average Period of Expense Recognition	48 months
Unrecognized Compensation Cost	$ 4.8
Performance Period	1/1/2017-12/31/2019
Vesting Dates	Quarterly in 2020

[1] Total compensation costs are net of shares cancelled.

XML

STOCK-BASED COMPENSATION (Narrative) (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 3.7	$ 2.8
Shares of restricted stock outstanding	2,447,351
Unrecognized compensation cost	$ 29.3
Percentage of operating partnership units distributions	10.00%
Restricted stock | Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	51,999
Vesting period, years	3 years
Unrecognized compensation cost	$ 1.1
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	428,670
Unrecognized compensation cost	$ 8.6
RSUs | January 1, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	140,416
LTIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	1,098,829
Unrecognized compensation cost	$ 9.8
LTIP | January 1, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	399,726
Relative TSR PRSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	919,852
Unrecognized compensation cost	$ 10.9
Relative TSR PRSUs | January 1, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	285,338

XML

BORROWING ACTIVITIES AND ARRANGEMENTS (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017	Dec. 31, 2016
Secured borrowings:
Secured borrowings - net	[1]	$ 54,052	$ 54,365
Unsecured borrowings:
Revolving line of credit		123,000	190,000
Term loans - net		1,094,875	1,094,343
Other		255,899	256,846
Total secured and unsecured borrowings - net		4,300,865	4,366,854
Secured Borrowings
Secured borrowings:
Secured borrowings - net		$ 54,052	54,365
Secured Borrowings | HUD mortgages assumed December 2011
Debt Instrument [Line Items]
Maturity	[2]	2044
Rate	[2]	3.06%
Secured borrowings:
Secured borrowings - net	[2]	$ 54,636	54,954
Secured Borrowings | Deferred financing costs - net
Secured borrowings:
Deferred financing costs - net		(584)	(589)
Unsecured borrowings
Unsecured borrowings:
Discount - net		(16,669)	(17,151)
Total unsecured borrowings		3,028,938	3,028,146
Unsecured borrowings | Deferred financing costs - net
Unsecured borrowings:
Deferred financing costs - net		(5,125)	(5,657)
Deferred financing costs - net		$ (27,393)	(27,703)
Unsecured borrowings | Revolving line of credit
Debt Instrument [Line Items]
Maturity		2018
Rate		2.25%
Unsecured borrowings:
Revolving line of credit		$ 123,000	190,000
Unsecured borrowings | Tranche A-1 term loan
Debt Instrument [Line Items]
Maturity		2019
Rate		2.48%
Unsecured borrowings:
Unsecured borrowing		$ 200,000	200,000
Unsecured borrowings | Tranche A-2 term loan
Debt Instrument [Line Items]
Maturity		2017
Rate		2.44%
Unsecured borrowings:
Unsecured borrowing		$ 200,000	200,000
Unsecured borrowings | Tranche A-3 term loan
Debt Instrument [Line Items]
Maturity		2021
Rate		2.48%
Unsecured borrowings:
Unsecured borrowing		$ 350,000	350,000
Unsecured borrowings | Omega OP Term loan
Debt Instrument [Line Items]
Maturity	[1]	2017
Rate	[1]	2.44%
Unsecured borrowings:
Term loans - net	[1]	$ 100,000	100,000
Unsecured borrowings | 2015 term loan
Debt Instrument [Line Items]
Maturity		2022
Rate		3.80%
Unsecured borrowings:
Revolving line of credit		$ 250,000	250,000
Unsecured borrowings | 2023 notes
Debt Instrument [Line Items]
Maturity		2023
Rate		4.375%
Unsecured borrowings:
Aggregate principal amount		$ 700,000	700,000
Unsecured borrowings | 2024 notes
Debt Instrument [Line Items]
Maturity		2024
Rate		5.875%
Unsecured borrowings:
Aggregate principal amount		$ 400,000	400,000
Unsecured borrowings | 2024 notes
Debt Instrument [Line Items]
Maturity		2024
Rate		4.95%
Unsecured borrowings:
Aggregate principal amount		$ 400,000	400,000
Unsecured borrowings | 2025 notes
Debt Instrument [Line Items]
Maturity		2025
Rate		4.50%
Unsecured borrowings:
Aggregate principal amount		$ 250,000	250,000
Unsecured borrowings | 2026 Notes
Debt Instrument [Line Items]
Maturity		2026
Rate		5.25%
Unsecured borrowings:
Aggregate principal amount		$ 600,000	600,000
Unsecured borrowings | 2027 notes
Debt Instrument [Line Items]
Maturity		2027
Rate		4.50%
Unsecured borrowings:
Aggregate principal amount		$ 700,000	700,000
Unsecured borrowings | Other
Debt Instrument [Line Items]
Maturity		2018
Unsecured borrowings:
Other		$ 3,000	3,000
Unsecured borrowings | Subordinated debt
Debt Instrument [Line Items]
Maturity		2021
Rate		9.00%
Unsecured borrowings:
Subordinated debt		$ 20,000	$ 20,000

[1] These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

[2] Reflects the weighted average annual contractual interest rate on the mortgages at March 31, 2017 excluding a third-party administration fee of approximately 0.5% annually. Secured by real estate assets with a net carrying value of $64.8 million as of March 31, 2017.

XML

BORROWING ACTIVITIES AND ARRANGEMENTS (Parentheticals) (Details) - USD ($) $ in Thousands			3 Months Ended
		Apr. 04, 2017	Mar. 31, 2017	Dec. 31, 2016
Tranche A-2 term loan | Subsequent Event
Debt Instrument [Line Items]
Aggregate principal amount		$ 200,000
2024 notes | Subsequent Event
Debt Instrument [Line Items]
Maturity		2024
Aggregate principal amount		$ 400,000
Secured Borrowings | HUD mortgages assumed December 2011
Debt Instrument [Line Items]
Percentage of third-party administration fee			0.50%
Real estate assets with a net carrying value			$ 64,800
Maturity	[1]		2044
Rate	[1]		3.06%
Unsecured borrowings | Tranche A-2 term loan
Debt Instrument [Line Items]
Maturity			2017
Rate			2.44%
Unsecured borrowings | 2024 notes
Debt Instrument [Line Items]
Maturity			2024
Rate			5.875%
Aggregate principal amount			$ 400,000	$ 400,000

[1] Reflects the weighted average annual contractual interest rate on the mortgages at March 31, 2017 excluding a third-party administration fee of approximately 0.5% annually. Secured by real estate assets with a net carrying value of $64.8 million as of March 31, 2017.

XML

FINANCIAL INSTRUMENTS (Detail) - USD ($) $ in Thousands		Mar. 31, 2017	Dec. 31, 2016
Assets:
Investments in direct financing leases - net		$ 604,777	$ 601,938
Mortgage notes receivable - net		644,696	639,343
Other investments - net		255,899	256,846
Liabilities:
Revolving line of credit		123,000	190,000
2015 tern loan		1,094,875	1,094,343
HUD debt - net	[1]	54,052	54,365
Carrying Amount
Assets:
Investments in direct financing leases - net		604,777	601,938
Mortgage notes receivable - net		644,696	639,343
Other investments - net		255,899	256,846
Total		1,505,372	1,498,127
Liabilities:
Revolving line of credit		123,000	190,000
Tranche A-1 term loan		199,124	198,830
Tranche A-2 term loan		200,000	200,000
Tranche A-3 term loan		347,605	347,449
Omega OP term loan	[1]	100,000	100,000
2015 tern loan		248,145	248,064
HUD debt - net	[1]	54,052	54,365
Subordinated debt - net		20,460	20,490
Other		3,000	3,000
Total		4,300,865	4,366,854
Carrying Amount | 4.375% notes due 2023
Liabilities:
Notes Payable		692,598	692,305
Carrying Amount | 5.875% notes due 2024
Liabilities:
Notes Payable		395,236	395,065
Carrying Amount | 4.95% notes due 2024
Liabilities:
Notes Payable		392,922	392,669
Carrying Amount | 4.50% notes due 2025
Liabilities:
Notes Payable		245,953	245,949
Carrying Amount | 5.25% notes due 2026
Liabilities:
Notes Payable		593,792	593,616
Carrying Amount | 4.50% notes due 2027
Liabilities:
Notes Payable		685,418	685,052
Carrying Amount | 4.75% notes due 2028
Liabilities:
Notes Payable		(440)
Fair Value
Assets:
Investments in direct financing leases - net		601,522	598,665
Mortgage notes receivable - net		652,487	644,961
Other investments - net		248,959	253,385
Total		1,502,968	1,497,011
Liabilities:
Revolving line of credit		123,000	190,000
Tranche A-1 term loan		200,000	200,000
Tranche A-2 term loan		200,000	200,000
Tranche A-3 term loan		350,000	350,000
Omega OP term loan	[1]	100,000	100,000
2015 Term loan		250,000	250,000
HUD debt - net	[1]	52,771	52,510
Subordinated debt - net		23,909	23,944
Other		3,000	3,000
Total		4,436,599	4,444,772
Fair Value | 4.375% notes due 2023
Liabilities:
Notes Payable		710,967	693,505
Fair Value | 5.875% notes due 2024
Liabilities:
Notes Payable		434,814	432,938
Fair Value | 4.95% notes due 2024
Liabilities:
Notes Payable		413,512	406,361
Fair Value | 4.50% notes due 2025
Liabilities:
Notes Payable		250,500	249,075
Fair Value | 5.25% notes due 2026
Liabilities:
Notes Payable		627,443	611,461
Fair Value | 4.50% notes due 2027
Liabilities:
Notes Payable		696,683	$ 681,978
Fair Value | 4.75% notes due 2028
Liabilities:
Notes Payable

[1] These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

XML

FINANCIAL INSTRUMENTS (Parentheticals) (Detail)	Mar. 31, 2017
4.375% notes due 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.375%
5.875% notes due 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	5.875%
4.95% notes due 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.95%
4.50% notes due 2025
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.50%
5.25% notes due 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	5.25%
4.50% notes due 2027
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.50%
4.75% notes due 2028
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.75%

XML

EARNINGS PER SHARE/UNIT - Computation of basic and diluted earnings per share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net income	$ 109,112	$ 58,196
Less: net income attributable to noncontrolling interests	(4,672)	(2,641)
Net income available to common stockholders/Omega OP Unit holders	$ 104,440	$ 55,555
Denominator:
Denominator for basic earnings per share	197,013	188,228
Effect of dilutive securities:
Common stock equivalents/units	347	1,175
Noncontrolling interest - Omega OP Units	8,814	8,947
Denominator for diluted earnings per share	206,174	198,350
Earnings per share - basic:
Net income available to common stockholders (in dollars per share)	$ 0.53	$ 0.30
Earnings per share - diluted:
Net income (in dollars per share)	$ 0.53	$ 0.29
Omega OP
Numerator:
Net income	$ 109,112	$ 58,196
Less: net income attributable to noncontrolling interests
Net income available to common stockholders/Omega OP Unit holders	$ 109,112	$ 58,196
Denominator:
Denominator for basic earnings per unit	205,827	197,175
Effect of dilutive securities:
Common stock equivalents/units	347	1,175
Noncontrolling interest - Omega OP Units
Denominator for diluted earnings per unit	206,174	198,350
Earnings per share - basic:
Net income available to Omega OP Unit holders (in dollars per share)	$ 0.53	$ 0.30
Earnings per unit - diluted:
Net income (in dollars per share)	$ 0.53	$ 0.29

XML

SUBSEQUENT EVENTS (Narrative) (Detail) $ in Thousands, £ in Millions	1 Months Ended		3 Months Ended
	May 25, 2017 USD ($)	Apr. 28, 2017 USD ($)	Jun. 30, 2017 USD ($)	May 25, 2017 GBP (£)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Subsequent Event [Line Items]
Long-term line of credit					$ 123,000	$ 190,000
Term loans - net					$ 1,094,875	$ 1,094,343
Subsequent Event
Subsequent Event [Line Items]
Net write-offs associated with unamortized deferred financing costs		$ 4,700
Unsecured borrowings | 2017 Omega OP Term Loan Facility | Subsequent Event
Subsequent Event [Line Items]
Term loans - net	$ 100,000
Credit facility, description of variable rate basis	LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor's, Moody's and/or Fitch Ratings
Maturity date	May 25, 2022
Amount of guaranty of unsecured indebtedness	$ 50,000
Unsecured borrowings | 2017 Omega Credit Facilities | Subsequent Event
Subsequent Event [Line Items]
Long-term line of credit	1,800,000
Maximum borrowing capacity	2,500,000
Net write-offs associated with unamortized deferred financing costs			$ 5,500
Unsecured borrowings | Omega Credit Facility | Tranche A-1 Term Loan Facility | Subsequent Event
Subsequent Event [Line Items]
Term loan/facility terminated	200,000
Unsecured borrowings | Omega Credit Facility | Tranche A-2 Term Loan Facility | Subsequent Event
Subsequent Event [Line Items]
Term loan/facility terminated	200,000
Unsecured borrowings | Omega Credit Facility | Tranche A-3 Term Loan Facility | Subsequent Event
Subsequent Event [Line Items]
Term loan/facility terminated	350,000
Unsecured borrowings | Omega Credit Facility | Senior unsecured 2014 revolving credit facility | Subsequent Event
Subsequent Event [Line Items]
Term loan/facility terminated	$ 1,250,000
Unsecured borrowings | Minimum | 2017 Omega OP Term Loan Facility | Subsequent Event
Subsequent Event [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage	0.90%
Unsecured borrowings | Maximum | 2017 Omega OP Term Loan Facility | Subsequent Event
Subsequent Event [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage	1.90%
Unsecured borrowings | Revolving Credit Facility | 2017 Omega Credit Facilities | Subsequent Event
Subsequent Event [Line Items]
Long-term line of credit	$ 1,250,000
Credit facility, description of variable rate basis	LIBOR plus an applicable percentage (with a range of 100 to 195 basis points) based on our ratings from Standard & Poor's, Moody's and/or Fitch Ratings
Maturity date	May 25, 2021
Revolving credit facility to be drawn in Alternative Currencies or U.S. Dollars in tranche one	$ 900,000
Revolving credit facility to be drawn in Alternative Currencies or U.S. Dollars in tranche two	$ 350,000
Unsecured borrowings | Revolving Credit Facility | Minimum | 2017 Omega Credit Facilities | Subsequent Event
Subsequent Event [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage	1.00%
Unsecured borrowings | Revolving Credit Facility | Maximum | 2017 Omega Credit Facilities | Subsequent Event
Subsequent Event [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage	1.95%
Unsecured borrowings | 2017 U.S. Term Loan Facility | 2017 Omega Credit Facilities | Subsequent Event
Subsequent Event [Line Items]
Long-term line of credit	$ 425,000
Credit facility, description of variable rate basis	LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor's, Moody's and/or Fitch Ratings
Maturity date	May 25, 2022
Unsecured borrowings | 2017 U.S. Term Loan Facility | Minimum | 2017 Omega Credit Facilities | Subsequent Event
Subsequent Event [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage	0.90%
Unsecured borrowings | 2017 U.S. Term Loan Facility | Maximum | 2017 Omega Credit Facilities | Subsequent Event
Subsequent Event [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage	1.90%
Unsecured borrowings | 2017 Sterling Term Loan Facility | 2017 Omega Credit Facilities | Subsequent Event
Subsequent Event [Line Items]
Long-term line of credit | £				£ 100
Credit facility, description of variable rate basis	LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor's, Moody's and/or Fitch Ratings
Maturity date	May 25, 2022
Unsecured borrowings | 2017 Sterling Term Loan Facility | Minimum | 2017 Omega Credit Facilities | Subsequent Event
Subsequent Event [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage	0.90%
Unsecured borrowings | 2017 Sterling Term Loan Facility | Maximum | 2017 Omega Credit Facilities | Subsequent Event
Subsequent Event [Line Items]
Pricing of credit facility at LIBOR plus an applicable percentage	1.90%

XML

SUBSEQUENT EVENTS (Narrative) (Detail 1) - USD ($) $ in Millions		1 Months Ended
	Apr. 04, 2017	Apr. 28, 2017	Mar. 31, 2017
4.75% notes due 2028
Subsequent Event [Line Items]
Rate			4.75%
4.50% notes due 2025
Subsequent Event [Line Items]
Rate			4.50%
5.875% notes due 2024
Subsequent Event [Line Items]
Rate			5.875%
Subsequent Event
Subsequent Event [Line Items]
Net proceeds from the offering after deducting underwriting discounts and expenses	$ 690.7
Redemption related costs and write offs		$ 16.5
Call premium		11.8
Net write-offs associated with unamortized deferred financing costs		$ 4.7
Subsequent Event | Tranche A-2 term loan
Subsequent Event [Line Items]
Prepay senior unsecured incremental term loan facility	$ 200.0
Subsequent Event | 4.75% notes due 2028
Subsequent Event [Line Items]
Maturity	2028
Rate	4.75%
Aggregate principal amount	$ 550.0
Maturity date	Jan. 15, 2028
Percentage of notes sold at an issue price	98.978%
Subsequent Event | 4.50% notes due 2025
Subsequent Event [Line Items]
Maturity	2025
Rate	4.50%
Aggregate principal amount	$ 150.0
Maturity date	Jan. 15, 2025
Percentage of notes sold at an issue price	99.54%
Subsequent Event | 5.875% notes due 2024
Subsequent Event [Line Items]
Maturity	2024
Rate	5.875%
Aggregate principal amount	$ 400.0
Maturity date	Apr. 28, 2017